[COMPANY_001] Confidential Page 2
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Table of contents
Table of contents ................................................................................................................. [ADDRESS_742265] of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 11
Amendment 6 (28 -Feb-2019) ............................................................................................ 13
Amendment 5 (13 -Feb-2018) ............................................................................................ 18
Amendment 4 (17 -Nov-2016) ........................................................................................... 22
Amendment 3 (28 -Jul-
2016) ............................................................................................. 27
Amendment 2 .................................................................................................................... 32
Amendment 1 .................................................................................................................... 38
Protocol summary .............................................................................................................. 40
1Background ........................................................................................................................ 48
1.1
Overview of disease pathogenesis, epid emiology  and current treatment .............. 48
1.1.1 Locally  advanced unresectable or metastatic non- small cell lung 
cancer (NSCLC) .................................................................................... 48
1.1.2 Targeted therapi[INVESTIGATOR_565223] C
............................................................... 49
1.1.3 cMET in NSCL C
................................................................................... 50
1.2 Introduction to study  treatment .............................................................................. 51
1.2.1 Overview of INC280 ............................................................................. 51
2Rationale ................................ ................................ ................................ ............................ 58
2.1 Study  rationale and purpose ................................................................................... 58
2.2 Rationale for the stud y design ............................................................................... 58
2.2.1 Rationale for cMET GCN cohorts ........................................................ 59
2.2.2 Rationale for cMET mutation cohorts ................................................... 60
2.2.3 Rationale for treatment
-naïve cohort with cMET dy sregulation .......... 61
2.2.4 Rationale for additional Cohort 6 in pretreated NSCL C with cMET 
dysregulation ......................................................................................... 62
2.2.5
Rationale for additional Cohort 7 in treatment- naïve NSCL C with 
cMET mutati on ..................................................................................... 62
2.3 Rationale for dose and regimen selection .............................................................. 62
2.4
Rationale for choice of combination drugs............................................................ 64
2.5 Rationale for choice of comparators drugs ............................................................ 64
3Objectives and endpoints ................................ ................................ ................................ ...64
4Study  design ................................ ................................ ................................ ...................... 67

[COMPANY_001] Confidential Page 3
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
4.1 Description of stud y design ................................ ................................ ................... 67
4.1.1 Molecular pre -screening ........................................................................ 71
4.1.2 Main screening ...................................................................................... 72
4.1.3 Treatment .............................................................................................. 72
4.1.4 Follow -
up .............................................................................................. 73
4.1.5 Survival follow -
up ................................................................................ 73
4.2 Timing of interim anal yses and design adaptations ............................................... 73
4.3 Definition of end of the study ................................................................................ 74
4.4 Early study termination .......................................................................................... 74
5Population .......................................................................................................................... 74
5.1 Patient population .................................................................................................. 74
5.2 Inclusion criteria .................................................................................................... 75
5.3 Exclusion criteria ................................................................................................... 77
6Treatment ................................ ................................ ................................ ........................... 80
6.1 Study  treatment ...................................................................................................... 80
6.1.1 Dosing regimen ..................................................................................... 80
6.1.2 Ancillary  treatmen ts.............................................................................. 81
6.1.3
Rescue medication ................................................................................ 81
6.1.4 Guidelines for continuation of treatment .............................................. 81
6.1.5 Treatment duration ................................................................................ 81
6.2 Dose escalation guidelines ..................................................................................... 81
6.3 Dose modifications ................................................................................................ 81
6.3.1 Dose modification and dose delay ........................................................ 81
6.3.2 Dose reduction and re -escalation .......................................................... 82
6.3.3 Treatment interruption and 
treatment discontinuation .......................... 89
6.3.4 Follow -up for toxicities ......................................................................... 89
6.3.5 Anticipated risks and safety  concerns of the study drug ....................... 94
6.4
Concomitant medications ................................ ................................ ...................... 95
6.4.1 Permitted concomitant therap y ............................................................. 95
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 96
6.4.3 Prohibited concomitant therap y
............................................................ 97
6.5
Patient numbering and treatment assignment ........................................................ 98
6.5.1
Patient numbering ................................................................................. 98
6.5.2 Treatment assignment ........................................................................... 98
6.5.3 Treatment blinding ................................................................................ 99
6.6 Study  drug preparation and dispensation ............................................................... 99

[COMPANY_001] Confidential Page 4
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
6.6.[ADDRESS_742266]....................................................... 130
8.2 Serious adverse events ......................................................................................... 131
8.2.1
Definitions........................................................................................... 131
8.2.2
Reporting............................................................................................. 131
8.3 Emergency  unblinding of treatment assignment ................................................. 132
8.4 Pregnancies .......................................................................................................... 132
8.5 Warnings and precautions .................................................................................... 133
8.6 Data Monitoring Committee ................................................................................ 133
8.7 Steeri ng Committee
............................................................................................. 133
9Data collection and management ..................................................................................... 133
9.1 Data confidentiality ............................................................................................. 133
9.2 Site monitoring .................................................................................................... 134

[COMPANY_001] Confidential Page 5
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
9.3 Data collection................................ ................................ ................................ .....134
9.4 Database management and quality  control .......................................................... 135
10Statistical methods and data anal ysis.............................................................................. 136
10.1 Analy sis sets ........................................................................................................ 137
10.1.1 Full Anal ysis Set ................................................................................. 137
10.1.2 Safety  Set
............................................................................................ 137
10.1.3
Per-Protocol Set .................................................................................. 137
10.1.4 Pharmacokinetic anal ysis set
............................................................... 137
10.2 Patient demographics/other baseline characteristics ........................................... 137
10.3 Treatments (stud y treatment, concomitant therapi[INVESTIGATOR_014], compliance) ..................... 137
10.4 Primary  objective ................................................................................................. 138
10.4.1 Variable ............................................................................................... 138
10.4.2 Statistical hy pothesis , model, and method of analysis ........................ 138
10.4.3 Handling of missing values/censoring/discontinuations ..................... 139
10.4.4 Supportive analy ses............................................................................. 139
10.5 Secondary  objectives ........................................................................................... 139
10.5.1 Key secondary  objective(s) ................................................................. 139
10.5.2 Other secondary  efficacy objectives ................................................... 140
10.5.3 Safety  objectives ................................................................................. 141
10.5.4 Pharmacokinetics ................................................................................ 142
143
10.5.6 Resource utilization ............................................................................. 145
145
145
10.7 Interim anal ysis.................................................................................................... 145
10.8
Sample size calculation........................................................................................ 147
10.9 Power for anal ysis of key secondary  variables
.................................................... 150
11Ethical considerations and administrative procedures .................................................... 150
11.1 Regulatory
 and ethical compliance ...................................................................... 150
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_742267] keepi[INVESTIGATOR_5304]
..................... 152
11.7 Confidentia lity of study  documents and patient records ..................................... 153
11.8
Audits and inspections......................................................................................... 153

[COMPANY_001] Confidential Page 6
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
11.9 Financial disclosures ................................ ................................ ............................ 153
12Protocol adherence .......................................................................................................... 153
12.1 Amendments to the protocol ................................................................................ 153
13References (available upon request) ................................................................................ 154
14Appendices ...................................................................................................................... 160
14.1 Appendix 1: 
Harmonization of efficacy anal ysis of solid tumor studies 
(RECI ST1.1)................................ ................................ ................................ .......[ADDRESS_742268] overall response ........................................................................... 171
14.1.18 Time to event variables ....................................................................... 173
14.1.19 Progression
-free survival .................................................................... 173
14.1.20 Overall survival ................................................................................... 173
14.1.21 Time to progression ............................................................................. 173
14.1.22 Time to treatment failure ..................................................................... 174
14.1.23 Duration of response ........................................................................... 174
14.1.24 Time to response ................................................................................. 175
14.1.25 Definition of start and end dates for time to event variables .............. 175
14.1.26 Handling of patients with non -measurable disease only  at baseline ...176
14.1.27 Sensitivity  analy ses............................................................................. 177
14.1.28 Data handling and programming rules ................................................ 179
14.1.29 Study /project specific decisions .......................................................... 179

[COMPANY_001] Confidential Page 7
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.[ADDRESS_742269] -treatment follow -up (study  phase completion) ................ 180
14.1.32
Medical validation of programmed overall lesion response ............... 180
14.1.33 Programming rules .............................................................................. 181
14.1.34
Calculation of ‘time to event’ variables.............................................. [ADDRESS_742270] known date patient alive or death ............... 181
14.1.37 Non-target lesion response .................................................................. 182
14.1.38 Study /project specific programming ................................................... 182
14.1.39 Censoring reason ................................................................................. 182
14.1.40 References (available upon request) ................................................... [ADDRESS_742271] of appendices
Appendix 1: Response Evaluation Criteria in Solid Tumors (RECI ST) Version 1.[ADDRESS_742272] of tables
Table 2
-1 DLTs experienced with single agent INC280 as of 28-Sep-2014......... 62
Table 3-1 Objectives and related endpoints ................................ .......................... 65
Table 6-1 Dose and treatment schedule................................................................. 81
Table 6
-2 Dose reduction steps for INC280 .......................................................... 82
Table 6
-3 Criteria for interruption and re- initiation of INC280 treatment ............ 83
Table 6-4 Follow -up evaluations for selected toxicities*...................................... 89
Table 6
-5 Drugs to be used with caution while on study ................................ ......96
Table 6-6 Drugs prohibited while on study ........................................................... 97
Table 6
-7 Drugs with a known risk of Torsades des Pointes prohibited while 
on study ................................ ................................ ................................ .97
Table 6-8 Preparation and dispensing ................................................................... 99
Table 6
-9 Packaging and labeling ......................................................................... 99
Table 7
-1 Visit evaluation schedule ................................ ................................ ....102
Table 7-2 Imaging collection plan ................................ ................................ .......115
Table 7-3 ECOG performance status scale ................................ .......................... 119
Table 7-4 Clinical laboratory  parameters collectio n plan ................................... 120

[COMPANY_001] Confidential Page 8
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Table 7-[ADDRESS_742273] Binomial 95 percent Confidence Intervals for Various 
Sample Sizes and Observed ORRs in each Cohort/Sub- cohort 1a, 
1b, 2, [ADDRESS_742274] Binomial 95 percent Confidence Intervals for Various 
Sample Sizes and Observed ORRs in each Sub -cohort 5a, 5b and 
Cohort 7 ............................................................................................... 148
Table 10
-7 Operating Characteristics for Sub -cohort 1a, Sub- cohort 1b, Cohort 
2 and Cohort 4 ..................................................................................... 148
Table 10
-8 Operat ing Characteristics for Cohort 3 ............................................... 149
Table 10
-9 Operating Characteristics for Sub -cohort 5a, 5b and Cohort 7 ........... 149
Table 14-1 Response criteria for target lesions ..................................................... 167
Table 1
4-2 Response criteria for non -target lesions .............................................. 169
Table 14
-3 Overall lesion response at each assessment ........................................ 170
Table 14
-4 Overall lesion response at each assessment: patients with non -
target disease onl y................................ ................................ ............... 177
Table 14-5 Options for event dates used in PFS, TTP, duration of response ........ 178

[COMPANY_001] Confidential Page 9
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
List of abbreviations
ADME Absorption Distribution Metabolism Excretion
AE Adverse Event
ALKP Alkaline Phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area under the curve
AUCinf Area under the plasma concentration versus time curve from time zero to infinity
BID bis in diem / twice a day
BLRM Bayesian Logistic Regression Model
BIRC Blinded Independent Review Committee
BOR Best Overall Response
BSC Best Supportive Care
CxDx Cycle x Day x
CDx Companion Diagnostic s
CEP7 Centromere of chromosome 7
Cmax Maximum (peak) concentration of drug
CI Confidence Interval
CNS Central Nervous System
CR Complete Response
CRF/ eCRF Case Report/Record Form / electronic Case Report/Record Form
CRO Contract Research Organization
CSR Clinical Study R eport
CSR addendum An ad dendum to Clinical Study Report (CSR) that captures all the additional information that 
is not included in the CSR
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of Variation
CYP Cytochrome P450 isoenzyme
DCR Disease Control Rate
DILI Drug Induced Liver Injury
DOR Duration of Response
DLT Dose Limiting Toxicity
DS&E Drug Safety and Epi[INVESTIGATOR_565224] -PET FluoroDeoxyGlucose Positron Emission Tomography
FISH Fluorescence In Situ Hybridization
FFPE Formalin Fixed Paraffin Embedded
GCN Gene Copy Number
Hgb Hemoglobin
IB Investigator Brochure
i.v. intravenous(ly)

[COMPANY_001] Confidential Page 10
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
IC50 Half maximal inhibitory concentration
ICF Informed Consent Form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IHC Immunohistochemistry
ILD Interstitial Lung Disease
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
NGS Next Generation Sequencing
NOAEL No-observed -adverse -effect level
NSCLC Non-Small Cell Lung Cancer
NTI Narrow therapeutic index
o.d./QD omnia die / quaque die / once a day
ORR Overall response rate
OS Overall Survival
PD Progressive Disease
POS Probability of Success
PFS Progression Free Survival
p.o. per os / by [CONTACT_1966] / orally
PHI Protected Health Information
PK Pharmacokinetics
PPI [INVESTIGATOR_565225] A me asure of the time between the start of the Q wave and the end of the T wave in the 
heart's electric cycle
QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate using Friderica’s correction
RT-PCR Reverse Transcription Polyme rase Chain Reaction
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
REB Research Ethics Board
RECIST Response Evaluation Criteria In Solid Tumors
RoW Rest of the World
RP2D Recommended pha se two dose
SAE Serious Adverse Event
SD Stable Disease
SDH Sorbitol Dehydrogenase
SOP Standard Operating Procedure
TBIL Total Bilirubin
TKI Tyrosine Kinase Inhibitor
Tmax Time of occurrence for maximum (peak) drug concentration
TTP Time to Progres sion
TTR Time to Response
ULN Upper Limit of Normal
US [LOCATION_002]
wt Wild-type

[COMPANY_001] Confidential Page 11
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study subject or study patient
Control drug A study treatment used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. ,
treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually expressed as
number of days (e.g. ,: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. , prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational 
new drug.”
Investigationa l treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes approved 
drugs used outside of their indication/approved dosage, or that are tested in a fixed 
combination. Investigational treatment generally does not include other study 
treatments administered as concomitant background therapy required or allowed by 
[CONTACT_230753]/dosage
Medication number A unique id entifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that 
was not included in the investigationa l treatment
Subject Number (Subject 
No.)A unique identifying number assigned to each patient/subject/healthy volunteer who 
enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening , baseline, titration, washout, etc.
Personal Data Subject information collected by [CONTACT_201039]. This data includes subject identifier information, study 
information and biological samples.
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides 
evidence of preplanned analyses
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatmen t arm assignment
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether lymph nodes contain cancer, and whether the cancer has spread from the 
original site to other parts of the body
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, including placebo and 
active dr ug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combinat ion.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason

[COMPANY_001] Confidential Page 12
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Supportive treatment Refers to any treatment required by [CONTACT_140946] a study treatment, e.g., 
premedication of vitamin supplementatio n and corticosteroid for pemetrexed 
disodium.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified timepoints
Withdrawal of consent Withdrawal of consent from the study occurs only when a subject does not want to 
participate in the study any longer, and does not allow any further collection of 
personal data

[COMPANY_001] Confidential Page 15
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Updated to reflect addition of new Cohort 7
Section 5.1 Patient population
Updated to reflect the addition of Cohort 7 treatment -naïve patients with c MET mutation s
regardless of 
cMET GCN
Section 5.2 I nclusion criteria
Updated Criterion #[ADDRESS_742275] the inclusion of treatment-naïve patients with c MET 
mutation sregardless of cMET GCN in Cohort 7
Fixed a topographical error introduced with Protocol Amendment 5 which leads to 
renumbering of Inclusion Criteria
Section 6.1.1 Dosing regimen
Updated to reflect that similarly  to Cohort 6, there will be no food restriction for patients 
enrolled in Cohort 7
Section 6.4 Concomitant medications
Updated presentation of concomitant medications to be listed in only  one table with the 
most stringent practice of use  
Section 6.4.2 Permitted concomitant therap y requiring caution and/or action
Updated to reflect latest PK data on studies CI NC280A2108 b
ased on final anal ysis
Table 6- [ADDRESS_742276] stringent practice
Section 6.4.2 Prohibited concomitant therap y 
Table 6-6 updated to remove note and align with general change on concomitant 
medications use
Table 6-7 updated to remove note and align with general change on concomitant 
medications use
Section 6.5.2 Treatment assignment
Updated to reflect new Cohort 7 with inclusion of treatment -
naïve patients with c MET 
mutati onsregardless of cMET GCN
Table 7
-1Visit Evaluation Schedule
Updated tumor biopsy  requirement at pre -screening
Updated to correct the missing collection of diagnosis and extent of cancer at molecular 
pre-screening
 
Section [IP_ADDRESS] Tumor sample requirement
Updated to reflect use of tumor biopsy  for amplification and/or mutation status
Updated to include a possible request of additional tumor tissue retrospectively , if 
available, for development of future NGS c ompanion diagnostic

[COMPANY_001] Confidential Page 17
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Updated to clarify  PFS definition and censoring
Updated to add that Cohort 7 may  also be combined with Sub- cohort 5b 
Section [IP_ADDRESS] Outline of the data anal ysis
Updated to remove IHC assessments and related analy sis
Section [IP_ADDRESS].2 Basic tables, figures and listings
Updated to remove IHC assessments and related analy sis
Section 10.7 I nterim Analy sis
Updated to clarify  that no i nterim analy sis “for futility ”is planned for S ub-cohort s 5a and 
5b, Cohort 6 and 7
Section 10.8 Sample size calculation
Updated to reflect increase in overall patient sample size from 429 to 456 
based on new 
Cohort 7 and add number of patients in Cohort 7
Updated Table 10 -9 to add Operating Characteristics for Cohort 7
Updated wording to include the utility  of Cohort 6
Section 13 References 
Updated for new references used in updated sections
Additional revisions including editorial changes were made throughout the protocol.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board s
(IRBs)/Independent Ethics Committee s(IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Amendment 5 (13 -Feb -2018)
Amendment rationale
As of 09-Feb-2018, a total of [ADDRESS_742277] been enrolled in the study [54/69 patients in 
Sub-
cohort 1a [cMET gene cop y number (GCN ) ≥10]; 42/69 patients in Sub- cohort 1b 
(cMET GCN ≥ 6 and < 10); 54/69 patients in Cohort 2 (cMET GCN ≥ 4 and < 6); 30/69
patients in Cohort 3(cMET GCN < 4); 64/69 patients in Cohort 4 (cMET mutations 
regardless of cMET GCN ); 6/27 patients in Sub- cohort 5a (treatment naïve and cMET 
GCN ≥10); and 19/27 patients in Sub- cohort 5b (treatment naïve and cMET mutations 
regardless of cMET GCN )].
Cohort 3 (as of 31-Aug-2016) and Sub-cohort 1b/Cohort 2(as of 17-Nov-2016) have been 
closed due to futility  based on the planned interim anal yses as outlined in the protocol. 
As of 05-Dec- [ADDRESS_742278] successfull y passed the planned interim 
analysis for futility  and enrollment is continuing as planned. 
The main purpose of this amendment is :
1.To update the exclusion criteria, the list of prohibited medications, the list of medications 
to be used with caution and the criteria for dose modifications based on the latest INC280 
clinical data as per [Investigator’s Brochure edition 9] with primary  focus on:
Pneumonitis/ILD events that have been reported with I NC280 monotherap y
Results from the Clinical Pharmacology  Drug -Drug -Interaction studies 
[CINC280A2102] , [CINC280A2103] and [CINC280A2105]
2.To introduce a new expansion Cohort 6 for enrollment of approx im
ately  additional 30
patients with advanced NSCL Cpretreated 
with one prior line of systemic therapy
harbor ing either cMET amplification (GCN ≥10) or cMET mutation s(irrespective of 
cMET GCN) . The aim isto generate supportive safety  and efficacy  data in this second line 
patient population, which currentl y account sfor the majority  of patients enrolled in the 
respective 
Sub-Cohort 1a and C ohort [ADDRESS_742279] study  [CINC280A2108] prelimi nary results, w hich showed no 
positive food effect of high fat meal on INC280 exposure, I NC280 will be given to 
patients enrolled in Cohort [ADDRESS_742280] ions of the protocol were changed:
Protocol Summary : Updated to align with the amended protocol

[COMPANY_001] Confidential Page 19
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Section [IP_ADDRESS] Non- clinical experience
Updated “Nonclinical pharmacokinetics (PKs) and metabolism” and “Safety  
pharmacology  and toxicology ” with the most up to date information 
Section [IP_ADDRESS] Clinical experience
Updated “Clinical safet y and tolerability ”, “Clinical pharmacod ynamics” and “Clinical 
pharmacokinetics” with the most up to date information following the release of 
[Investigator’s Brochure edition 9]
Section 2.2 Rationale for the study  design
Updated to reflect the implementation of Cohort 6
Section 4.1 Description of study  design
Updated the patient sample size to [ADDRESS_742281] the inc lusion of Cohort 6
Updated to include a clarification regarding the availability  of EGFR and ALK status for 
treatment 
naïve patients potentially  eligible for Sub- cohort 5a and 5b
Updated to include additional anal yses planned due to the implementation of C ohort 6
Figure 4 -1 Overall study  Design
Updated to reflect the implementation of Cohort 6
Section 4.2 Timing of interim anal yses and design adaptations
Clarified that no interim anal ysis will be performed for Cohort 6
Section 5.1 Patient population
Updated to reflect the implementation of Cohort [ADDRESS_742282] 
failed 1 prior line of s ystemic therapy  for advanced/metastatic disease
Section 5.2 I nclusion Criteria
Inclusion Criterion #3 – Updated to reflect the implementation of Cohort 6 (inclusion of 
patients with either cMET GCN ≥ 10 without cMET mutation or cMET mutation 
regardless of cMET GCN). Also included a clarification regarding the availability  of 
EGFR and ALK status for treatment naïve patients. 
Inclusion Criterion #4 – Clarified that to be eligible for Cohort 6, patients must have failed 
one prior line of s ystemic therapy  for advanced/metastatic disease (stage IIIB or IV 
NSCL C).
Section 5.3 Exclusion Criteria 
Exclusion Criteria #11 –Updated to remove restriction for strong and moderate inhibitors 
of CYP3A4 based on the recent dat afrom Clinical Pharmacology  DDI studies .
Exclusion Criteria #16 –Updated to include Cohort 6
Exclusion Criteria #22 –Added a new eligibility  criterion to exclude patients with 
presence or history  of interstit ial lung disease or interstitial pneumonitis, including 
clinically  significant radiation pneumonitis (i.e., affecting activities of daily  living or 
requiring therapeutic intervention).

[COMPANY_001] Confidential Page 20
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Section 6.1.1 Dosing regimen
Updated to allow administration of INC280 with or without food for patients enrolled in 
Cohort 6 only
Table 6- 3 Criteria for interruption and re -initiation of INC280 treatment
Updated to mandate discontinuation of study  drug treatment for some adverse events with 
specified severit y
Updated to incl ude a section for Respi[INVESTIGATOR_565226] L ung Disease ( ILD)/Pneumonitis
Table 6- 4 Follow -up evaluations for selected toxicities
Updated to include a section on Respi[INVESTIGATOR_565227] c guidance on 
follow up of ILD/Pneumonitis
Section 6.4 Concomitant medications
Updated to further stress out that for medications listed in more than one table the more 
stringent practice is to be applied (that is, the medication is prohibited) . Drugs that appear 
in more than one table are underlined and bolded.
Section 6.4.2 Permitted concomitant therap y requiring caution and/or action
Updated  permitted concomitant therapy  based on most recent data
Table 6- [ADDRESS_742283] recent data
Section 6.4.3 Prohibited concomitant therap y
Updated section based on most recent data
Table [ADDRESS_742284] 
recent data
Table 6- [ADDRESS_742285] recent data
Section 6.5.2 Treatment assignment
Update dto reflect the addition of Cohort 6
Section 7.1.2 Screening
Updated to clarify  re-testing and re -screening 
Table 7
-6 ECG collection plan for remaining patients, including patients in Cohort 6
Updated to include Cohort 6
Table 7-8 Pharmacokinetic blood collection log for remaining patients, including patients in 
Cohort 6
Updated to include Cohort 6

[COMPANY_001] Confidential Page 21
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
 
Section 8.1.[ADDRESS_742286]
Updated to include adverse events of special interest to be monitored in alignment with 
the recently  released 
[Investigator’s Brochure edition 9]
Section 10 Statistical methods and data analy sis
Updated to reflect the inclusion of Cohort 6
Clarified that no interim analysis is planned for Cohort 6
Section 10.4.2 Statistical hy pothesis, model, and method of anal ysis
Provided clarification regarding the null hy
pothesis rejection
Section 10.4.4 Supportive anal yses
Updated to reflect the additional analy sis as result of inclusion of Cohort 6
Section 10.5.2 Other s econdary  efficacy  objectives
Updated to reflect the additional analy sis as result of inclusion of Cohort 6
Section 10.8 Sample size calculation 
Updated the patient sample size to [ADDRESS_742287] the  inc lusion of Cohort 6 
Updated to include Cohort 6 samples size
Section 13 References
Updated the reference list
Additional revisions including editorial changes were made throughout the protocol.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are requir ed to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 22
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Amendment 4 (17-Nov -2016)
Amendment rationale
As of 15-Nov-2016, a total of [ADDRESS_742288] been enrolled in the study [19patients in 
Cohort 1a(GCN ≥10) ; 42patients in Cohort 1b (GCN ≥ 6 and < 10); 54 patients in Cohort 2
(
GCN ≥ 4 and < 6); 30 patients in Cohort 3(GCN < 4); and 12patient sin Cohort 4 (cMET 
exon 14 skippi[INVESTIGATOR_565228])].
As of 30-Aug-2016, Cohort 3 has been suspended due to futili ty based on the planned interim 
analyses as outlined in the protocol .No new safety  signal for INC280 has been observed
.
The main purpose of this amendment is toimplement a new Cohort 5 to investigate the safety  
and antitumor activity  of INC280 in treatme nt-naïve patients foradvanced/metastatic disease 
(stage IIIB or IV) NSCLC harboring cMET exon 14 skippi[INVESTIGATOR_86040] s(regardless of cMET 
amplification) or very  high cM ET gene amplification (GCN ≥ 10 without cMET mutations).
Increasing data confirm thatcMET dysregulations such as cMET exon 14 skippi[INVESTIGATOR_565229] s
of response to cMET inhibition in NSCL C patients, irrespective of the number of prior lines 
of therapy  including some preliminary  evidence inthe treatment -naïve setting (Frampton 
2015, Jenkins 2015 , Mendenhall 2015, Paik 2015 , Waqar 2015 , Liu 2015 , Schuler 2016, 
Drilon 2016
).
Promising activity  with INC280 in cMET dysregulated (either cMET amplified or cMET 
exon 14 skippi[INVESTIGATOR_565228]) advanced NSCL C has been observed in the phase I study 
[CINC280X2102] (Schuler 2016). In patients with cMET amplified (GCN ≥6) NSCL C ,a 
47% Overall Response Rate (ORR) and amedian Progression Free Survival (PFS) of 7.4 
months w erereported .
While these promising results were obtained mainly  in pretreated patients, three patients (who 
declined chemotherap y) were enrolled as treatment -naïve. Two of these patients harbored 
cMET exon 14 skippi[INVESTIGATOR_86040] (one had concurrent cMET amplification). Both patients 
gained benefit from INC280 treatment (tumor shrinkage -53.3% and -48.5%) ,one achie ving 
confirmed response. This result was consistent with the overall benefit gained by [CONTACT_565278]  (pretreated with 1 and 3 prior lines of 
systemic therap y, respectively )with 3 out of 4 in cMET mutated patients achieved confirme d 
partial responses . Overall, INC280 was well tolerated in both treatment -naïve and pretreated 
NSCL C patients.
Additional preliminary  activity  in NSCL C patients harboring cMET mutations, including in 
the treatment -naïve setting, has been reported with another cMET inhibitor (crizotinib). 
Overall [ADDRESS_742289] been treated and 8 out of 18 evaluable patients (44%) 
achieved a confirmed partial response, including at least 1 of the 3 treatment -naïve patients 
enrolled ( Drilon 2016).
While the data are still preliminary , cMET exon 14 skippi[INVESTIGATOR_565230]/or high cMET 
gene amplification are emerging as independent tumor drivers . Patients harboring such cMET 
dysregulations can benefit from treatment with cMET inhibitors such as INC280, irrespective 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
of prior lines of therapy ,and including treatment -naïve patients, with acceptable safet y profile. 
This concept was successfully  confirmed in the treatment -naïve advanced NSCL C setting 
with other targeted agents directed against established molecular drivers such as EGFR 
mutation, ALK and ROS1 translocation ,which demonstrated greater efficacy  when compared 
with platinum -doublet chemotherap y (Rosell [ADDRESS_742290] 2013, Solomon 2014 ). These data 
also confirmed that the safet y profile of such targeted agents does not differ in the treatment -
naïve setting compared to the pretreated setting.
There is no cMET inhibitor currently  approved for cMET dysregulated NSCL C and the 
activity  of platinum- based chemotherap y in patients with treatment -naïve advanced NSCL C 
harboring cMET exon 14skippi[INVESTIGATOR_565230]/or high level of cMET amplification (GCN 
≥10) is unknown.
In the current [CINC280A2201] study  design, NSCL C patients with very high cMET 
amplification (GCN ≥ 10) or cMET exon 14 skippi[INVESTIGATOR_86039] (regardless of GCN) are 
eligible for enrollment in Cohort 1 (Sub- cohort 1a) and Cohort 4 (respectivel y), only if 
previously  treated with 1 or 2 prior lines of systemic therapi[INVESTIGATOR_014]. Therefore, to ensure a proper 
assessment and adequate representation of treatment -naïve NSCL C patients in advanc ed 
setting harboring very high cMET amplification (GCN ≥10) and/or cMET mutation, an 
additional cohort (Cohort 5) is being implemented as follows:
Cohort 5: 
Treatment -naïve patients with cMET d ysregulation 
Sub-cohort 5a : Patients with a cMET GCN ≥10(without cMET mutations)
Sub-cohort 5b: Patients with c MET mutations regardless of cMET GCN
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The following sec tions of the protocol were changed:
Protocol Title: updated to reflect the new stud y design
Protocol Summary : Updated to align with the amended protocol
Section 2.2 Rationale for the study  design
Updated to include rationale for changes in stud y design: the implementation of Cohort 5 
for inclusion of patients who are treatment -naïve for advanced/metastatic disease in 2 Sub-
cohorts (5a 
-patients with cMET GCN of ≥10, 5b -patients with cMET mutations 
regardless of cMET GCN)
Table 3-1 Objectives and related endpoints
Updated Other secondary objective #4 to align with the inclusion of treatment -naïve 
patients
Section 4.1 Description of study  design
Updated the patient sample size to [ADDRESS_742291] the inclusion of treatment -naïve patients for 
advanced/metastatic disease in Cohort 5 with the2 Sub-cohorts (5a -patients with cMET 
GCN of ≥10and5b -patients with cMET mutations regardless of cMET GCN )

[COMPANY_001] Confidential Page 24
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Updated to include an option for central pre -screening by  [CONTACT_077], if assay  becomes available 
Updated to clarify  that EGFR wt must be documented in the patient source documents 
before patient c an be consented for molecular pre-screening ,except if performed by  [CONTACT_565279]
Updated to clarify  that patients with previously  determined cMET mutation or 
amplification by  a [COMPANY_001] designated central labo
ratory  (as detected by  a validated NGS 
assay ), will be allowed to enter the screening phase of the INC280A2201 study
Added that all efficacy  analy ses for Cohort 5 will also be performed separately  for each of 
the 2 Sub- cohorts ,similar to Cohort 1
Added that no interim analy sis will be performed for Cohort 5
Simplified language on when primary  anal ysis will be performed
Updated to include the ORR that will be considered sufficiently  efficacious in treatment -
naïve setting (Cohort 5) and included 2 hy pothese s testing for Sub- cohorts 5a and 5b
Figure 4 -1Overall study  Design
Updated to reflect the implementation of Cohort 5 with Sub- cohorts 5a and 5b
Secti on 4.2 Timing of interim anal yses and design adaptation
Clarified that no interim anal ysis will be performed for Cohort 5
Section 5.1 Patient Population
Clarified that for eligibility  in Cohort 5, patients should not have received systemic 
therap yfor advanced/metastatic disease
Section 5.2 Inclusion Criteria
Inclusion Criterion #3 – Updated to reflect the implementation of Cohort 5 to allow 
inclusion of tre atment -naïve patients for advanced/metastatic disease as 2 Sub-cohort s(5a 
-patients with cMET GCN of 
≥10, 5b - patients with cMET mutations regardless of 
cMET GCN )
. Updated to clarify  that EGFR wt must be documented in the patient source 
documents before patient can be consented for molecular pre
-screening, except if 
performed b y NGS and local status is not available
Inclusion Criterion #4 – Updated to include criteria for eligibility  of the treatment- naïve 
patients for advanced/metastatic disease
Exclusi on Criterion #16 – update to clarify that this criterion willapply  only  forpatients in
Cohorts 1-4
Section 6.5.2 Treatment assignment
Updated to reflect the implementation of Cohort 5 for treatment -naïve patients for 
advanced/metastatic disease as 2 Sub-cohort s(5a -patients with cMET GCN of ≥10 , 5b -
patients with cMET mutations regardless of cMET GCN
)
Table 7-1 Visit evaluation schedule
Updated to c larify  that information on prior local testing for cMET amplification and 
cMET mutation may include prior c entral NGS result s, if applicable

[COMPANY_001] Confidential Page 26
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Section 13 References
Updated the reference list
Additional revisions including editorial changes were made throughout the protocol.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 27
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Amendment 3 (28 -Jul-2016)
Amendment rationale
As of 20- Jul-2016, a total of [ADDRESS_742292] been enrolled in the stud y.
The main purpose of this amendment is to:
Further investigate and better characterize the optimal GCN as predictor of response to 
INC280 b y implementing two sub- cohorts within the high cMET amplified Cohort 1 
[gene copy number (GCN) ≥ 6]
Remove the restrictions on the use of proton pump inhibitors (PPI s) as concomitant 
medications
Changes to implement two sub -cohorts within the high cMET amplified Cohort 1
Emerging data from the ongoing phase I study  [CINC280X2102] firmly  supports that there is 
activity  of single agent INC280 in cMET dy sregulated NSCL C, especially  in NSCL C patients 
with high cMET amplification and cMET exon 14 skippi[INVESTIGATOR_86039] ( Schuler 2016).
In the 15 patients with cMET GCN ≥6, who had at least one post baseline tumor assessment 
orwho haddiscontinued study  treatment early, confirmed partial responses were seen in 7/15 
patients [Overall Response Rate (ORR) 47%, Disease Control Rate (DCR) 80% and Kaplan –
Meier median Progression Free Survival (PFS) 7.39 months (95% CI 3.84
–22.11)]. Three out 
of these 7 confirmed responders per local assessment had very high cMET gene amplification 
(GCN ≥10) ;however, 2 of these responders also harboured a concurrent cMET exon 14 
skippi[INVESTIGATOR_86040]. Therefore, based on this data generated from the [CINC280X2102] study , 
thesingle contribution of the very high cMET amplification to the response of INC280 still 
remains to be elucidated and further optimization of appropriate GCN cut off is warranted .
Currently  in the CINC280A2201 study , 
patients with high cMET amplified NSCL C defined 
as GCN ≥ 6 are being enrolled in Cohort 1, while NSCL C patients harboring cMET exon 14 
skippi[INVESTIGATOR_86039] (irrespective of the level of cMET amplification) are enrolled in Cohort 4. 
While detailed epi[INVESTIGATOR_565231], the prevalence of cMET amplification in 
NSCL C is known to diminish with the increase in GCN (Schildhaus 2014). With the 
emerging data, the assumption that patients with higher GCN may derive greater benefit from 
cMET inhibition with higher chance ofresponse to treatment require further more robust 
exploration . 
To ensure an adequate representation and proper assessment of NSCL C patients 
with very high amplified disease and to avoid the uneven enrichment in the lower GCN range 
of this cohort, the following 2 sub -cohorts are being implemented within Cohort 1:
Cohort 1: Patients with a cMET GCN of ≥ 6
Sub-cohort 1a: Patients with a cMET GCN of ≥ 10, or
Sub-cohort 1b: Patients with a cMET GCN of ≥ 6 and <10
Each of the two sub-cohorts will be tested independentl y. Thischange will allow to 
adequatel y assess the indi vidual contribution of the two GCN ranges to the activity  of INC280 
in Cohort 1 patients and to assess the likelihood of differential response at the high amplified 
range as previousl y suggested by [CONTACT_565280] (2014) .

[COMPANY_001] Confidential Page 28
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The category  of GCN ≥ [ADDRESS_742293] extensive analy sis ever conducted in 11,205 lung cancer specimens (Ou 2016 ). 
Interestingly , in this study  the overlap of amplification with cMET exon 14 skippi[INVESTIGATOR_86040], 
which is still a matter of debate, was lower at theGCN ≥ 10 range compared with the one 
observed at thelower GCN cut offs (Awad 2016 , Tong 2016). Similarly , very high cMET 
amplified tumor samples are expected to be mutually  exclusive to RTK/RAS/PI 3K driver 
events ( Tong 2016
).
Removing restrictions on the concomitant use of proton pump inhibitors (PPIs)
Current clinical data supports the concomitant administration of I NC280 with PPI s. 
INC280 is known to exhibit a pH -dependent solubility  profile with a low solubility  at high pH 
level s
(Section 3.1 in the current INC280 Investigator’s Broc hure) . A study  to evaluate the 
effect of a proton pump inhibitor on the PK of a single dose of INC280 tablet (600 mg) was 
completed in healthy  volunteers [CINC280A2101] .Daily  treatment of [ADDRESS_742294] reduction in the 
extent of INC280 absorption with a 25.2% 
decrease in AUCinf and a 37.5% decrease in Cmax. Considering the 42% and 65% variability  
in AUC observed in patient streated in single agent studies [CINC280X2102] and 
[CINC280X1101] , respectively, a decrease of approximately  25% in AUC of INC280 when 
administered with a proton pump inhibitor (PPI) is not considered clinically  significant. 
Preliminary  data in NSCL C patients [CINC280X2202] indicated that maintaining plasma 
trough conce ntrations above certain threshold over time was required for efficacy . In the 
proton pump inhibitor DDI study , the impact on the 12-hour post-dose concentration of 
INC280 (defined as trough 
concentration for BID dosing) was minimal with only a ~7% 
reduction after rabeprazole treatment. Therefore, the concomitant use of PPIs is unlikely  to 
have an impact on the efficacy  of INC280, and the PPI [INVESTIGATOR_565232] a concomitant 
medication can be removed from this protocol for patients requiring PPI [INVESTIGATOR_565233]. 
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following sections of the protocol were changed:
List of abbreviations: Updated to align with the amended protocol
Protocol Summary : Updated to align with the amended protocol
Section [IP_ADDRESS].2 Nonclinical Pharmacokinetics (PKs) and metabolism
Update to include the brain to blood ratio of approximately  0.1
Section [IP_ADDRESS].1: Clinical Safety  and Tolerability
Updated to align with the current INC280 Investigator’s Brochure 
Section [IP_ADDRESS].2 Clinical Efficacy
Updated to align with most recent data as of 15 -Mar-2016 from the INC280X2102 study
Section [IP_ADDRESS].4: Clinical Pharmacokinetics:

[COMPANY_001] Confidential Page 29
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Updated with the most recent PK data available as of 28-Sep-2015
Updated with the most recent available clinical data from CINC280A2101 detailing the 
effect of PPI s on the PK of a single dose of INC280 
Updated with the most recent available clinical data from CINC280X2107 detailing the 
food effect on the rate and extent of I NC280 exposure. 
Section 2.2. Rational for the study  design
Updated to include rationale for the changes in study  design: the implementatio n of 2 sub
-
cohorts within Cohort 1 (1a -cMET GCN ≥ 10, 1b -cMET GCN ≥ 6 and < 10)
Table 3- 1 Objectives and Endpoint
Updated objectives to include sub-cohorts (where applicable) 
Section 4.1 Description of Study  Design
Updated thepatient sample size to 345patients from [ADDRESS_742295] theimplementation of Sub-cohorts 1a and 1b 
within Cohort 1
Clarified that separate efficacy  anal yses for Sub- cohort 1a and 1b will be performed
Clarified that the primary anal ysis for any  cohort that was stopped for futility  may  be 
combined with the primary  anal yses for other cohorts that were not stopped for futility
Updated h ypothesis testing to [ADDRESS_742296] the implementation of Sub-cohorts 1a 
and 1b within Cohort 1
Figure 4 -1 Overa ll study  Design
Updated to reflect the implementation of Sub -cohort 1a and 1b within Cohort 1
Section 4.2 Timing of interim anal yses and design adaptations
Updated to reflect the implementation of Sub-cohort 1a and 1b within Cohort 1
Section 5.1 Patient Population
Clarified that for eligibility in Cohort [ADDRESS_742297] failed (versus received) one 
or two prior lines of s ystemic therapy
Section 5.2 I nclusion Criteria
Inclusion Criterion #3 – Updated to include Sub -cohort 1a and 1b within Cohort 1
Inclusion Criterion #4 – clarified that patients must have failed (versus received) 1 or 2 
lines of prior therap y and added “Treatment failure is defined as documented disease 
progression or intolerance to treatment”
Inclusion Criterion #7 –corrected the conversion of glucose 175mg/mL  from 9.8mmol/L  
to 9.7mmol/L .
Section 5.3 Exclusion Criteria
Exclusion Criterion #7 –removed the exception that was allowing patients enrollment 
with indolent malignancies that currently  do not require treatment
Exclusion Cr iteria #11 
– removed proton pump inhibitors (PPI) from the list of prohibitive 
medications

[COMPANY_001] Confidential Page 32
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Amendment [ADDRESS_742298] patient 
treated on 16- Jul-2015. 
The main purpose of this amendment is to implement a fourth cohort (Cohort 4) to the study  
design in light of the emerging data showing that NSCL C patients harboring cMET mutations 
can benefit from the treatment with cMET inhibitors. Moreover the amendment will also 
provide an update onINC280 safet y data aligning with the most current edition of the 
Investigator’s Brochure. 
Changes to the study design
Since the release of the last Amendment 1,cMET mutatio ns leading to exon 14 deletion 
[referred to as cMET mutation(s) hereafter] have been identified as an additional actionable 
target for cMET inhibition in NSCL C and promising preliminary  efficacy  data have been 
published with cMET inhibitors, including INC280, in this setting (Paik 2015, Jenkins 2015, 
Waqar 2015, Mendenhall 2015, Frampton 2015, Liu 2015). With this Amendment 2, Cohort [ADDRESS_742299] be determined at a 
[COMPANY_001] -designated central laboratory  along with their cMET amplification status. Patients 
with cMET mutations will be enrolled in Cohort 4, irrespective of their cMET amplification 
status, while patients without cMET mutations will be enrolled in Cohorts 1-3 based on their 
cMET amplification status. For patients already  enrolled 
in the study  prior to the 
implementation of this amendment, the cMET mutation status will be determined 
retrospectivel y; however these patients will remain in the cohort to which they were initiall y 
enrolled. Sensitivity  analysis on the primary  endpoint where patients with cMET mutations 
will be exclud edfrom Cohorts 1, 2 and 3 may  also be performed.
Changes r elated to INC280 safety
Concurrent elevation of ALT and/or AST and total bilirubin: After 28-Sep-2014 (cut-off 
date of the current [Investigator’s Brochure, edition 5.2]
), a  patient experienced a 
serious, unexpected, possibly  related adverse event of abnormal liver function tests during 
treatment with a combination of INC280 and gefitinib while enrolled in the study 
[CINC280X2202 ]
. The investigator assessed the adverse event suspected to be related to the 
combination of INC280 and gefitinib. This adv erse event met the criteria of Hy ’s Law and the 
hepatotoxicity  could not be attributed solel y to either drug alone or to the combination.
The protocol is therefore being amended to modify the existing dose modifications guidelines 
for hepatotoxicity  in regard to discontinuing study  medication(s) with concurrent elevation of 
ALT and/or AST > 3 × ULN and total bilirubin > 2 × ULN with ALP < 2 × ULN, in the 
absence of signs of cholestasis, hemoly sis, and alternat ive causes of the liver injury  [e.g., 
concomitan t use of hepatotoxic drug(s), alcoholic hepatitis, etc.]. Specific work -up guidelines 
for potential Drug Induc ed Liver Injury  (DILI) cases have also been added to the protocol. 
The dose modification rules as well as the follow -up evaluations for hepatic toxicities have 
also been updated accordingl y.

[COMPANY_001] Confidential Page 38
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Amendment [ADDRESS_742300] should be part of the non-squamous NSCL C patient’s 
standard of care, such as the EGFR mutation testing.
Therefore along with the EGFR molecular status, also the ALK rearrangement status should
be documented in the source document of 
all patients enrolled in this study . The inclusion 
criterion [ADDRESS_742301] be 
determined at a [COMPANY_001] -designated central laboratory .
Changes to the protocol
The following sections of the protocol were changed:
Protocol Summary  Table, Section 2.2, Section 4.1, Section 5.1, Section 5.2, Section 5.3, 
Table [ADDRESS_742302] along with their cMET amplificati
on status.
Section 4.1.2, updated to indicate that the ALK rearrangement status will be determined 
centrall y
,as applicable.
Section 5.1, updated to indicate that patients with ALK -negative rearrangement should be 
enrolled.
Section 5.2, inclusion criterion 3 updated to include that patients with ALK -negative 
rearrangement should be enrolled and ALK rearrangement status should be documented and if 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
local ALK testing is not available, the status will be determined centrall y with a validated test 
along with the cMET amplification status.
Section 5.3, exclusion criterion 4 added to indicate that patients with ALK -positive
rearrangement are excluded.
Table 7-1, updated to indicate that confirmation of ALK -negative rearrangement status is 
required at pre -screening and to clarify sample requirement for ALK testing, as applicable.
Section [IP_ADDRESS], tumor sample requirement added for ALK testing, as applicable.
Section 
[IP_ADDRESS], data collection updated to include that ALK rearrangement status will be 
collected.
Section [IP_ADDRESS], tumor sample requirement added for ALK testing, as applicable.
Table [ADDRESS_742303] 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. The changes herein affect the Informed Consent. Sites are required to update 
and submit for approval a revised Informed Consent that takes into account the changes 
described in this protoco l amendment.

[COMPANY_001] Confidential Page 40
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Protocol summary  
Protocol number CINC280A2201
Title A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with 
EGFR wild-type (wt), advanced non -small cell lung cancer (NSCLC) 
Brief title Study of oral cMET inhibito r INC280 in patients with EGFR wild-type (wt), advanced 
non-small cell lung cancer (NSCLC)
Sponsor and Clinical 
Phase[COMPANY_001], Phase II
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale Currently, there is no approved therapy for tumors with cMET dysregulations 
(mutations/amplification/overexpression). INC280 is an orally bioavailable, highly 
potent and selective cMET inhibitor in biochemical and cellular assays and capable of 
blocking cMET activation. Pre -clinical and early clini cal data showed single-agent 
antitumor activity with a manageable safety profile in NSCLC with cMET mutations 
and/or amplification and/or overexpression.
Primary  Objective(s) 
and Key  Secondary  
ObjectivePrimary objective: To demonstrate the antitumor acti vity of INC280, as measured by 
[CONTACT_34426] (ORR) by [CONTACT_565281] (BIRC) 
assessment , by [CONTACT_9084] /sub-cohort
Key secondary objective: To evaluate duration of response (DOR) as assessed by 
[CONTACT_14988] , by [CONTACT_9084] /sub-cohort
Secondary  Objectives Objective 1: To evaluate ORR and DOR by [CONTACT_3138] , by [CONTACT_9084] /sub-
cohort
Objective 2: To evaluate time to response (TTR), disease control rate (DCR) and 
progression -free survival (PFS) by [CONTACT_565282] , by 
[CONTACT_9084] /sub-cohort
Objective 3: To evaluate overall survival (OS) , by [CONTACT_9084] /sub-cohort
Objective 4: To evaluate INC280 safety profile as monotherapy in NSCLC patients 
withadvanced/metastatic disease
Objective 5: To characterize the pharmacokinetics of INC280 
Study  design This is aprospectively designed ,multicenter, open -label, phase II study of single -
agent INC280. Patients with stage IIIB or IV EGFR wt (for exon 19 deletions and exon 
21 L858R substitution mutations) and ALK-negative rearrangement NSCLC will be 
pre-screened for cMET amplification and mutation status . Enrolled patients will be 
assigned to seven cohorts . All patients in Cohort s 1, 2, 3, and [ADDRESS_742304] failed 1 or 
2 prior lines of systemic therapy for advanced/metastatic disease . Patients enrolled in 
Cohort 5and Cohort [ADDRESS_742305] be treatment-naïve for advanced/metastatic disease .
Patients enrolled in Cohort [ADDRESS_742306] failed 1 prior line of systemic therapy for 
advanced/metastatic disease .Patients with cMET mutation swill be enrolled in Cohort
4, Sub- cohort 5b, and Cohort 7irrespective to their cMET GCN. Patients without 
cMET mutations will be enrolled in Cohorts 1-3and Sub-cohort 5a,based on their 
cMET GCN . Cohort 6 will enroll patients with advanced NSCLC harboring either cMET 
amplificatio n (GCN≥10) or cMET mutations (irrespective of cMET GCN). Patients will 
be eligible for enrollment in Cohort 6 only upon enrollment completion of the 
respective Sub -cohort 1a or Cohort 4.
Study  cohort summary :
Cohort 1: P re-treated p atients with cMET gene c opy number (GCN) ≥ 6,including :
Sub-cohort 1a: Patient s with a cMET GCN ≥10,or
Sub-cohort 1b: Patients with a cMET GCN ≥ 6 and < 10, or
Cohort 2: P re-treated p atients with cMET GCN ≥ 4and < 6, or
Cohort 3: P re-treated patients with cMET GCN < 4 ,or
Cohort 4: P re-treated patients with cMET m utations regardless of cMET GCN , or
Cohort 5: Treatment-naïve p atients with cMET dysregulation , including:
Sub-cohort 5a: Patients with a cMET GCN ≥10, or

[COMPANY_001] Confidential Page 42
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Association for the Study of Lung Cancer, and Association for Molecular 
Pathology (Lindeman et al 2013 ). The EGFR wild-type status (for exon 19 
deletions and exon 21 L858R substitution mutations) must be documented in 
the patient source documents before the patient can be consented for pre-
screening for cMET amplification and cMET mutation status (except for 
patients who are treatment-naïve potentially eligible forSub-
Cohort s5a, 5b
and Cohort 7orif molecular pre-screening will be performed by [CONTACT_565283]) . Patients with NSCLC of pure squamous cell 
histology can enter pre-screening without EGFR mutation testing or result ;
however patients with pure squamous cell histology and are known to have 
EGFR mutation s in exons 19 or 21 will be exc luded,
AND ALK rearrangement negative . This should have been assessed as part 
of the patient standard of care by a validated test. The ALK rearrangement 
negative status must be documented in the patient source documents before 
the patient can be consented for pre-screening for cMET amplification , 
except for patients who are treatment -naïve potentially eligible for Sub-
Cohort s5a, 5b and Cohort 7; if local ALK testing is not available, patient 
status will be determined centrally along with the cMET status. Patients with 
NSCLC of pure squamous cell histology can enter pre -screening without ALK 
testing or result, however patients with pure squamous cell histology that are 
known to have ALK rearrangement will be excluded .
AND (as determined by [CONTACT_565284] a [COMPANY_001] designated 
laboratory )either: 
Cohort 1: Pre-treated p atien ts with cMET GCN ≥ 6, including: 
Sub-cohort 1a: Patients with cMET GCN ≥ 10,or
Sub-cohort 1b: Patients with cMET GCN ≥ 6 and < 10 ,or
Cohort 2: Pre-treated p atients with cMET GCN ≥4 and < 6, or
Cohort 3: Pre-treated p atients with cMET GCN < 4 , or
Cohort 4: Pre-treated p atients with cMET mutations regardless of cMET 
GCN , or
Cohort 5: Treatment-naïve patients with cMET dysregulation, including: 
Sub-cohort 5a: Patients with cMET GCN ≥ 10, or
Sub-cohort 5b: Patients with cMET mutations regardless of cMET 
GCN, or
Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET 
mutations or cMET mutations regardless of cMET GCN
Cohort 7: Treatment- naïve patients with cMET mutations regardless of cMET 
GCN
cMET (and ALK, if applicable) testing may be perfor med while patient is still 
receiving anti-cancer therapy. However, the patient can only be screened for the 
main study once the patient has discontinued the last prior systemic treatment 
due to either disease progression or intolerance .
To be eligible for Cohort s 1-4,patients must have failed one or twoprior lines of 
systemic therap yfor advanced/metastatic disease (stage IIIB or IV NSCLC). To 
be eligible for Cohort 6, patients must have failed one prior lineof systemic 
therapy for advanced/metastatic disease (stage IIIB or IV NSCLC). Treatment 
failure is defined as documented disease progression or intolerance to treatment.
Maintenance therapy given after 1stline chemotherapy will be considered as part 
of the 1stline if given to patients with document ed response or stable disease 
before starting the maintenance therapy. Neo-adjuvant and adjuvant systemic 
therapi[INVESTIGATOR_565234] [ADDRESS_742307] received any 
systemic therapy for advanced/metastatic disease (stage IIIB or IV NSCLC). Neo -
adjuvant and adjuvant systemic therapi[INVESTIGATOR_565235] > 12 months from the end of the neo-adjuvant or 
adjuvant systemic therapy .

[COMPANY_001] Confidential Page 43
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
At least one measurable lesion as defined by [CONTACT_393] 1.1. A previously irradiated 
site lesion may only be counted as a target lesion if there is clear sign of 
progression s ince the irradiation.
Patients must have recovered from all toxicities related to prior anticancer 
therapi[INVESTIGATOR_252361] ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are 
allowed to enter the study.
Patients must have adequate organ function includi ng the following laboratory 
values at the screening visit:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/Lwithout growth factor support
Platelets ≥ 75 x 109/L
Hemoglobin (Hgb) > 9g/dL
Calculated creatinine clearance (using Cockcroft -Gault formula) ≥45 mL/ min
Total bilirubin ≤1.[ADDRESS_742308]
Aspartate transaminase (AST) ≤[ADDRESS_742309] ≤[ADDRESS_742310]
Alanine transaminase (ALT) ≤[ADDRESS_742311], except for patients with liver 
metastasis, who may only be included if ALT ≤[ADDRESS_742312]
Alkaline phosphatase (ALP) ≤ [ADDRESS_742313]
Asymptomatic serum amylase ≤ grade 2. Patients with grade [ADDRESS_742314] no 
signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g.,
elevated P -amylase, abnormal imaging findings of pancreas, etc.)
Serum lipase ≤ULN
Fasting plasma glucose ≤ 175 mg/dL (≤ 9.7 mmol/L)
Patients must have the following laboratory values within the laboratory 
normal limits or correcte d to within normal limits with supplements during 
screening:
Potassium
Magnesium 
Phosphorus 
Total calcium (corrected for serum albumin) 
ECOG performance status (PS) of 0 or 1
Willing and able to comply with scheduled visits, treatment plan and laborator y 
tests
Exclusion criteria Prior treatment with crizotinib, or any other cMET or HGF inhibitor
Patients with known hypersensitivity to any of the excipi[INVESTIGATOR_252362]280
(crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl 
sulfate, ma gnesium stearate, colloidal silicon dioxide, and various coating 
premixes)
Patients with characterized EGFR mutations that predict sensitivity to EGFR 
therapy, including, but not limited to exon 19 deletions and exon 21 mutations
Patients with characteriz ed ALK-positive rearrangement
Patients with symptomatic central nervous system (CNS) metastases who are 
neurologically unstable or have required increasing doses of steroids within the 2 
weeks prior to stu dy entry to manage CNS symptoms
Presence or hist oryof carcinomatous meningitis
Presence or history of a malignant disease other than NSCLC that has been 
diagnosed and/or required therapy within the past 3 years. Exceptions to this 
exclusion include the following: completely resected basal cell and squamou s cell 
skin cancers, and completely resecte d carcinoma in situ of any type
Clinically significant, uncontrolled heart diseases such as:
Unstable angina within 6 months prior to screening
Myocardial infarction within 6 months prior to screening

[COMPANY_001] Confidential Page 44
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
History of documented congestive heart failure ([LOCATION_001] Heart Association 
functional classification III -IV)
Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 
mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without 
antihyperte nsive medication. Initiation or adjustment of antihypertensive 
medication (s) is allowed prior to screening
Ventricular arrhythmias
Supraventricular and nodal arrhythmias not controlled with medication
Other cardiac arrhythmia not controlled with medicatio n
QTcF ≥ 450 ms (male patients), ≥ 460 ms (female patients) on the screening 
ECG (as mean of triplicate ECG)
Thoracic radiotherapy to lung fields ≤ [ADDRESS_742315] not recovered from radiotherapy -related toxicities. For all other 
anatomic sites (including radiotherapy to thoracic vertebrae and ribs), 
radiotherapy ≤ [ADDRESS_742316] not 
recovered from radiotherapy -related toxicities. Palliative radiotherapy for bone 
lesions ≤ 2 weeks prio r to starting INC280 is allowed
Major surgery (e.g., intra -thoracic, intra -abdominal or intra -pelvic) within 4 weeks 
prior (2 weeks for resection of brain metastases) to starting INC280 or who have 
not recovered from side effects of such procedure. Video-ass isted thoracic 
surgery (VATS) and mediastinoscopy will not be counted as major surgery and 
patients can be enrolled in the study ≥1 week after the procedure
Patients receiving treatment with medications that meet one of the following 
criteria and that cannot be discontinued at least 1 week prior to the start of 
treatment with INC280 and for the duration of the study:
Strong indu cers of CYP3A4
Impairment of GI function or GI disease that may significantly alter the absorption 
of INC280 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarr hea, or 
malabsorption syndrome)
Unable or unwilling to swallow tablets as per dosing schedule
Patients receiving unstable or increasing doses of corticosteroids. If patients are 
on corticosteroids for endocrine deficiencies or tumor -associated symptoms other 
than CNS related, dose must have been stabilized (or decreasing) for at least [ADDRESS_742317] dose of INC280
Patients receiving treatment with any enzyme -inducing anticonvulsant that cannot 
be discontinued at least [ADDRESS_742318] dose of INC280, and for the duration 
of the study. Patients on non -enzyme -inducing anticonvulsant s are eligible
Applicable to C ohort s 1-4 and Cohort 6 only: Previous anti -cancer and 
investigational agents within 4 weeks or ≤ 5x half -life of the agent (whichever is 
longer) before first dose of INC280. If previous treatment is amonoclonal 
antibody, then the treatment must be discontinued at least [ADDRESS_742319] 
dose of INC280
Other severe, acute, or chronic medical or psychotic conditions or laboratory 
abnormalities that in the opi[INVESTIGATOR_565236], or that may interfere with the interpretation of 
study results
Any other condition that would, in the Investigator’s judgment, contraindicate 
patient’s participation in the clinical study due to safety con cerns or compliance 
with clinical study procedures, e.g., infection (including active hepatitis B and C ), 
inflamma tion, intestinal obstruction, unable to swallow med ication, social/ 
psychological issues, etc.
Pregnant or nursing (lactating) women
Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective contraception during 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Data Anal ysis to Address Other Objectives:
ORR will be analyzed per investigator assessment by [CONTACT_9084] /sub-cohort . 
Other secondary efficacy assessments (DOR, TTR, DCR, PFS) will be analyzed as 
per investigator assessment and as per BIRC by [CONTACT_9084] /sub-cohort . Confirmation of 
response is required for all response endpoints, as per RECIST 1.1.
DOR, PFS and OS will be described by [CONTACT_565285] -Meier methods, including 
estimated median (in months) with 95% CI, 25th and 75th percentiles and Kaplan -
Meier estimated probabilities with corresponding 95% CIs at several time points. 
The assessment of safety will be based mainly on the frequency of adverse events 
and on the number of laboratory values that fall outside of pre-determined ranges. 
Other safety data (e.g., electrocardiogram, vital signs) will be considered as 
appropriate. The safety summary tables will include only assessments collected no 
later than 30 days after study treatment discontinuation .
Interim analy sis for futility  assessment:
In Cohort 1, the interim analysis will be performed separately for each of the two sub-
cohorts. 
Interim analyses for each cohort/sub -cohort are planned when at least [ADDRESS_742320] 6 cycles of treatment (18 weeks) or have 
discontinued treatment earlier. The decision to stop for futility for the respective 
cohort/sub -cohort at interim will be based on the probability of success (POS) at the 
end of the study. POS is the probability of a positive conclusion of the study if the 
study continued beyond interim, (i.e., until the final analysis), given the interim 
observed data. The respective cohort/sub -cohort will be stopped for futility at the 
interim analysis if the respective POS is less than 10%. All evaluable patients at the 
time of the data cut-off for the interim analysis will be used to obtain the futility 
boundary using the POS criteria. The interim analysis will be performed by [CONTACT_9084]/sub -
cohort in which the patients are enrolled. In addition, for Sub-cohorts 1a and 1b, and 
Cohort 2 and Cohort 3, sensitivity analys is on the primary endpoint may be performed 
excluding patients with cMET mutations.
Sub-cohort 1a, Sub -cohort 1b , Cohort 2 andCohort 4
With 28 evaluable patients for interim analysis in each of the Sub-cohorts 1aand 1b, 
and Cohorts 2 and 4, if ≤ 7 responses are observed then the respective cohort/sub -
cohort will be stopped for futility. If at the time when the 28thpatient is enrolled a 
minimum of [ADDRESS_742321] not yet been observed, accrual in the cohort/sub -
cohort may be temporarily s uspended until either the minimum number of 8 
responders is observed or results of the interim analysis allow the cohort/sub -cohort to 
continue.
Cohort 3 
With 20 evaluable patients for interim analysis in Cohort 3, if ≤ [ADDRESS_742322] not yet been observed, 
accrual in the cohort may be temporarily suspended until either the minimum number 
of 6 responders are observed or results of the interim analysis allow that cohort to 
continue.
No interim analysis for futility is planned for Sub-cohorts 5a and 5b,Cohort 6and 
Cohort 7 .
Sample size:
Approximately 456 patients (69 patients per Cohort/S ub-cohort 1-4; 27 patient s per 
Sub-cohort 5a and 5b; approximately 30 patients in Cohort 6, approximately 27
patients in Cohort 7) will be enrolled in the study if none of the cohorts/sub-cohorts is 
stopped for futility at the time of the interim analysis. For Cohort 2 (cMET GCN ≥4 and 
< 6), the study targets to have at least 40% of patients with cMET GCN ≥ 5 and < 6 at 
the time of the interim analysis, and if Cohort 2 continues to full enrollment, also at the 
final analysis.
With 28 evaluable patients in each of the Sub-cohorts 1 a and 1b, and Cohort 2and
Cohort 4 for interim analysis, there is a > 50% probability of stoppi[INVESTIGATOR_565237] /sub-cohort for futility when the true ORR is < 25%. When the true ORR is 35% 

[COMPANY_001] Confidential Page 47
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
then the probability of positive conclusion at the final analysis based on 69 patients is 
≥ 44%. If the true ORR is > 45% or higher, the probability of positive conclusion at the 
final analysis is more than 90%. For Sub-cohorts 1a and 1b, Cohort s2 and 3, 
sensitivity analysis on the primary endpoint may be performed excluding patients with 
cMET mutations.
With 20 evaluable patients in Cohort 3 for interim analysis, there is a > 90% probability 
of stoppi[INVESTIGATOR_565238] 10%. When the true ORR is 
20%, then the probability of stoppi[INVESTIGATOR_565239] > 80% and the 
probability of positive conclusion at the final analysis is < 1%.
No interim analysis for futility is planned for C ohort 5 , Cohort 6 or Cohort 7 .
In expansion Cohort 6, approximately 30 pre-treated patien ts with cMET GCN of ≥ 10 
and cMET mutations regardless of cMET GCN are expected to be enrolled . Data from 
Cohort 6 will help to further characterize the safety and efficacy of INC280 in the pre-
treated Sub-Cohort 1a and Cohort 4. In addition to presenting the efficacy data of 
Cohort 6, analysis may also be carried out combining the patients with a cMET GCN 
of ≥ 10 from Sub-cohort 1a and Cohort 6to further evaluate the precision of the 
efficacy estimates . Similar analysis may be carried out for pre-treated patient s with 
cMET mutations regardless of cMET GCN combining the patients from C ohort 4 and 
Cohort 6.
In expansion Cohort 7, approximately 27 treatment -naïve patients with cMET 
mutations regardless of cMET GCN are expected to be enrolled . Data from Cohort 7
willhelp to further characterize the safety and efficacy of INC280 inthe treatment -
naïve patient group with cMET mutations regardless of cMET GCN . Analysis may be 
carried out c ombining the patients from Sub -cohort 5b and C ohort 7.
Key words cMET, NSCLC, IN C280

[COMPANY_001] Confidential Page 48
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_5307]
1.1.1 Locally  advanced unresectable or metastatic non -small cell lung 
cancer (NSCLC)
Lung cancer has been the most common cancer in the world for several decades. In 2012, 
there were an estimated 1.8 million new cases, representing 12.9% of all new cancers 
worldwide. It was also the most common cause of death from cancer, with 1.6 million deaths 
representing 19.4% of the total deaths from cancer ( Globocan 2012 ). For 2014, approximately 
160,000 deaths are expected in the US (Siegel et al 2014 )and 273,000 in the European Union 
(Malvezzi et al 2014 ).
The World Health Organization (WHO) divides lung cancer into 2 major classes based on its 
biology , therap y, and prognosis: non-small cell lung cancer (NSCL C) and small cell lung 
cancer. NSCL C accounts for more than 85% of alllung cancer cases, and it includes 2 major 
types: (1) non-squamous carcinoma (including adenocarcinoma, large -cell carcinoma, other 
cell types); and (2) squamous cell (epi[INVESTIGATOR_015]) carcinoma. Adenocarcinoma (40% of lung 
cancers ; 47% in NSCL C )is the most common type of lung cancer seen in the [LOCATION_002] 
and is also the most frequently  occurring cell ty pe in nonsmokers ( NCCN Guidelines 2014 ).
One reason for the high mortality  rate of lung cancer is theadvanced stage at diagnosis; only 
25-30% of new NSCL C cases are diagnosed with localized disease that is potentially  curable 
with surgery  (Nguyen et 
al 2012). The majority  of patients are diagnosed wit h locally 
advanced or metastatic disease and they  are not candidates for surgery .
Platinum -based combination therap y is superior to best supportive care in patients with 
advanced, incurable disease. Platinum -doublet chemotherap y (i.e., cisplatin or carbopl atin in 
combination with other chemotherap y agents, with or without bevacizumab) has been the 
standard first-line treatment for patients with locally  advanced or metastatic NSCL C (Ettinger 
2010, NCCN Guidelines 2014) unless a patient has a known “druggable” mutation, and is a 
candidate for a targeted therap y (as discussed below). Overall response rate (ORR) with 
chemotherap y in first line has achieved a plateau and most platinum 
based regimens yield an 
ORR of 25-35% (NCCN Guidelines 2014). For NSCLC patients with non-squamous 
histology , pemetrexed -based 
platinum doublet therap y is a well-established standard first-line 
treatment option. In a phase III, non-inferiorit y trial of chemotherap y -naïve patients with 
Stage IIIB or IV NSCLC, pemetrexed plus cisplatin (P/C) has shown to be non-inferior and 
better tolerated than gemcitabine/cisplatin (G/
C) with a median overall survival (OS) of 10.3 
months for both combinations (Scagliotti et al 2008 ). However, with respect to OS in the 
various histological subty pes, P/C was superior to G/C in the subset of patients with 
adenocarcinoma and large
-cell carcinoma.
In recent years maintenance therapy  has emerged as an approach to try to improve the OS 
rates in patients with advanced NSCLC with tumor response or stable disease after first line 
therap y. Several types of maintenance therapy  are available (i.e., continuation with the non-

[COMPANY_001] Confidential Page 49
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
platinum portion of the platinum doublet until disease progression or switching to a different 
regimen) and its selection depends on tumor histology , presence of gene mutations or 
rearrangements, and patient performance status. Maintenance therapy  is not considered the 
standard of care for all patients ( Horn 2014 ). Outcomes of treatment of advanced/metastatic 
NSCL C in the first -line setting with standard platinum -doublet chemotherapy  (with or without 
maintenance) remain poor, with median progression free survival (PFS) and OS of 5- 7 months 
and 10-16 months, respectivel y (Scagliotti 2008 , Ciuleanu 2009, Ettinger 2010, Paz - Ares 
2012).
Docetaxel, pemetrexed, erlotinib, or platinum doublet sare recommended as second -line 
therap y regimens for unselected 
patients who have experienced disease progression during or 
after first-line therapy (NCCN Guidelines 2014). The reported response rates to second -line 
chemotherap y have generally  been less than 10% , with median PFS and OS generally  below 3 
and 8 months respectively  (de Marinis 2008 , Weiss 2013). Upon progression after second -line 
chemotherap y, patients may be candidates for further treatment, although randomized 
evidence is scarce and most data 
come from phase II trials or retrospective analyses. 
Pemetrexed, docetaxel, gemcitabine or erlotinib are recommended in third line if they have 
not been alread y given. Patients have often limited response to third line therap y, although it 
may have a useful palliative effect (Shepherd 2005, de Marinis 2008, Eccles 2011, NCCN 
Guidelines 2014 , Reck 2014, Besse 2014 ) .
Overall, current treatments are not considered satisfactory  for most NSCLC patients and the 
prognosis continues to be poor despi[INVESTIGATOR_565240], with a 5 -year overall survival 
rate of onl y 15% ( Nguyen et al 2012 ).
1.1.[ADDRESS_742323] few years, improved knowledge of NSCL C biology  has led to the 
identification of aberrant molecular events crucial for malignant transformation and cancer 
cell survival. These aberrant molecular events are critical oncogenic drivers and represent 
potential therapeutic targets (Gettinger and Lynch2011). As a result, “molecular subsets” of 
NSCL C patients who may be candidates for targeted therap y were defined and new targeted 
treatment options are available. In particular, activating mutations in epi[INVESTIGATOR_13392] (EGFR) and anaplastic lymphoma kinase (ALK) translocations are strong predictors 
of improved efficacy  of EGFR and ALK Tyrosine Kinase Inhibitors (TKIs) when compared 
with standard chemotherap y in patients harboring EGFR activating mutations and ALK 
translocations, respe ctively ,and represent a new paradigm in the treatment of NSCL C 
(Fukuoka [ADDRESS_742324] 2013 , Shaw 2013a , Shaw 2013b ).Importantly , due to the 
high oncogenic addiction to the molecular abnormality  during the course of the disease, the 
efficacy  of these targeted therapi[INVESTIGATOR_565241] (generally 
excluding therapi[INVESTIGATOR_565242] ) before receiving the given targeted therapy  
(Camidge et al 
2012).
The success of EGFR and ALK TKIs ,highlights the importance of identify ing specific 
molecular drivers of NSCL C to appropriatel y direct targeted agents in specific patient 
populations. The landscape of NSCL C treatment is changing and the treatment paradigm of 
“one size fits all” is switching to a personalized therap y.

[COMPANY_001] Confidential Page 50
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
1.1.3 cMET in NSCLC
cMET is a receptor tyrosine kinase involved in embry ogenesis, organogenesis and tissue 
damage repair (Birchmeier 1998, Birchmeier 2003). cMET -pathway  dysregulation through 
genomic amplification, receptor overexpression, mutations, autocrine or paracrine secretion of 
its ligand (hepatic growth factor [HGF ]) has shown to be oncogenic, promoting cell-cell 
detachment and metastasis, epi[INVESTIGATOR_018] -mesenchy mal transition, invasion, angiogenesis, 
proliferation and survival ( Christensen et al 2005 ).
[IP_ADDRESS] cMET amplification as an oncogenic driver in NSCLC
cMET dysregulation
, in particular gene amplification ,leading toincreased cMET signaling 
driving cell proliferation and survival ,was reported in several human cancers, including lung, 
breast, ovarian and gastrointestinal malignancies. Preclinical findings suggested that lung 
cancer cell lines harboring cMET gene amplification are dependent on cMET for growth and 
survival (Lutterbach et al 2007) and significant growth inhibition and apoptosis areobserved 
in cMET overexpressing cell lines when exposed to compounds blocking the cMET pathway 
(Christensen 2005, Liu 2008). Both cMET amplification and overexpression are linked to 
acquired 
resistance to EGFR inhibitors (EGFRi) in lung cancer in preclinical models and the 
clinical setting (Bean 2007 ,Engelman 2007, Cappuzzo 2009a ). cMET amplification seem sto 
correlate with poor prognosis in several tumor types including lung cancer, where it was 
associated with higher grade s at diagnosis and poor survival (Cappuzzo et al2009b ). In a 
large retrospective series of 435 surgicall y resected NSCL C patients, cMET amplif ication by 
[CONTACT_4656] (MET/CEP7 ratio ≥
2.2 - average ratio of cMET gene to chromosome 7 centromere 
signals ) was reported in ~4% of the patients ( Cappuzzo et al 2009b).
cMET amplification isreported in ~4% of NSCL C (TCGA web portal 2015, Schildhaus 
2014). cMET amplification appear sto be mutually  exclusive with all other oncogenic drivers 
in NSCL C (Cancer Genome Atlas Research Network 2014 ).Gene amplification is recognized 
to be the main oncogenic driver in NSCL C (Cap
puzzo et al 2009a ).
[IP_ADDRESS] cMET mutation as an oncogenic driver in NS CLC 
cMET mutatio ns leading to exon 14 deletion [referred t o as cMET mutation(s) hereafter ]have 
been identified as an additional actionable target for cMET inhibition in NSCL C (Kong -
Beltran et 
al 2006). The loss of exon 14 deletes the region of the protein required for the Cbl 
E3 
ligase to bind to cMET and target it for degradation. This results in extended cMET 
occupancy  at the membrane and ultimately  activation of the receptor. Based on the limited 
epi[INVESTIGATOR_565243] 2-4% of NSCL C 
with adenocarcinoma histology  and in ~1% of NSCL C with other histologies and the overlap 
between high cMET amplification (GCN>6) and cMET mutations is still to be determine d; 
notably  no overlap between cMET mutations and either EGFR mutations or ALK 
translocation is expected (TCGA web portal 2015, internal [COMPANY_001] data). Promising efficacy 
data have 
been published with cMET inhibitors, including INC280, in this setting (Frampton 
2015, Jenkins 2015, Mendenhall 2015, Paik 2015 , Waqar 2015, Liu 2015 , Schul er 2016, 
Drilon 2016
).

[COMPANY_001] Confidential Page 51
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[IP_ADDRESS] cMET inhibitors in NSCLC
Recent clinical studies suggest that inhibitors of cMET may provide a valuable therapeutic 
option in the treatment of NSCL C and other diseases linked with dysregulated cMET 
signaling. Anti- tumor activity  of this class of agents has recentl y been reported in patients 
with locally  advanced or metastatic NSCLC whose tumors contain cMET amplification . In a 
study  with crizotinib (inhibitor of ALK and cMET), 5 responses were reported (1 complete 
and 4 partial responses) in 12 patients with cMET FISH intermediate (MET/CEP7 ratio > 2.2 
and <5) and highly  (MET/CEP7 ratio ≥ 5) amplified NSCL C (Camidge 2014). Howe ver, 2 
other anti-cMET compounds (onartuzumab and tivantinib) failed to demonstrate any clinical 
benefit when combined with EGFR TKIs in recently  reported phase III trials ,presumabl y at 
least in part due to the lack of proper patient selection (Cap
puzzo 2014). In the onartuzumab 
phase III study , cMET positive patients were defined as IHC 2+ or 3+ for cMET 
overexpression (Spi[INVESTIGATOR_15174] 2014) and in the tivan tinib study  there was no selection for cMET 
dysregulation ( Scagliotti 20 15).
Current clinical data on the activity  of cMET inhibitors in cMET- mutated NSCL C are still 
very limited as this has not been a ssessed in any  prospective clinical studies. Single institution 
series and single case reports have 
been published showing preliminary  promising efficacy  in 
NSCL C patients with cMET mutations irrespective of the histology  when treated with either 
crizotini b (9 cases), cabozantinib (1 case) and INC280 (2 cases): 10 patients showed PR, 1 
showed SD and only 1  case experienced PD (even if in the context of a mixed response). 
Activity  was observed irrespective of the histology  and of the line of therapy . (Frampton 2015 , 
Jenkins 2015, Mendenhall 2015 , Paik 2015 , Waqar 2015; Liu 2015).
1.2 Introduction to study  treatment
1.2.1 Overview  ofINC280
The chemical name [CONTACT_252397]280 drug substance is 2-fluoro -N-methy l-4-(7-(quinolin - 6-
ylmethy l)imidazo[1,2 -b][1,2,4]triazin -2-yl)benzamide dihy drochloride monohy drate. 
INC280 dihydrochloride monohy drate is a slightly  hygroscopic light yellow powder. The 
solubility  of INC280 dihydrochloride at 25°C is approximately  3.47
mg/mL  in water; 0.08
mg/mL  in pH 6.8 and 0.72 mg/mL  in pH 3.0 buffer.
INC280 is an orally  bioavailable highl y potent and selective cMET inhibitor capable of 
blocking cMET activation. In preclinical studies, INC280 treatment induces regression of 
tumors in lung cancer models with cMET amplification and/or overexpression. Activity in 
these tumor models correlates with inhibition of cMET pathway  signaling, as measured by 
[CONTACT_51213]- cMET levels. Encouraging early clinical activity  has been observed with INC280 as 
single agent in an ongoing phase I trial in patients with metastatic NSCLC (unpublished data 
summarized below). 
These data suggest that INC280 represents a promising therapeutic option in the treatment of 
NSCL C with dy sregulated cMET signaling.
For more in formation, please refer to the current [INC280 Investigator’s Brochure ].

[COMPANY_001] Confidential Page 52
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[IP_ADDRESS] Non- clinical experience
[IP_ADDRESS].[ADDRESS_742325] the cMET kinase in vitro [inhibitory  
concentration (IC)50 = 0.13 ± 0.05 nM], and is highl y specific for cMET with > 10,000- fold 
selectivity  over several other human kinases tested. Potent activity  of blocking cMET 
activation has been observed in cell-based biochemical and functional assay s that measure c
-
MET- mediated signal transduction, as well as cMET -dependent cell proliferation, survival, 
and migration.
In cMET–dependent mouse tumor models (including lung cancer models) , INC280 exhibits
dose-depende nt antitumor activity  and causes tumor regression at well tolerated doses that 
exceeded IC90 coverage (Liu et 
al 2011). Importantly , plasma levels of INC280 correlates 
with both the dose administered and the extent of tumor growth 
inhibition in vivo .
In cMET/HGF -driven tumor models grown as xenografts in mice, oral dosing of INC280 
demonstrated significant in vivo activity  in blocking both c-MET phosphory lation and tumor 
growth. Activation of cMET in such responsive models is either due to strong cMET 
overexpression (mostly as a consequence of gene amplification, e.g. in gastric or 
hepatocellular carcinoma) or HGF secretion resulting in an autocrine loop (e.g. in 
glioblastoma). 
Collectively , the data suggest that INC280 possesses potent in vitro and in vivo biological and 
pharmac ologic activities, and further support its clinical development as a potentially  effective 
oral treatment for human cancers with cMET d ysregulation .
[IP_ADDRESS].2 Nonclinical pharmacokinetics (PKs) and metabolism
INC280 was absorbed rapi[INVESTIGATOR_565244], dogs and monkey s. Theabsolute oral bioavailability  
following a single low dose was low in dogs (28%), and moderate to complete in rats and 
monkey s (>66%). Single and multiple dose toxicokinetic studies in rats and monkey s showed 
increase in plasma maximum observed concentra tion (Cmax) and area under the 
concentration -time curve (AUC) values of INC280 with increased dose, but the increases 
were not alway s dose -proportional.
INC280 plasma protein binding was moderate to high across species, and was 96% in humans
with no concen tration dependency . The in vitro blood -to-plasma ratio in humans was 1.5
(concentration range of 10-
1000 ng/mL ). After oral dose of [14C]-INC280 in male pi[INVESTIGATOR_565245], INC280 and/or its metabolites were widel y and rapi[INVESTIGATOR_565246]. Melanin containing structures such as ey e (choroid) and ey e (ciliary body ) appeared to 
show specific uptake and prolonged retention of drug related material. The presence of total 
radiolabeled components in those tissues was at least partly reversibl e. INC280 can penetrate 
across the blood -brain barrier with a brain to blood ratio of approximately  0.1.
Systemic clearance (CL) was low-to-moderate in mice, rats, dogs and monkey s. The 
estimated terminal half-life (T1/2) was short in mice, rats and dogs but long in monkey s. 
Metabolism is the predominant mechanism of elimination of INC280 in rats and monkey s 
after oral administration. The hydroxylated metabolite M8 and the imidazo -triazinone (lactam) 
M16 were main metabolites observed in plasma and excret a of rats and monkey s. After single 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
oral administration of [14C]INC280 to rats and monkey s, the majorit y of the radioactivity  was 
excreted at the end of the observation period. The major portion of administered radioactivit y 
was recovered in feces and only a minor fraction in urine. Direct renal excretion of INC280 
was negligible and biliary  excretion/intestinal secretion contributed only to a minor extent to 
the overall elimination of INC280.
INC280 is predominantly  metabolized by [CONTACT_1995] P450 (CYP) 3A4 with a contribution 
by [CONTACT_231114]. INC280 showed inhibitory  potency  in vitro against CYP1A2, 2C8, 2C9, 
2C19 and 3A4/5. INC280 also display ed inhibition of multidrug resistant 1/Permeabilit y 
glycoprotein (P-gp), multi -xenobiotic resistance (MXR)/bre ast cancer resistant protein 
(BCRP), organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 mediated 
substrate efflux or uptake. Therefore, at clinically  relevant doses, potential drug-drug 
interactions are possible due to inhibition of CYP1A2, 2C8, 2C9, 2C19 and 3A4/5 metabolic 
enzy mes, and/or due to inhibition of P-gp, BCRP, and OATP1B1/1B3 transporters. The 
clinical DDI stud y results are presented in Section [IP_ADDRESS].4.
For more detailed inform ation refer to the current [INC280 Investigator’s Brochure ].
[IP_ADDRESS].3 Safety pharmacology and toxicology
A series of preclinical safet y studies were completed to support human clinical trials with 
INC280, including safety  pharmacology  studies, genetic toxicology studies, general 
toxicology  studies (single -and repeat -dose studies) in the mouse, rat, and Cynomolgus 
monke y (in rats and monkey s up to 13 weeks in duration), and embry ofetal developmental 
studies in rats and rabbits. Additionally , photosensitization poten tial was also assessed.
Safet y pharmacology  studies indicate that INC280 had no significant effects on 
central 
nervous system (CNS) and respi[INVESTIGATOR_565247], and no effects on cardiovascular 
function in monkey s. INC280 inhibited hERG potassium cur rent b y 50% at 18.7  M.
Repeat -dose toxicity studies in animals reveal that kidney s, pancreas, CNS /brain, and 
potentially  the liver may  constitute the target organs or sy stems. 
Kidney  toxicity  was observed in the 28-day monkey  study where mild-to-moderate deposits 
of amphophilic, crystalline -like material surrounded by [CONTACT_565286]/or tubular lumen were present in the 75 and 150mg/kg/day , but not in 
the 30 mg/kg/day  groups. It was noted that the results from the 13 -week monkey  study  did not 
reveal any kidney  toxicity  at doses up to 75 mg/kg/day .INC280 inhibits renal transporter 
MATE1 and MATE2K with a Ki of 0.28 µM in vitro. A small portion of creatinine could be 
cleared via active tubular secretion by  [CONTACT_565287] ( Lepi[INVESTIGATOR_365177] 
2014).
The findings in pancreas were observed in rats and monkey s in the 28-day and 13-week 
studies, including pancreatic acinar cell vacuolation and/or apoptosis without inflammation, 
and elevations of amylase or lipase. In the 28-day monkey  study, a dose of 30mg/kg/day  was 
identified as a NOAEL because of the low grade and reversible pancreatic findings present at 
that dose. In the 28-day rat study , themid-dose groups (60mg/kg/day  in males and 30
mg/kg/day  in females) also showed reversible low -grade pancreatic changes. Reversibility  has 
been clearl y demonstrated in both species. Similarly , in the 13
-week rat study , reversible 
pancreatic acinar cell va cuolation was observed at the doses of ≥ 60 mg/kg for males and ≥ 30 

[COMPANY_001] Confidential Page 55
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
frequent AEs suspected to be related to INC280 of any grade reported in the 
[CINC280A2201 ] study ,which remains as the reference study  for the safet y profile of
INC280 monotherap y, were edema perip heral (122 patients, [40.4%]), nausea (99 patients, 
[32.8%]), blood creatinine increased (58patients, [19.2%]), vomiting (58 patients, [19.2%]), 
decreased appetite (40 patients, [13.2] and fatigue (40 patients, [13.2%]) and diarrh ea (35 
patients, [11.6]) and the majority were Grade 1/2. The Grade 3/4 AEs suspected to be related 
to INC280 in the [CINC280A2201] study  included edema peripheral (19 patien
ts, [6.3]) and 
lipase increased (15 patients, [5.0%]), fatigue (10 patients, [3.3%]), alanine aminotransfer ase 
increased (12 patients, [4.0%]), vomiting (6 patients, [2.0%], nausea and hypophosphat emia 
(each i n 5 patients, [1.7%], aspartate aminotransferase (5 patients, [1.7%]).
The safet y profile of INC280 (capmatinib) has been confirmed to be manageable acros s all 
cohorts in INC280A2201 and no new safet y signals have been observed.
Pneumonitis and ILD have been reported from both INC280 single agent and combination 
studies with the EGFR TKI s,including events with fatal outcom e. Investigators are advised to 
carefully  monitor patients for signs and symptoms of pneumonitis and implement dose 
modification and follow up evaluations described in the protocol in all INC280 studies, both 
single agent and in combination studies.
The maximum tolerated dose (MTD) for INC280 capsules or tablets as single agent was not 
reached. The RP2D for INC280 as a single agent has been determined to be 600mg BID in 
capsule formulation and [ADDRESS_742326] and more information, 
please refer to the current [I NC280 Investigator’s Brochure ].
[IP_ADDRESS].2 Clinical efficacy
Based on available data as of 15-Mar-2016, from study  [INC280X2102 ]preliminary  clinical 
activity  has been observed with INC280 as single agent therap y in NSCL C. Confirmed partial 
responses were observed in11/55 (ORR 20%) evaluable NSCL C patients (defined as those 
with at least one post -baseline tumor assessment or have discontinued treatment at the time of 
the data cut -off) enrolled in the 2 expansion phase s(treated at the RP2D of 400 mg BID tablet 
or 600 mg BID capsule) and DCR was 51%. In evaluable patients with cMET IHC 3+
(regardless of GCN) , 
confirmed partial responses were seen in 9/37 patients (ORR 24%) and 
DCR was 60%, while in evaluable patients with cMET GCN ≥6(IHC 3+, except 2 patients 
with IHC2+), confirmed partial responses were seen in 7/15 patients (ORR 47%) and DCR 
was 80%. Kaplan –Meier median PFS was 3.55 months (95% CI 1.84 –7.33) in the total 
NSCL C population (n=55) ,while in patients with cMET GCN ≥6 median PFS was extended 
to 7.39 mont hs (95% CI 3.84–22.11). Four NSCLC patients with cMET exon 14 mutations 
were identified by [CONTACT_565288]: all 4 were 
IHC3+ and 3/4 had a GCN ≥10, 
while the GCN was missing in 1 patient; confirmed PR was achieved in 3 patients (2 with 
GCN >10 and 1 with unknown GCN) ,while one achieved unconfirmed PR (Schuler et al 
2016). ALK status was available for 51/55 patients and all 51 (100%) were negative for ALK 
rearrangement. EGFR status was availab le in 50/55 patients and 49 (98%) were EGFR wt.
Thus, the preliminary  efficacy  data suggest that patients with NSCL C whose tumors are 
EGFR wt and have cMET amplification and/or mutations may obtain therapeutic benefit from 
treatment with single -agent I NC28
0.Based on these preliminary  but promising results, a more 

[COMPANY_001] Confidential Page 56
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
thorough investigation of the activity  of INC280 in patients with EGFR wt NSCL Cwith 
varying degrees of cMET amplification and/or cMET mutations is warranted in order to 
determine those individual s most likely  to benefit from treatment with single -agent INC280 .
Promising activity  in cMET mutated NSCL C patients with INC280 as single agent therapy 
with INC280 400 mg BID, both in pretreated (Cohort 4) and particularl y in treatment naïve
(Sub- cohort 5b) setting was observed as of 09 Aug 2018 cut-off date: ORR by [CONTACT_565289] 
39.1% (95% CI 27.6–51.6) in 2/3 line patients (n=69, Cohorts 4) and 72.0% (95% CI 50.6–
87.9) 
in treatment naïve patients (n=25, Sub -cohort 5b) ( Wolf et al 2018).
[IP_ADDRESS].3 Clinical pharmacodynamics
In study  [CINC280X2102] (with single -agent INC280 in patients with cMET-dependent 
advanced solid tumors), pharmacod ynamic effect (inhibition of the phosphory lation of cMET 
in paired biopsies) was observed in one colorectal cancer patient treated at 450 mg BID in 
capsules .
[IP_ADDRESS].4 Clinical pharmacokinetics
As of 28-Sep-2018, INC280 (capsule and tablet) single agent stead y state pharmacokinetic 
(PK) data are available from five clinical studies ([CINC280X2101 T
], [CINC280X2102] , 
[CINC280X1101 ] [CINC280A2201] and [CINC280X2201] ), and from four combination 
studies, INC280 plus gefitinib [CINC280X2202] , INC280 plus cetuximab [CINC280X2104] , 
INC2 80 plus EGF816 [CINC280X2105C ]and INC280 plus BKM120 (buparlisib) 
[CINC280X2204] . After oral administration, INC280 was rapi[INVESTIGATOR_565248] (Tmax) ranging from 1 to 2 hours for tablets and 
from 1 to 4 hours for capsules. The elimination half-life estimated from [CINC280X 1101]
ranged from 3.5 to 6.3hours across the cohorts. Accumulation in INC280 exposure following 
repeated administration of 400 mg BID tablets is low, with geometric mean accumulation 
ratio of 1.4-fold in the single agent [CINC280A2201] study . Steady  stateINC280 exposure is 
expected to be reached by [CONTACT_565290]. The mean plasma 
exposures (Cmax and AUC) for INC280 generally increased with dose up to 600 mg QD and 
600 mg BID administration with capsule formulation. The mean plasma exposure increase is 
roughl y dose proportional for INC280 tablet from 200 to 400 mg BID. 
Arelative bioavailability study [CINC280X2103] was conducted to compare the INC280 MF 
(market form) tablet formulation to INC280 capsule formulation. The outcome ofthis study 
showed that tablets provided higher systemic exposures (Cmax and AUC) and lower inter-
subject variability  following a single oral administration of 600 mg INC280 in health y 
subjects. Tablet PK data are available in cancer patients at different doses (150 mg to 400 mg 
BID) in various INC280 studies. In the study  [CINC280X2102] , the INC280 MF tablet at 400 
mg BID (N=8) provided comparable mean AUC0 -12h,ss (1. 05-fold) and slightl y higher 
Cmax,ss (1. 44 -fold) compared with the INC280 capsule at 600mg BID (RP2D, N=45) in the 
limited subjects tested. In the ongoing phase 2 [CINC280A2201] study  with FMI tablet, the 
exposures (both Cmax and AUC) were comparable to what was obs erved in [CINC280X2102]
study  at 400 mg BID. Based on the tablet PK and safet y data from these studies, the dosage of 
INC280 at 400 mg BID in tablet form has been declared as the RP2D for the single agent 
studies.

[COMPANY_001] Confidential Page 57
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The effect of food on the rate and extent of INC280 exposure was assessed after a single oral 
dose administration of 600 mg INC280 tablet in health y subjects [CINC280X2107 ].
Compared to fasting conditions, a low fat meal increased AUCinf and Cmax by 1.20- and 
1.11- fold, respectivel y; and a high fat meal increased AUCinf and Cmax by 1.46- and 1.15 -
fold, respectivel y.Pharma cokinetics data from study  [CINC280A2108 ]in which INC280 
tablet was administered with food in cancer patients, indicated no clinically relevant food 
effect .At400 mg BID dose, steady  state AUC was similar to the exposure observed in study 
[CINC280A2201] ,therefore INC280 can be administered without regard to food .
INC280 display ed pH-dependent solubility  in vitro. A study  to evaluate the effect of a long 
acting proton pump inhibitor on the PK of a single dose of INC280 tablet was completed in 
healthy  volunteers [CINC280A2101] . Daily  treatment with [ADDRESS_742327] reduction in the extent of INC280 absorption with a 25.2% decrease in 
AUCinf and a 37.5% decrease in Cmax. Similarly, PK data from patients on the concurrent 
useof PPI [INVESTIGATOR_565249] (Proton Pump Inhibitor) use from the study  
[CINC280A2108] showed a ~30% lower AUC0 -[ADDRESS_742328] of INC280 on the PK of CYP3A4 substrate (midazolam) and 
CYP1A2 substrate (caffeine) in patients with MET dysregulated solid tumors was completed 
[CINC280A2103 ]. Multiple doses of INC280 tablets at 400 mg BID did not lead to clinically 
significant increase of CYP3A4 substrate (midazolam) exposure. However, AUC of CYP1A2 
substrate (caffeine) increased by 135%. Therefore, INC280 is not a CYP3A4 inhibitor, but a 
moderate CYP1A2 inhibitor. 
A study  to evaluate the effect of INC280 on the PK of Pgp substrate (digoxin) and BCRP 
substrate (rosuvastatin) in patients with MET dysregulated solid tumors was completed 
[INC280A2105] . Multiple doses of INC280 tablets at 400 mg BID led to a 74% increase in 
digoxin Cmax and a 47% increase in AUC. Rosuvastatin Cmax and AUC increased 204% and 
108%, respectivel y. Therefore, INC280 is an inhibitor of P-gp as well as BCRP transporters, 
with clinically  relevant DDI potential.
A study  to evaluate the effect of itraconazole (strong CYP3A4 inhibitor) and rifampi[INVESTIGATOR_2513] 
(strong CYP3A4 inducer) on the single -dose pharmacokinetics of INC280 in healthy  subjects 
was completed [CINC280A2102 ]. When co-administered with itraconazole, INC280 AUC 
increased by [CONTACT_3450]  40%. There was no change in Cmax. When co-administered with 
rifampi [INVESTIGATOR_2513], INC280 AUC and Cmax decreased by [CONTACT_3450]  66% and 56%, respectivel y.
The result indicated that INC280 is not a sensitive CYP3A4 substrate. Given that the 
reduction in exposure by [CONTACT_297417]3A4 inducers could potentially  compromise the efficacy , 
the co ncurrent use of strong CYP3A4 inducers with INC280 should be avoided .
INC280 does not show a risk of 
QT prolongation. Preliminary  analysis on 110 patients in 
study  [CINC280A2201 ]showed that no patients had new post-baseline QTcF values greater 
than 500 ms. Changes from baseline (ΔQTcF) greater than 60 ms were not observed and 
changes greater than 30 ms and below 60 ms were observed in 4 patients (4/110, 3.6%). The 
observed mean QTcF changes from baseline around Tmax ([ADDRESS_742329]-dose) were 5.21 ms 
onCycle 1 Day 1  and -0.54 ms on Cycle 1 Day 15. Based on the PK/QT analysis, the 
estimated mean ΔQTcF (upper one -sided 95% CI ) at mean steady  state INC280 concentration 

[COMPANY_001] Confidential Page 58
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[ADDRESS_742330]-dose (4584 ng/mL) was 0.11 ms (1.85 ms) at the recommended phase 2 dose of 
400 mg BID with tablets. The upper one-sided 95% CIs for the estimated mean ΔQTcF at 
clinically  relevant INC280 concentrations are below the regulatory  threshold of 10 ms. For 
more information, please refer to the current INC280 [Investigator’s Brochure ].
2 Rationale
2.1 Stud y rationale and purpose
cMET dysregulation (amplification, overexpression and mutations) constitutes an oncogenic 
driver in several tumor types, including lung cancer. Currentl y, there is no approved therapy 
for tumors with cMET dysregulations and therefore there is a high unmet medical need to 
develop therapy  capable of cMET inhibition for the treatment of these tumors . INC280 is a 
highl y potent and selective cMET inhibitor in biochemical and cellular assay s and capable of 
blocking cMET activ ation. Overall, the emerging precli nical and clinical data suggest that 
INC280 may have a favorable benefit -risk ratio for the treatment of cMET dysregulated 
advanced lung cancer . The definition of cMET amplification and the activity  in cMET 
amplified and/or cMET mutated NSCL C is based on limited clinical data and exploration of 
INC280 activity  in patients with different level sof gene amplification and with mutation is 
warranted.
2.2 Rationale for the study  design
This is a prospectivel y designed, multicenter , open -label, phase II study  to evaluate the 
efficacy  and safet y of single -agent INC280 in patients with EGFR wt (for exon 19 deletions 
and exon 21 L858R substitution mutations) and ALK -negative rearrangement , advanced 
(stage IIIB or IV) NSCL C harboring cMET amplification and/or cMET mutations with
advanced/metastatic disease. Patients with cMET mutation swill be enrolled in Cohort 4, Sub-
cohort 5band Cohort 7, irrespective to their cMET GCN. Patients without cMET mutations, 
will be enrolled in Cohorts 1-3and S ub- cohort 5a,based on their cMET GCN. All patients in 
C
ohorts 1, 2, 3, and [ADDRESS_742331] failed 1 or 2 prior lines of systemic therap yfor 
advanced/metastatic disease , while patients enrolled in Cohort 5and expansion Cohort [ADDRESS_742332] 
be treatment -naïve for advanced/metastatic disease. Expansion Cohort 6 will be opened for 
both cMET high amplified (GCN ≥10) and cMET mutated NSCL C patients who have failed 1 
prior line of s ystemic therapy  for advanced/metastatic disease.
The primary  objective is to evaluate the antitumor activity  of INC280 in the described patient 
population. The primary  measure of antitum or activity  is ORR according to RECI ST 1.1 and 
as determined by[CONTACT_397740] (BIRC) to ensure unbiased 
assessment ofresponse rate. A s upportive analy sis will be performed to assess the ORR bas ed 
on investigator assessment. Response rate is an appropriate primary  endpoint that can be 
adequatel y assessed and may predict clinical benefit in the context of this single -agent, phase 
II trial inNSCL C patients with cMET amplification and/or mutations. The suitability  of such 
design and ORR end point has been demonstrated by [CONTACT_217928]’ approval sof 
crizotinib and ceritinib in ALK-positive rearrangement NSCL Cin studies with similar design.
Data on ORR will be supplemented with data on duration of response (DOR) and time to 
respo nse (TTR).

[COMPANY_001] Confidential Page 59
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The study  design will incorporate a Bayesian interim monitoring for Cohorts 1, 2, 3 and 4, 
based on pre-
specified response criteria (see Section 10.7) f or a decision onwhether to 
continue enroll ment 
or stop for futility  each of the respective study  cohorts.
The study  will also monitor and assess safet y of INC280 as monotherapy , thedisease control 
rate (DCR), progression -free survival (PFS), overall survival (OS)  
 ofINC280 treatment. These endpoints are considered to be 
important supportive endpoints to better assess the potential clinical benefit of INC280 .
2.2.1 Rationale for cMET GCN cohorts
In terms of GCN , any value above 2 can be considered as amplifi ed compared to normal 
tissue when looking across a population of cells. Gene copy numbers in the range of 4-5 are 
commonly  considered low level amplification, whereas gene copy  numbers of 6 and above are 
considered high (Schildhaus 2014). The use of GCN ≥ 6 as a cut-off to determine high 
amplification is an accepted and routinely  used cut-off in pathology  labs to determine high 
gene cop y number in several settings (Schildhaus 2014 ). For cMET in NSCL C, of the initial 5
responders observed on the 
phase I study [CINC280X2102] , 3had GCN higher than 6 while 2
had no FISH result available ( Ma et al 2015 ). 
More recent data from the same study  [CINC280X2 102] firmly  support that there is activit y 
of INC280 in patients with cMET amplified NSCL C with cMET GCN ≥6 where confirmed 
partial responses were seen in 7/15 evaluable patients (ORR 47%), DCR was 80% and 
Kaplan –Meier median PFS was 7.39 months (95% CI 3.84–22.11) (Schuler 2016). Of these 7 
responder s, 3 patients had a GCN ≥10,however, 2of these confirmed responders with a GCN 
≥10 also harboured a concurrent cMET exon 14 skippi[INVESTIGATOR_86040]. Therefore, the 
contribution of the very high cMET amplification to the response of INC280 still remains to 
be elucidated and further optimization of appropriate GCN cut off is warranted. The GCN ≥[ADDRESS_742333] extensive 
analysis ever conducted in 11,205 lung cancer specimens ( Ou 2016
). 
Preliminary  efficacy  data has also been observed with crizotinib in NSCL C patients with 
MET/CEP7 ratio of > 2.2 ( Camidge 2014 ). Four out of six patients with MET/CEP7 ratio of > 
5 achieved response, five responses out of 12 patients with MET/CEP7 ratio of > 2.2 were 
observed and no responses were seen in 2 subjects with low level amplification of 
(MET/CEP7 ratio ≤ 2.2) suggesting a differential gradient of response at higher level of 
amplification.
While detailed epi[INVESTIGATOR_565231], the prevalence of cMET amplification in 
NSCL C is known to diminish with the increase in GCN (Schildhaus 2014). With the 
emerging data, the assumption that patients with higher GCN may derive grater benefit from 
cMET inhibition with higher chance of response to treatment require further more robust 
exploration. To characterize the efficacy  of INC280 in NSCL C patient
swith very high 
amplified disease and to ensure an adequate representation of patients with GCN ≥10, 2 sub-
cohorts will be implemented in the high amplified Cohort 1 (cMET GCN of ≥ 6) that will 
enroll either patients with a cMET GCN of ≥ 6 and <10 or patients with a cMET GCN of ≥ 10. 
This will allow for adequate and robust characterization of the individual contribution of the 
two GCN ranges to the activity  of INC280 in high amplified patients and to assess the 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
There is a growing body  of clinical evidence that shows that cMET mutation , in particular , is
a predictor of response to cMET inhibitors irrespective of the line of treatment (Frampton et al 
2015, Schuler et al 2016 , Drilon et al 2016, Awad et al 2017 , Drilon et al 2017, Felip et al 
2018, Wolf et al 2018).   
Based on these emerging data,the activity  of cMET inhibitors warrants further exploration 
also in cMET -mutated NSCL C
.
2.2.3 Rationale for treatment -naïve cohort with cMET dysregulation
Increasing data confirms that cMET dy sregulations such as cMET exon 14 skippi[INVESTIGATOR_565250] C patients, irrespective of the number of prior lines 
of therapy  including some preliminary  evidence in the treatment -naïve setting (Frampton 
2015, Jenki ns 2015, Mendenhall 2015, Paik 2015 , Waqar 2015 , Liu 2015 , Schuler 2016, 
Drilon 2016
, Felip et al 2018, Drilon et al 2017 , Wolf et al 2018).
Promising activity  with INC280 in cMET dysregulated 
(either cMET amplified or cMET 
exon 14 skippi[INVESTIGATOR_565228]) advanced NSCL C has been observed in the phase I study 
[CINC280X2102] (Schuler 2016). In patients with cMET amplified (GCN ≥6) NSCL C a 
47% ORR and  median PFS of 7.4 months was reported. While these promising results were 
obtai ned mainly  in pretreated patients, three patients (who declined chemotherap y) were 
enrolled as treatment -naïve. Two of these patients harbored cMET exon 14 skippi[INVESTIGATOR_565251] 
(one had concurrent cMET amplification). Both patients gained benefit from INC280 
treatment (tumor shrinkage -53.3% and -48.5%) achieving confirmed and unconfirmed partial
responses, respectivel y. This result was consistent with the overall benefit gained by [CONTACT_565278]  (pretreated with 1 and 
3 prior lines of 
systemic therapy , respectively ), leading to an ORR of 75% in cMET mutated patients (3 out 
of 4 patients achieved confirmed and durable partial responses). Overall, INC280 was well 
tolerated in both treatment- naïve and pretreated NSCL C patients.
While the data are still preliminary , cMET exon 14 skippi[INVESTIGATOR_565230]/or high cMET 
gene amplification are emerging as independent tumor drivers and patients harboring such 
cMET dysregulations can benefit from treatment with cMET inhibitors such as INC280, 
irrespective of prior lines of therap y and including treatment -naïve patients with acceptable 
safet y profile. This concept was successfull y confirmed in the treatment -naïve advanced 
NSCL C setting with other targeted agents directed against established molecular drivers such 
as EGFR mutation, ALK and ROS1 translocation which showed greater efficacy  when 
compared with platinum -doublet chemotherap y (Rosell 2012, Sequist 2013 , Solomon 2014 ). 
These data also confirmed that the safet y profile of such targeted agents does not differ in the 
treatment -naïve setting compared to the pretreated sett ing.
There is no cMET inhibitor currently  approved for cMET dysregulated NSCL C and the 
activity  of platinum- based chemotherap y in patients with treatment -naïve advanced NSCL C 
harboring cMET exon 14 skippi[INVESTIGATOR_565230]/or high level of cMET amplification (GCN 
≥10) is unknown.

[COMPANY_001] Confidential Page 62
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
2.2.4 Rationale for additional Cohort 6 in pretreated NSCLC with cMET 
dysregulation
While enrollment in the pretreated cohorts with cMET ampli fication less than 10 GCN (Sub-
cohort 1b, Cohort 2 and Cohort 3) was stopped following the prepla nned interim analy ses for
futility , Sub-cohort 1a (GCN ≥10) and Cohort 4 (cMET mutations) passed the futility  criteria 
and enrollment is continuing until completion for these 2 cohorts.
Inexpansion Cohort 6, 
approx imately  additional 30patients with adva nced NSCL C pretreated 
with one prior line of systemic therapy  harboring either cMET amplification (GCN ≥10) or 
cMET mutation s(irrespective of cMET GCN) will be enrolled after enrollment of the 
respective Sub-
cohort 1a /Cohort 4 is completed .
The main purpos e of this additional cohort is to generate supportive safety  and efficacy  data 
in this second line patient population (which currently  accounts for the majority  of patients 
enrolled in the respective Sub-cohort 1a and Cohort 4).T herefore Cohort 6 is consi dered
representative of the overall targeted patient population of pretreated cMET high amplified 
and mutated NSCL C.
2.2.5 Rationale for additional Cohort 7in treatment -naïve NSCLC with cMET 
mutation
In light of the promising data generated in cMET mutated NSCL C in treatment naive setting 
in Sub-cohort 5b (Wolf et al 2018 -see Section [IP_ADDRESS].2 ), the main purpose of Cohort [ADDRESS_742334] been treated with INC280 as a single agent with 
either the capsule formulation (N=192 ) or tablet formulation (N=11). Five DLTs were 
experienced with INC280 as a single agent with the capsule formulation and no DLTs were 
observed with the tablet formulation (see Table 2 -1).
Table 2
-1 DLTs experienced w ith single agent INC280 as of 28 -Sep-2014
Study  and Treatment N Dose Limiting Toxicities
Study  CINC280X1101
INC280 capsules:
100 mg QD
200 mg QD
400 mg QD
500 mg QD
600 mg QD
800 mg QD
400 mg BID
600 mg BID3
4
3
4
4
4
4
3None
None
None
None
None
None
None
Grade 2 malaise and suicidal ideation
INC280 tablets:
200mg BID 3 None

[COMPANY_001] Confidential Page 63
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Study  and Treatment N Dose Limiting Toxicities
400mg BID 3 None
Study  CINC280X2101
INC280 capsules:
[ADDRESS_742335] and ALKP increase
None
None
None
None
None
None
None
None
Study  CINC280X2102
INC280 capsules:
100 mg BID
200 mg BID
250 mg BID
350 mg BID
450 mg BID
600 mg BID escalation
600 mg BID expansion4
5
4
3
9
8
53None
Grade 3 fatigue
Grade 3 blood bilirubin increased
None
Grade 3 fatigue
None
None
INC280 tablets:
400mg BID 5 None
Based on the data from study  [CINC280X2102] , and the observation that exposure did not 
further increase from 600 mg to 800 mg QD dosing, the RP2D of INC280 monotherap y in 
adults (in capsules) is [ADDRESS_742336] adverse events (AEs) 
being manageable and of grade 1 and grade 2 severity .
As of 28-Sep-2014 ([ Investigator’s Brochure edition 5.2] data cut-off date), preliminary  PK 
data were available from 10 
patients treated with the INC280 tablet formulation as single 
agen t at 200 mg or 400 mg BID dose. Based on the limited data, mean Cmax at stead y-state 
following administration of INC280 tablets at 400 mg BID was 41% higher than that 
following capsules administration at 600 mg BID. Considering the 67% variability  (CV%) 
observed with the capsule formulation at 600 mg BID, tablets at 400 mg BID (CV%= 30%) 
provided exposures within the range of exposures observed with capsules at 600 mg BID (the 
RP2D in study  [CINC280X2102] ).
In study [CINC280X2101] (single agent capsules), dose-
dependent inhibition of phospho-
cMET was observed across 11 dose cohorts (10 mg QD up to 400 mg QD or 300 mg BID) 
and complete inhibition was observed at trough concentration on Day 15 at 200 mg BID
single agent capsules . In addition, complete inhibition of tumor cMET phosphory lation in 
patients was observed at 450 mg BID single agent capsules in study  [CINC280X2102] and at 
400 mg BID capsules in combination with gefitinib in study  [CINC280X2202] . Based on the 
observed 400 mg BID tablet exposure, which appears to be higher in mean level but within 

[COMPANY_001] Confidential Page 64
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
the range of600 mg BID capsule exposure, the 400 mg BID tablet dose and regimen is 
expected to provide high enough inhibition levels to be efficacious. For details, refer to 
Section [IP_ADDRESS].4 and [Investigator’s B rochure edition 5. 2].
Based on the available tablet PK and safet y data, the dosage of INC280 at [ADDRESS_742337]
udies.
2.4 Rationale for choice of combination drugs
Not applicable .
2.5 Rationale for choice of comparators drugs
Not applicable .
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1below.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 06 (Clean ) Protocol No. CINC280A2201
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
To evaluate the antitumor activity of INC280, as measured 
by [CONTACT_34426] (ORR) by [CONTACT_565291] (BIRC) assessment , by [CONTACT_9084]/sub -
cohortORR, p roportion of patients with a best overall response defined as complete 
response or partial response (CR+PR) by [CONTACT_565292] 1.1Refer to Section 10.4
Key secondary
To evaluate duration of response (DOR) as assessed by 
[CONTACT_14988] , by [CONTACT_9084] /sub-cohortDOR , calculated as the time from the date of the first documented CR or PR 
by [CONTACT_397741] 1.[ADDRESS_742338] documented progression or death due to 
any cause for patients with PR or CRRefer to Section 10.5.1
Other secondary
1.To evaluate ORR and DOR by [CONTACT_3138] , 
by [CONTACT_9084] /sub-cohortORR (CR+PR) and DOR per RECIST 1.1 by [CONTACT_565293] 10.5.2
2.To evaluate time to response (TTR), disease control 
rate (DCR) and progression -free survival (PFS) by 
[CONTACT_565294] , by [CONTACT_9084] /sub-
cohortAll calculated per RECIST 1.1 , both by [CONTACT_565295] :
TTR, calculated as the time from first dose of INC280 to first documented 
response (CR+PR) for patients with PR or CR
DCR, calculated as the pr oportion of patients with best overall response 
of CR, PR, or SD
PFS, defined as time from first dose of INC280 to progre ssion or death 
due to any causeRefer to Section 10.5.2
3.To evaluate overall su rvival (OS) , by [CONTACT_9084] /sub-cohort OS, defined as time from first dose of INC280 to death due to any cause Refer to Section 10.5.2
4.To evaluate INC280 safety profile as monotherapy in 
NSCLC patients with advanced/ metastatic diseaseIncidence of adverse events and serious adverse events, change in vital 
signs, laboratory results (hematology, blood chemistry, and urinalysis) and 
ECG.Refer to Section 10 .5.3
5.To characterize the pharmacokinetics of INC280 and 
metabolite CMN288Plasma concentration -time profiles and pharmacokinetic parameters estimated 
by [CONTACT_105] -compartmental analysis or population PK modelingRefer to Section 10.5.4

[COMPANY_001] Confidential Page 66
Amended Protocol Version 06 (Clean ) Protocol No. CINC280A2201
Objective Endpoint Anal ysis

[COMPANY_001] Confidential Page 67
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
4 Study  design
4.1 Description of study  design
This is a prospective ly designed, multicenter, open -label, phase II study  to evaluate the 
efficacy  and safet y of single-agent INC280 in patients with EGFR wt(for exon 19 deletions 
and exon 21 L858R substitution mutations) , ALK -negative rearrangement, advanced (stage 
IIIB or IV) NSCL C harboring cMET amplification and/or mutations . 
Approximately 456male and female patients aged 18 or over will be enrolled in this study  in 
7separate cohorts [138 in Cohort 1(69 patients per each S ub-cohort 1a and 1b) and 69 
patients in each Cohorts 2, 
3, and 4; 54 patients in Cohort 5 (27 patients per each Sub- cohort 
5a and 5b); approximately  30 patients inCohort 6; approximately  27in Cohort 7]depending 
on their cMET amplificat ion and/or mutation status and prior treatment status
.A Bayesian 
interim monitoring for Cohorts 1, 2, 3 and 4, based on pre-specified response criteria is used 
(see Section 10.7) for a decision on whether to continue enrollment or stop for futility  in the 
respective cohort. Due tothe promising data for the treatment naïve patients from 
[INC280X2102] study , drug tolerabilit
yas observed inthe other cohorts, and the outcome of 
the fu tility  interim anal yses in Sub -cohort 1a and Cohort 4, as well as the small sample size of 
Sub-cohorts 5a and 5b, interim analy ses for futility  arenot being implemented in the 
treatment naïve Sub-cohorts
, Cohort [ADDRESS_742339] as per the Molecular 
Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Ty rosine Kinase 
Inhibitors from College of American Pathologists, International Association for the Study  of 
Lung Cancer, and Association for Molecular Pathology (Lindeman et al 2013 ). The EGFR wt
status (for exon 19 deletions and exon 21 L858R substitution mutations) must be documented 
in the patient source documents before patient can be consented for cMET amplification and 
mutation pre-screening (except for patients who are treatment -naïve potentially  eligible for
Sub-cohort 5a and 5b or ifmolecular pre-screening will be performed by  [CONTACT_565296]) .ALK rearrangement status, if known, should also be documented in the 
patient’s source documents prior to cMET testing ,except for patients who are treatment -naïve 
potentially  eligible for Sub-cohort s5a,and 5band Cohort 7. IfALK testing is not available
for a patient , their AL
K status will be determined centrally  with a validated test along with 
their cMET amplification and cMET mutation status. Patients with NSCLC of pure squamous 
cell histology  can enter pre-screening without EGFR mutation or ALK testing or result , 
however patients with pure squamous cell histology  and are known to have EGFR mutation s 
in ex ons 19 and 21 or ALK -positive rearrangement will be ex cluded
.
Patients will bepre-screened for cMET amplification based on GCN (and ALK rearrangement 
status, if applicable) by [CONTACT_565297]-PCR at a [COMPANY_001] -designated 
central laboratory following the signing of the molecular pre-screening Informed Consent 
Form (ICF).Next Generation Sequencing (NGS) may be used as primary  pre-screening 
diagnostic, if assay  becomes available . Patients with previously  determined cMET mutation 
or amplification by a [COMPANY_001] designated central laboratory  (as detected by [CONTACT_565298] 68
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
validated NGS assay used in this protocol )who have consented for the use of those results,
will be allowed to enter directly  the screening phase of the INC280A2201 study .For patients
coming from another [COMPANY_001] study  using the same central lab or being rescreened, repeat 
tumor biopsy  or additional archival tumor may  not be required provided the central laboratory 
confirms adequate tumor tissue remains for the required study  anal yses.
All patients in Cohorts 1, 2, 3, and [ADDRESS_742340] failed 1 prior line of systemic therap y for 
advanced/metastatic disease.
Patients with cMET mutation will be enrolled based on the prior therapy  status in Cohort 4or 
Sub- cohort 5bor Cohort 7, irrespective of their cMET GCN. Patients without cMET 
mutations, will be enrolled in Cohort 1(Sub- cohorts 1a or 1b), Cohort 2, and Cohort 3and 
Sub- cohort 5a , based on their cMET GCN and prior treatment status. Patients enrolled in 
Cohort 6 can be either with cMET GCN ≥[ADDRESS_742341] results from the pre-screening analy sis 
performed by [CONTACT_447267] -designated laboratory  will be used to assign patients into the 
following 7 cohorts:
Cohort 1: Pre-treated p atients with cMET GCN ≥ 6, including: 
Sub-cohort 1a: Patients with a cMET GCN of ≥ 10, or
Sub-cohort 1b: Patients with a cMET GCN of ≥ 6 and < 10
, or
Cohort 2: P re-treated p atients with cMET GCN ≥ 4and < 6, or
Cohort 3: P re-treated 
patients with cMET GCN < 4, or
Cohort 4: Pre-treated patients with cMET mutations regardless of cMET GCN, or
Cohort 5: Treatment -naïve patients with cMET dysregulation, including:
Sub-cohort 5a: Patients with a cMET GCN ≥10, or
Sub-cohort 5b: Patients with cMET mutations regardless of cMET GCN , or
Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET mutations or 
cMET mutations regardless of cMET GCN or,
Cohort 7: Treatment -naïve patients with cMET mutations regardless of cMET GCN
For the interim and final analy ses in Cohort 2 (cMET GCN ≥ 4 and < 6), the study  targets to 
have at least 40% of patients with cMET GCN ≥ 5 and 
< 6.Enrollment in each cohort will be 
controlled via Interactive Response Technology  (
IRT) system .
Each cohort /sub-cohort of the study  will enroll patients in parallel. Patients in all cohorts will 
be treated with 400mg INC280 twice daily (BID) using thetablet formulation, administered 
orally on a continuous dosing schedule .
Efficacy  assessment of tumor response and progression will be performed every  6 weeks ( i.e.,
every  2  c ycles) from the first day of treatment with INC280 until RECI ST 1.1 disease 
progression as determined by [CONTACT_565299] (BIRC). This schedule must be followed regardless of dose interruptio ns. 

[COMPANY_001] Confidential Page 69
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Confirmation of response is required for all response endpoints, as per RECI ST 1.1. All 
radiological assessments obtained at screening/ baseline, during treatment and during the 
follow -up phase should be performed using the same modality  (method) and wi ll be submitted 
to the designated independent imaging vendor for review by [CONTACT_14988] .
Approximately 30enrolled patients at selected sites (regardless of cohort assignment) will 
have full PK samples and ECGs collected. T he rest of the patients will have sparse PK 
samples and ECGs collected (see Table 7-6 and Table 7 -7). At the time of eligibility 
confirmation, the IRT system will inform the site about whic
h PK and ECG schedule should 
be followed b y the patient .
In Cohort [ADDRESS_742342] 28 evaluable patients in each cohort/sub- cohort. 
Interim analy ses for futility  for Cohort [ADDRESS_742343] 6 cycles of treatment (18 weeks) or have discontinued the study  treatment 
earlier. The decision to stop for futility  at interim will be based on the probability  of success 
(POS) which will be calculated based on the evaluable patients in each cohort /sub-cohort . One 
(or more) of the cohorts /sub-cohorts will be stopped for futility  if the respective POS is less 
than 10% at the interim analy sis. In each 
of Sub-cohort s 1aand 1bandCohorts 2 and 4, if 7 or 
fewer responses are observed in 28 evaluable patients at interim analysis, then the respective 
cohort /sub-cohort will be stopped for futility . If at the time when the 28thpatient is enrolled a 
minimum of [ADDRESS_742344] not yet been observed, accrual in the cohort /sub-cohort may 
be temporaril y suspended until either the minimum number of 8 responders is observed or 
results of the interim analy sis allow the cohort /sub-cohort to continue. In Cohort 3, if 5or 
fewer responses are observed in [ADDRESS_742345] not yet been observed, accrual may be temporarily suspended in the cohort 
until either the minimum number of 6respon ders is observed or results of the interim analy sis 
allow the cohort to continue. No interim analysisfor futility is planned for C ohort 5,Cohort 6
and 7 .
The primary  analysis will be conducted when all treated patients in their respective 
cohort/sub
-coho rt (if not stopped for futility  at interim analysis) have completed at least 6 
cycles of treatment (18 weeks) or discontinued treatment earlier. Due to the expected 
difference in enrollment rate for each cohort /sub-cohort , the primary  analysis for the different 
cohorts /sub-cohorts may occur at different times. The primary  anal ysis for any  cohort that was 
stopped for futility  may  be combined with the primary  anal yses for other cohorts.
In Cohorts 1, 2, [ADDRESS_742346] clinically 
relevant efficacy if an ORR of ~
35% isobserved in that cohort /sub-cohort for the 
corresponding primary  analysis. In addition, 5 hypotheses will be tested as following for the 
cohorts /sub-cohorts (Hi0and H i1correspond to cohort/sub
-cohort iwhere i=1a, 1b , 2,3 or 4) :
Hi0: ORR ≤ 25%

[COMPANY_001] Confidential Page 74
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
With [ADDRESS_742347] not yet been observed, accrual in the 
cohort may be temporarily  suspended until either the minimum number of 6responders are 
observed or results of the interim analysis allow the cohort to continue .
No interim anal ysisfor futility  assessment is planned for C ohort 5,Cohort 6 and Cohort 7.
All evaluable patients at the time of the data cut-off for the interim analy sis will be used to 
obtain the futility  boundary  using the POS criteria. The futility  boundary will be calculated 
according to the actual number of evaluable patients in the interim an alysis.
The statistical considerations for the interim anal ysis can be found in Section 10.7 .
4.3 Definition of end of the study  
Following the cut-off date for the primary  analysis reported in the primary  Clinical Study 
Reports (CSR) (s), the study  will remain open. After all of the primary  analyses for the 
different cohorts have been conducted, ongoing patients will continue to receive INC280 
treatment and be followed as per the schedule of assessments, as long as patients derive 
benefit from INC280 or until the end of study  defined as the earliest occurrence of one of the 
following:
All patients have died or discontinued from the study
Another c linical study  becomes available that can continue to provide INC280 in this 
patient population and all patients ongoing are eligible to be tra nsferred to that clinical 
study
INC280 is commerciall y available and ongoing patients are able to obtain reimbursement 
of commercial supply
The final analy sis will occur at the endof the study . All available data from all patients up to 
this cut-offdate will be analyzed and summarized in a final CSR .
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7.1.5 for a discontinued or withdrawn patient . The investigator may  be 
informed of additional proced ures to be followed in order to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible for informing I RBs and/or ECs of the earl y termination of the trial.
5 Population
5.1 Patient populatio n
This study  will enroll adult male and female patients with EGFR wt (for exon 19 deletions 
and exon 21 L858R substitution mutations) ,ALK -negative rearrangement, advanced (stage 
IIIB 
or IV) NSCL C who have failed one or two p rior lines of systemic therapy (Cohort s 1-4), 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
who have failed one prior line of systemic therapy  (Cohort 6),or who have received no 
systemic therapy  (Cohort 5and Cohort 7)for advanced/metastatic disease .
Treatment failure is defined as documented disease progression or intolerance to treatment. 
Patients enrolled in the study  are not permitted to participate in additional parallel 
investigational drug or device studies. 
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the ex clusion criteria are offered treatment in the study.
5.[ADDRESS_742348] to meet all of the following criteria:
Written informed consent must be obtained prior to any  screening procedures
1.Age ≥ 18 y ears
2.Stage IIIB or IV NSCL C (any  histology ) at the time of study  entry
3.Histologicall y or c ytologically  confirmed diagnosis of NSCL C that is:
a.EGFR wt. This
should have been assessed as part of the patient standard of care by a 
validated test for EGFR mutations, as per the Molecular Testing Guideline for 
Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 
from College of American Pathologists, International Association for the Study  of 
Lung Cancer, and Association for Molec ular Pathology (Lindeman et al 2013). The 
EGFR wtstatus (for exon 19 
deletions and exon 21 L858R substitution mutations) 
must be documented in the patient source documents before the patient can be 
consented for pre-screening for cMET amplification and cMET mutation status
(except for patients who are treatment -naïve potentially  eligible forSub- Cohort 5a , 5b
and Cohort 7 or if molecular pre-screening will be performed by [CONTACT_565300] ). Patients with NSCL C of pure squamous cell histology  can enter pre-
screening without EGFR mutation testing or result , however patients with pure 
squamous cell histology and are known to have EGFR mutation s in exons [ADDRESS_742349] be documented in the patient source documents before the patient can be 
consented for pre-screening for cMET amplification and cMET mutation status,
except for patients who are treatment- naïve potentially  eligible for Sub- Cohort s 5a, 5b
and Cohort 7; if local ALK testing is not available, patient status will be determined
centrall y along with the cMET status
. Patients with NSCL C of pure squamous cell 
histology  can enter pre-screening without ALK testing or result, however patients 
with pure squamous cell histology  that are known to have ALK rearrangement will be 
excluded.
c.AND (as determined by  [CONTACT_565284] a [COMPANY_001] designated laboratory ) either : 
Cohort 1: P re-treated p atients with cMET GCN ≥
6, including:
Sub-cohort 1a: Patients with cMET GCN of ≥10,
or
Sub-cohort 1b: Patients with cMET GCN of ≥ 6 and < 10, or

[COMPANY_001] Confidential Page 76
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Cohort 2: P re-treated p atients with cMET GCN ≥ 4and < 6, or
Cohort 3: P re-treated 
patients with cMET GCN < 4, or
Cohort 4: P re-treated patients with cMET mutations regardless of cMET GCN, or
Cohort 5: T reatment -naïve patients with cMET d ysregulation, including : 
Sub-cohort 5a: Patients with cMET GCN of ≥10, or
Sub-cohort 5b: Patients with cMET mutations regardless of cMET GCN , or
Coho rt 6: Pre -treated patients with either cMET GCN ≥ 10 without cMET 
mutation sor cMET mutation s regardless of cMET GCN, or
Cohort 7: T reatment -naïve patients with cMET mutations regardless of cMET 
GCN
cMET (and ALK, if applicable) testing may  be performed w hile patient is still 
receiving anti -cancer therapy . However, the patient can only  be screened for the main 
study  once the patient has discontinued the last prior systemic treatment due to either 
disease progression or intolerance .
4.To be eligible for Cohort s 1-4, patients must have failed one or two prior lines of sy stemic 
therap yfor advanced/metastatic disease (stage IIIB or IV NSCLC). To be eligible for 
Cohort 6, 
patients must have failed one prior line of systemic therap y for 
advanced/metastatic disease (stage IIIB or IV NSCL C).Treatment failure is defined as 
documented disease progression or intolerance to treatment. Maintenance therapy  given 
after first line chemotherapy  will be considered as part of the first line if given to patients 
with documented response or stable disease before starting the maintenance therap y. Neo-
adjuvant and adjuvant systematic therapi[INVESTIGATOR_565252] [ADDRESS_742350] received any  systemic therapy  
for advanced/metastatic disease (stage IIIB or IV NSCL C). Neo -adjuvant and adjuvant 
systemic therapi[INVESTIGATOR_565253] > [ADDRESS_742351] recovered from all toxicities related to prior anticancer therapi[INVESTIGATOR_565254] ≤ 1 (CTCAE v 4.03) . Patients with any  grade of alopecia are allowed to enter the 
study .
7.
Patients must have adequate organ function including the following laboratory  values at 
the screening visit:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/Lwithout growth factor support
Platelets ≥75 x 109/L
Hemoglobin (Hgb) > 9g/dL
Calculated creatinine clearance (using Cockcroft -Gault formula) ≥ 45 mL /min
Total bilirubin ≤1.[ADDRESS_742352]

[COMPANY_001] Confidential Page 77
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Aspartate transaminase (AST) ≤ [ADDRESS_742353] ≤5 x UL N
Alanine transaminase (ALT) ≤ [ADDRESS_742354], except for patients with liver metastasis, 
who may only be included if AL T ≤[ADDRESS_742355]
Alkaline phosphatase (ALP) 
≤ 5 x UL N
Asymptomatic serum amy lase ≤ grade 2. Patients with grade [ADDRESS_742356] no signs and/or 
symptoms suggesting pancreatitis or pancreat ic injury  (e.g. ,elevated P -amylase, 
abnormal imaging findings of pancreas, etc.)
Serum lipase ≤ULN
Fasting plasma glucose ≤ 175 mg/dL (≤ 9. 7 mmol/L)
Patients must have the following laboratory  values within the laboratory  normal limits 
or corrected to wi thin normal limits with supplements during screening:
Potassium
Magnesium 
Phosphorus 
Total calcium (corrected for serum albumin) 
8.
ECOG performance status (PS) of [ADDRESS_742357] not meet anyof the following criteria:
1.Prior treatment with crizotinib, or any  other cMET or HGF inhibitor
2.Patients with known hy persensitivity  to an y of the excipi[INVESTIGATOR_22880] I NC280 (crospovidone, 
mannitol, microcry stalline cellulose, povidone, sodium laury l sulfate, magnesium stearate, 
colloidal silicon dioxide, and various coating premixes).
3.Patients with characterized EGFR mutations that predict sensitivity  to EGFR therap y, 
including, but not lim ited to exon 19 deletions and exon 21 mutations.
4.Patients with characterized ALK -positive rearrangement.
5.Patients with sy mptomatic central nervous s ystem (CNS) metastases who are 
neurologicall y unstable or have required increasing doses of steroids within the 2 weeks 
prior to study  entry  to manage CNS sy mptoms
6.Presence or history  of carcinom atous meningitis
7.Presence or history  of a malignant disease other than NSCL C that has been diagnosed 
and/or required therap y within the past 3 y ears. Exceptions to this ex clusion include the 
following: completel y resected basal cell and squamous cell skin cancers, and completel y 
resected carcinoma in situ of an y type
8.Clinically  significant, uncontrolled heart diseases.
Unstable angina within 6 months prior to screening
Myocardial infarction within 6 months prior to screening

[COMPANY_001] Confidential Page 78
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
History  of documented congestive heart failure ([LOCATION_001] Heart Association 
functional classification III -IV)
Uncontrolled h ypertension defined b y a S ystolic Blood Pressure (SBP) ≥ 160 mm Hg 
and/or Dias tolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without 
antihy pertensive medication. I nitiation or adjustment of antihy pertensive medication(s) 
is allowed prior to screening
Ventricular arrh ythmias
Supraventricular and nodal arrh ythmias not controlled with medication
Other cardiac arrh ythmia not controlled with medication
QTcF ≥ 450 ms (male patients), ≥ 460 ms (female patients) on the screening ECG (as 
mean of triplicate ECG)
9.Thoracic radiotherap y to lung fields ≤ [ADDRESS_742358] not recovered from radiotherap y-related toxicities. For all other anatomic sites 
(including radiotherap y to thoracic vertebrae and ribs), radiotherap y ≤ [ADDRESS_742359] not recovered from radiotherap y-related toxicities. 
Palliative radiotherap y for bone lesions ≤ 2 weeks prior to starting INC280 is allowed
10.Major surgery  (e.g., intra -thoracic, intra- abdominal or intra -pelvic) within 4 weeks prior (2 
weeks for resection of brain metastases) to starting INC280 or who have not recovered 
from side effects of such procedure. Video -assisted thoracic surgery (VATS) and 
mediastinoscopy  will not be counted as major surgery  and patients can be enrolled in the 
study  ≥[ADDRESS_742360] 1 week prior to the start of treatment with INC280 and 
for the duration of the study :
Strong inducers of CYP3A4
12.Impairment of GI function or GI disease that may significantl y alter the absorption of 
INC280 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarr hea, or 
malabsorption sy ndrome)
13.Unable or unwilling to swallow tablets as per dosing schedule
14.Patients receiving unstable or increasing doses of corticosteroids. If patients are on 
corticosteroids for endocrine deficiencies or tumor -
associated symptoms other than CNS 
related, dose must have been stabilized (or decreasing) for at least [ADDRESS_742361] dose of INC280, and for the duration of the study . 
Patients on non
-enzy me-inducing anticonvulsants are eligible
16.Applicable to C ohort s 1-4 and Cohort 6 only: Previous anti -cancer and investigational 
agents within 4 weeks or ≤ 5x half -life of the agent (whichever is longer) before first dose 
of INC280. If previous treatment is amonoclonal antibody , then the treatment must be 
discontinued at least 4weeks bef ore first dose of INC280
. If previous treatment is an oral 
targeted agent, then the treatment must be discontinued at least [ADDRESS_742362] dose of INC280.

[COMPANY_001] Confidential Page 79
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
17.Other severe, acute, or chronic medical or psychotic conditions or labor atory 
abnormalities that in the opi[INVESTIGATOR_565255], or that may  interfere with the interpretation of study  results
18.Any other condition that would, in the Investigator’s judgment, contraindi cate patient’s 
participation in the clinical study  due to safet y concerns or compliance with clinical study 
procedures, e.g., infection (including active hepatitis B and C), inflammation, intestinal 
obstruction, unable to swallow medication, social / psy chological issues, etc.
19.Pregnant or nursing (lactating) women
20.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing and for 7days after stoppi[INVESTIGATOR_056]. Highl y effective contraception 
methods include:
Total abstinence (when this is in line with the preferred and usual lifesty le of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total hysterectomy or tubal ligation at least six weeks before taking 
study  treatment. Incase of oophorect omy alone, only when the reproductive status of 
the woman has been confirmed by  [CONTACT_104]
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partner should be the sole partner for that subject
Use of o ral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate < 1%), for example hormone 
vaginal ring or tr ansdermal hormone contraception .
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_742363] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g.,age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectomy or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by [CONTACT_50085]
21.Sexually  active males unless they use a condom during intercourse while taking drug and 
for 7days after stoppi[INVESTIGATOR_63950] a child in this period. A condom 
is required to be used also by [CONTACT_64064] a male 
partner in order to prevent deliver y of the drug via sem en.
22.Presence or history  of interstitial lung disease or interstitial pneumonitis, including 
clinically  significant radiation pneumonitis (i.e., affecting activities of daily  living or 
requiring therapeutic intervention).

[COMPANY_001] Confidential Page 80
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
6 Treatment
6.1 Stud y treatment
For this study , the term “investigational treatment” or “study  drug” refers to INC280. The 
dose and treatment schedule are listed in Table 6 -1.
The orally administered film-
coated tablet formulation will be provided in up to three 
strengths of 100 mg, 150 mgand 200 mg(if available) free base equivalent. For the list of 
excipi[INVESTIGATOR_840], please refer to current [Investigator’s Brochure ].
6.1.1 Dosing regimen
INC280 tablet will be adminis tered orally  on a continuous twice daily  (BID) dosing schedule ,
on a flat scale of mg/day and not individually  adjusted by [CONTACT_565301]. A 
complete cycle of treatment is defined as [ADDRESS_742364] the patient to take the study  drug exactly  as prescribed.
Except on days of PK sampling , patients should take 400 mgINC280 tablet stwice daily 
(BID) at approximately  the same time each day starting at Cy cle 1 Day  1.
Each dose of INC280 isto be taken with a glass of water (at least 8 ounces –
approximately  250 mL) and consumed over as short a time as possible (i.e.,not slower 
than 1 tablet every  2 minutes).
Patients should be instructed to swallow the tablets whole and not to chew them.
INC280 should be administered in the fasted state, at least 1 hour befor e or 2 hours after a 
meal. The morning and the evening doses should be taken 12 (± 4) hours apart, although 
12-hour interval is highl y recommended. The morning dose should be taken the same time 
each morning. If a dose is not taken within 4 hours of the planned dosing time, the missed 
dose should not be replaced
Only  for Cohort 6 and 7 , 
INC280 can be administered with or without food. 
On days when PK blood samples are to be collected, patients will be instructed to hold 
their dose until arrival at the study  center. INC280 will be administered at the site in the 
morning prior to the PK blood draws supervised by a
 member of the research team. The 
exact time of drug administration should berecorded in the appropriate eCRF. If a patient 
vomits within 4 hours of INC280 dosing, the time of vomiting should be recorded on the 
eCRF.
Patients should be instructed not to make up for missed doses or partial doses (i.e.,when 
the entire dose is not taken as instructed). A missed or partial dose will be defined as a 
case when the full dose is not taken within 4 hours of the scheduled twice daily  dosing. If 
that occurs, then the dose (or part remaining dose) should not be taken and dosing should 
restart with the next scheduled dose. If vomiting occurs, no attempt should be made to 
replace the vomited dose before the next scheduled dose.
During the whole duration of treatment with INC280, the patient is recommended to use 
precautionary  measures against ul traviolet exposure (e.g., use of sunscreen, protective 
clothing, avoid sunbathing or using a solarium).

[COMPANY_001] Confidential Page 81
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The investigator should instruct the patient to take INC280 exactly  as prescribed. All dosages 
prescribed and dispensed to the patient and all dose chan ges during the study  must be 
recorded on the Dosage Administration Record eCRF.
Table 6-1 Dose and treatment schedule
Study  
treatmentsPharmaceutical form and 
route of admini stration DoseFrequency  and/or 
Regimen
INC280 Tablet for oral use 400 mg ( 4x 100 mg or 2x 200 mg, if 
available , or 2 x 150 mg + 1 x 100 mg, if 
applicable )Twice Daily (BID )
6.1.2 Ancillary  treatments
Not applicable .
6.1.3 Rescue medication 
Not applicable.
6.1.4 Guidelines for continuation of treatment
For guidelines for dose modification of treatment, refer to Section 6.3.
6.1.5 Treatment duration
Patients may  be discontinued from treatment with INC280 earlier due to:
Diseas e progression according to RECI ST 1.[ADDRESS_742365] 1.1 -
defined PD 
(as determined by  [CONTACT_565302]) if, in the judgment of 
the investigato r, there is evidence of clinical benefit and the patient wishes to continue on 
the study  treatment. 
Unacceptable toxicity  that precludes further treatment
Discontinued treatment at the discretion of the investigator or the patient 
Death
Patient is lost t o follow -up
6.[ADDRESS_742366] preceding toxicity  as grade d by 
[CONTACT_560058] (NCI -CTCAE version 4.03). Any changes must be recorded 
on the Dosage Administration R ecord eCRF page .

[COMPANY_001] Confidential Page 82
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
General guidelines for dose modifications are presented in Table 6-3.
Unless otherwise indicated in Table 6-3, f or grade [ADDRESS_742367] resolution to grade 1 
followed by [CONTACT_252387]-initiation at the same dose level, dependi ng on the 
type of toxicity  as described in Table 6-3. For any grade 4 toxicity , patients should interrupt 
study  treatment until resolution to grade 1, followed by [CONTACT_252388] (refer to 
Table 6-3)
.
Any planned variance from the guidelines in Table 6-3, in view of patient safet y ( unless there 
is an urgent need for action ) when in the opi[INVESTIGATOR_565256], must first be discussed and approved by[CONTACT_565303] .
A patient must discontinue treatment with INC280 if, after treatment is resumed at thelowest 
allowed dose (200 mg BID) , the toxicity  recurs with the same or worse severity  despi[INVESTIGATOR_565257]. All interruptions or change to study d rug administration must be recorded on the 
Dose Administration Record eCRF page .
6.3.[ADDRESS_742368] dose allowed, 200 mg BID in tablets 
is expected to be pharmacologically active, as the observed 
stead y state plasma trough 
concentrations ([CINC280X1101] , [CINC280X2202] , n=6) were above the concentration 
associ ated with full cMET inhibition in xenograft mice model s(IC90, 120 nM total 
concentration).
Dose re-escalation of study  treatment to the previous dose level is allowed only once, and if 
no AE leading to dose modification is observed after at least 1 cycle (3 weeks) of study 
treatment at the reduced dose.
Table 6-2 Dose red uction steps for INC280
INC280 dose levels*
Starting dose level - 0 Dose level - 1 Dose level - 2
INC280 400 mg BID 300 mg BID 200 mg BID
*Dose reduction should be based on the worst toxicity demonstrated at the last dose.
**Dose reduction below 200 m g is not allowed.

[COMPANY_001] Confidential Page 83
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Table 6-[ADDRESS_742369] toxicity CTCAE GradeaDuring a cycle of therapy
No toxicity Maintain dose level
HEMATOLOGICAL
Neutrophil count decreased (ANC) Neutropenia
Grade 1 (ANC < LLN -1500/mm3 ; <LLN -1.5 x 109/L) Maintain dose level
Grade 2 (ANC < 1500 -1000/mm3 ; < 1.5 -1.0 x 109/L) Maintain dose level
Grade 3 (ANC < 1000 -500/mm3 ; < 1.0 -0.5 x 109/L) Omit dose until resolved to ≤ grade 2, then:
If resolved in ≤ 7 days, resume treatment at the same dose level
If resolved in > 7 days, then ↓1 dose level
Grade 4 (ANC < 500/mm3 ; < 0.5 x 109/L) Omit dose until resolved to ≤ grade 2 and then ↓1 dose level
Platelet count decreased ( Thrombocytopenia )
Grade 1 (PLT < LLN - 75,000/mm3 ; < LLN -75 x 109/L) Maintain dose level
Grade 2 (PLT < 75,000 - 50,000/mm3 ; < 75 -50 x 109/L) Maintain dose level
Grade 3 (PLT < 50,000 - 25,000/mm3 ; < 50 -25 x 109/L) Omit dose until resolved to ≤ grade 2, then:
If resolved in ≤ 7 days, the n maintain dose level
If resolved in > 7 days, then ↓1 dose level 
Grade 4 (PLT < 25,000/mm3 ; < 25 x 109/L) Omit dose until resolved to ≤ grade 2, then ↓1 dose level
Febrile neutropenia (ANC <1000/mm3 (<1.0 x 109/L), 
fever > 38. 3°C)Omit dose, then:
If resolved in ≤ 7 days, resume treatment at ↓1 dose level
Mandatory: If resolved in > 7 days, discontinue patient from study drug treatment

[COMPANY_001] Confidential Page 84
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Recommended dose modifications for INC280
Worst toxicity CTCAE GradeaDuring a cycle of therapy
Hemoglobin decreased (Anemia)
Grade 1 (Hg b< LLN -10.0 g/dL; < LLN -6.2 mmol/L; < 
LLN -100 g/L )Maintain dose level
Grade 2 (Hg b< 10.0 -8.0 g/dL; < 6.2 –4.9 mmol/L; < 100 
-80 g/L )Maintain dose level
Grade 3 (Hgb < 8.0 g/dL; < 4.9 mmol/L; < 80 g/L) Omit dose unt il resolved to ≤ grade 2, then:
If resolved in ≤ 7 days, resume treatment at the same dose level
If resolved in > 7 days, then ↓1 dose level
Grade 4 Omit dose until resolved to ≤ grade 2 and then ↓1 dose level
Mandatory: If toxicity recurs, discontinue patient from study drug treatment.
RENAL
Serum creatinine
Grade 1 (> ULN -1.[ADDRESS_742370]) Maintain dose level
Grade 2 (> 1.[ADDRESS_742371]) Omit dose until resolved to ≤ grade 1 or baseline, then resume treatment at the same dose level. 
Grade 3 (> 3.[ADDRESS_742372]) Omit dose until resolved to ≤ grade 1 or baseline, then resume treatment at ↓1 dose lev el. 
Grade 4 (> 6.[ADDRESS_742373]) Mandatory: Permanently discontinue patient from study drug treatment
HEPATIC
Isolated Total Bilirubin elevation *
Grade 1 (> ULN -1.[ADDRESS_742374]) Maintain dose level
Grade 2 (> 1.[ADDRESS_742375]) Omit dose until resolved to ≤ grade 1, then 
If resolved in ≤ 7 days, maintain dose level
If resolved in > 7 days, ↓1 dose level
Grade 3 (> 3.[ADDRESS_742376]) Omit dose until resolved to ≤ grade 1, then 
If resolved in ≤ 7 days, ↓1 dose level 
If resolved in > 7 days, discontinue INC280 pe rmanently
Grade 4 (> 10.[ADDRESS_742377]) Mandatory: Permanently d iscontinue patient from study drug treatment
Isolated AST or ALT elevation
Grade 1 (> ULN - 3x ULN) Maintain dose level
Grade 2 (> 3.0-5.[ADDRESS_742378]) Maintain dose level 
Grade 3 (> 5.[ADDRESS_742379]) Omit dose until resolved to ≤ grade 1 (or ≤ grade 2 if grade 2 elevation at baseline) then

[COMPANY_001] Confidential Page 85
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Recommended dose modifications for INC280
Worst toxicity CTCAE GradeaDuring a cycle of therapy
If resolved in ≤ 7 days, then resume treatment at the same dose level
If resolved in > 7 days, resume treatment at ↓1 dose level
Grade 4 (> 20.[ADDRESS_742380]) For patients with cl inical benefit from INC280 upon investigator’s judgement :
Omit dose until resolved to ≤ grade 1 (or ≤ grade 2 if grade 2 elevation at baseline), then resume 
treatment at ↓1 dose level. Only 1 dose reduction is allowed; if this AE reoccurs at Grade 3 or 
above, discontinue INC280 permanently.
For all other patients: 
Mandatory: Permanently discontinue patient from study drug treatment
Combined elevations of AST or ALT and Total Bilirubinb,d
For patients with normal baseline ALT andAST andtotal 
bilirubi n value:
AST or ALT > 3.[ADDRESS_742381] combined with total bilirubin > 
2.[ADDRESS_742382] or ALT or total 
bilirubin value: 
[AST or ALT > 2 x baseline AND > 3.[ADDRESS_742383]] OR [AST or 
ALT > 8.[ADDRESS_742384]] , whichever is lower, combined with
[total bilirubin > 2 x baseline AND > 2.[ADDRESS_742385]]Mandatory: Permanently discontinue patient from study drug treatment
METABOLIC
Asymptomatic amy lase and/or lipase elevation (If sy mptomatic elevations of any  grade , disc ontinue INC280 permanently )
Grade 1 (> ULN -1.[ADDRESS_742386]) Maintain dose level
Grade 2 (> 1.[ADDRESS_742387]) Maintain dose level
Grade 3 (> 2.[ADDRESS_742388]) Omit the dose until resolved to ≤ grade 2 , then
If resolved in ≤ 14 days, resume treatment at the same dose level
If resolved in > 14 days, then ↓1 dose level
Grade 4 (> 5.[ADDRESS_742389]) Mandatory: Permanently discontinue pa tient from study drug treatment

[COMPANY_001] Confidential Page 86
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Recommended dose modifications for INC280
Worst toxicity CTCAE GradeaDuring a cycle of therapy
CARDIAC
Electrocardiogram QT corrected (QTc) interval prolonged
Grade 1 (QTc F450-480 ms) and
Grade 2 (QTc F481-500 ms)Maintain dose level
Grade 3 (QTcF ≥ [ADDRESS_742390] two separate ECGs) Omit dose unt il resolved to ≤ grade 2, then:
If resolved in ≤ 7 days, resume treatment at the same dose level
If resolved in > 7 days, then ↓1 dose level
Grade 4 (QTc F≥ 501 or > 60 ms change from baseline 
and Torsades de pointes or polymorphic ventricular 
tachycardia or signs/symptoms of serious arrhythmia)Mandat ory: Permanently discontinue patient from study drug treatment
GASTROINTESTINAL
Pancreatitis
Grade 2 Maintain dose level
Grade ≥ 3 Mandatory: Permanently discontinue patient from study drug treatment
Diarrhea **
Grade 1 (despi[INVESTIGATOR_76303]-diarrhe al medication) Maintain dose level
Grade 2 (despi[INVESTIGATOR_76303]-diarrheal medication) Omit dose until resolved to ≤ grade 1, then maintain dose level.
If diarrhea returns as ≥ grade 2, then omit dose until resolved to ≤ grade 1, then resume treatment at ↓1 
dose level
Grade 3or 4(despi[INVESTIGATOR_76303]- diarrheal medication) Omit dose until resolved to ≤ grade 1, then resume treatment at ↓1 dose level
Vomiting
Grade 1 (despi[INVESTIGATOR_184825]-emetics) Maintain dose level
Grade 2 (despi[INVESTIGATOR_184825]-emetics) Omit dose until resolved to ≤ grade 1, then maintain dose level.
If vomiting returns as ≥ grade 2, then omit dose until resolved to ≤ grade 1, then ↓1 dose level.
Grade 3 (despi[INVESTIGATOR_184825]-emetics) Omit dose until resolved to ≤ grade2, then ↓1 dose level
Grade 4 (despi[INVESTIGATOR_184825]-emetics) Omit dose until resolved to ≤ grade 2, then ↓1 dose level
Nausea
Grade 1 or 2 (despi[INVESTIGATOR_184825]-emetics) Maintain dose level
Grade 3 (despi[INVESTIGATOR_184825]-emetics) Omit d ose until resolved to ≤ grade 1, then ↓1 dose level

[COMPANY_001] Confidential Page 87
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Recommended dose modifications for INC280
Worst toxicity CTCAE GradeaDuring a cycle of therapy
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
Rash/photosensitivity ***
Grade 1 Maintain dose level.
Grade 2 Maintain dose level.
Grade 3, despi[INVESTIGATOR_565258] ≤ 1, then:
If resolved in ≤ 7 days, then ↓resume treatment at 1 dose level
If resolved in > 7 days (despi[INVESTIGATOR_11932]), then discontinue patient from study drug 
treatment
Grade 4, despi[INVESTIGATOR_63988]: Omit dose and discontinue patient from study drug trea tment
RESPI[INVESTIGATOR_565259] (ILD)/Pneumonitis
Monitor patients for pulmonary symptoms indicative of ILD/Pneumonitis . In addition, withhold INC280 for acute onset of new or progressive une xplained pulmonary 
symptoms, such as dyspnea, cough and fever and during diagnostic workup for ILD /Pneumonitis to exclude alternative causes such as, but not limited to infections, 
lymphangitic carcinomatosis, cardiogenic edema, or pulmonary hemorrhage .
Grade 1 Interrupt INC280 during diagnostic workup for ILD /Pneumonitis .Exclude infections and other etiologies .
In presence of diagnosis of ILD/Pneumonitis after diagnostic workup , it is mandatory to permanently  
discontinue INC280.
Only in absence of diagno sis of ILD /Pneumonitis , study drug may be restarted at the same dose.
If it recurs after restarting of study drug ,permanently discontinue INC280 .
Grade 2Mandatory: Interrupt INC280 dose during diagnostic workup for ILD until improvement to ≤ Grade 1. Exclude 
infections and other etiologies.
In presence of diagnosis of ILD/Pneumonitis after diagnostic workup , it is mandatory to permanently  
discontinue INC28 0.
Only in absence of diagnosis of ILD/ Pneumonitis , study drug may be restarted following these guidelines :
If resolve sto ≤ Grade 1 in ≤ 7 days reduce study drug by 1 dose level
If fail sto resolve to ≤ Grade 1 within 7 days or recur safter resumption of study drug at decreased dose, 
permanently discontinue INC280
Grade 3 and Grade 4Mandatory: Permanently discontinue study drug

[COMPANY_001] Confidential Page 88
Amended Protocol Version 06 ( Clean ) Protocol No. C INC280A2201
Recommended dose modifications for INC280
Worst toxicity CTCAE GradeaDuring a cycle of therapy
Treat with IV steroids as clinically indicated. Oxygen therapy as indicated .
Fatigue/ Asthenia (General disorders and adminis tration site conditions)
Grade 1 or 2 Maintain dose level
Grade 3 Omit dose until resolved to ≤ grade 1, then :
If resolved in ≤ 7 days, resume treatment at same dose level
If resolved in > 7 days, resume treatment at ↓1 dose level
Peripheral edema 
Grade 1 or 2
Grade 3Maintain dose level 
Discontinue dose until resolv ed to ≤ Grade 1, then ↓1 dose level
Other adverse events
Grade 1 or 2 Maintain dose level, consider to initiate appropriate support medication.
For any intolerable grade 2 (e.g.: limiting instrumental ADL), consider omitting the dose until resolved to ≤
grade 1, then ↓1 dose level. 
Grade 3 Omit dose until resolved to ≤ grade 2, then ↓[ADDRESS_742391] preceding toxicity.
a Common Toxicity Criteria for Adverse Events (CTCAE Version 4.03).
b “Combined” defined as: total bilirubin increase to the defined threshold concurrently with ALT/AST increase to the defined threshold
c “Cholest asis” defined as: ALP elevation (> 2.[ADDRESS_742392] and R value (ALT/ ALP in x ULN) < 2.0) in patients without bone metastasis, or elevation of ALP liver fraction in 
patients with bone metastasis
d If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the instructions f or isolated elevation of total bilirubin and 
isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatme nt at the situation when omit dose is needed 
for one parameter and discontinue treatment is required for another parameter). After all elevations resolve to the defined thresholds that allow treatment re-initiation, re -
start the treatment either at the same dose or at one dose lower if meeting a criterion for dose reduction
* Note: If total bi lirubin > 3.[ADDRESS_742393] (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per institutional guidelines 
(e.g., review of peripheral blood smear and haptoglobin determination), then ↓1 dose level and con tinue treatment at the discretion of the investigator.
** Note: antidiarrheal medication is recommended at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt diarrhea
*** During the whole duration of treatment with INC280, the patient is recommend ed to use precautionary measures against ultraviolet exposure (e.g., use of sunscreen, 
protective clothing and avoid sunbathing o r using a solarium intensively.

[COMPANY_001] Confidential Page 89
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
6.3.3 Treatment interruption and treatment discontinuation
If the administration of INC280 is tempo rarily  interrupted for reasons other than toxicity , then 
treatment with INC280 may be resumed at the same dose. If the treatment with INC280 is 
withheld due to toxicity , the dose modification guidelines in Table 6-3should be followed. In 
any case, scheduled visits and all assessments (including tumor 
assessments) should continue 
to be performed, as described in Table 7-1.
If the treatment with INC280 is withheld for more than 21 
consecutive days (counting from 
the first day when a dose was interrupted ), then INC280 should be permanently  discontinued . 
Under exceptional circumstance, when the investigator believes that continuing treatment may 
still derive clinical benefit for the patient , study treatment may be resumed .However, the 
investigator must discuss and receive approval from [COMPANY_001] Medical Lead or designee prior 
to continuing INC280 treatment.
Patients who discontinue the study  due to a study drug related AE or an abnormal laboratory 
value must be followed as described in Section 6.3.[ADDRESS_742394] supportive care (BSC) as per standard local practice for the 
treatment of pre -existing medical conditions or adverse events that may  arise during the study . 
BSC is defined as drug or non-drug therapi[INVESTIGATOR_014], nutritio nal support, physical therapy , or any 
other treatment alternative that the investigator believes to be in the patient’s best interest, but 
excluding other anti-neoplastic treatments (with the exception of radiotherap y for control of 
bone metastases 
–see Section 6.4.1 ).
Table 6-4 Follo w-up evaluations for selected toxicities *
TOXICITY FOLLOW -UP EVALUATION
HEMATOLOGICAL
Febrile neutropenia,
Neutropenia ≥ CTCAE grade 3
Thrombocytopenia ≥ CTCAE grade 3
Anemia ≥ CTCAE grade 3Test weekly (or more frequently if clinically indicated ) until ≤ CTC AE 
grade 2.
Perform physical exam for check on bruising in case of major 
thrombocytop enia.
RENAL
Serum creatinine ≥ CTCAE grade [ADDRESS_742395] weekly (or more frequently if clinically indicated ) until ≤ CTCAE 
grade 1 or baseline.
Patients will be instructed to increase hydration until resolution to ≤ 
CTCAE grade 1 or baseline.

[COMPANY_001] Confidential Page 90
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
TOXICITY FOLLOW -UP EVALUATION
HEPATIC
Isolat ed total bilirubin elevation
Isolated AST/ALT elevation Total bilirubin CTCAE Grade 1:
Monitor LFTs per protocol or more frequently if clinically indicated 
Total bilirubin CTCAE Grade 2:
Weekly monitoring of LFTs, or more frequently if clini cally indicated, until 
resolved to ≤ 1.[ADDRESS_742396]
Total bilirubin CTCAE Grade 3:
Weekly monitoring of LFTs, or more frequently if clinically indicated, until 
resolved to ≤ 1.[ADDRESS_742397]. If resolved in > 7 days, after discontinuing the 
patient from INC280 permane ntly, the patient should be monitored 
weekly (including LFTs), or more frequently if clinically indicated, until 
total bilirubin have resolved to baseline or stabilization over 4 weeks
Total bilirubin CTCAE Grade 4:
After discontinuing the patient from INC 280 permanently, the patient 
should be monitored weekly (including LFTs), or more frequently if 
clinically indicated, until total bilirubin have resolved to baseline or 
stabilization over [ADDRESS_742398]/ALT CTCAE Grade 2 elevation:
For patients with baseline value ≤ 3.[ADDRESS_742399]: repeat LFTs as soon as 
possible, preferably within 48 -72 hours from awareness of the abnormal 
results; if abnormal lab values are confirmed upon the repeat test, then 
monitor LFTs weekly, or more frequently if clinically indicated, unti l 
resolved to ≤ 3.[ADDRESS_742400]
For patients with baseline value > 3.[ADDRESS_742401]: monitor LFTs per 
protocol or more frequently if clinically indicated
AST/ALT CTCAE Grade 3 elevation:
For AST/ALT elevation > 5.[ADDRESS_742402]:
For patients with baseline value ≤ 3.[ADDRESS_742403]: repeat LFTs as soon as 
possible, preferably within 48 -72 hours from awareness of the 
abnormal results; monitor LFTs weekly, or more frequently if clinically 
indicated, until resolved to ≤ 3.[ADDRESS_742404] 
For patients with baseline value > 3.[ADDRESS_742405]: repeat LFTs as 
soon as possible, preferably within 48 -72 hours from awareness of 
the abnormal results; if abnormal lab values are confir med upon the 
repeat test, then monitor LFTs, weekly, or more frequently if clinically 
indicated, until resolved t o ≤ 5.[ADDRESS_742406]/ALT elevation > 10.[ADDRESS_742407]: 
Repeat LFTs as soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results; monitor LFTs weekly, or more 
frequently if clinically indicated, until resolved to ≤ baseline
AST/ALT CTCAE Grade 4 elevation:
Repeat LFTs as soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results; monitor LFTs weekly, or more 
frequently if clinically indicated, until resolved to baseline or stabilization 
over [ADDRESS_742408] or ALT and total bilirubin:
After discontinuing the patient from INC280 permanently, repeat LFTs as 
soon as possible, preferably within [ADDRESS_742409], GGT, total bilirubin (fractionated [dire ct 
and indirect], if total bilirubin > 2.[ADDRESS_742410]), and alkaline phosphatase 
(fractionated [quantification of isoforms], if alkaline phosphatase > 2.[ADDRESS_742411].)

[COMPANY_001] Confidential Page 91
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
TOXICITY FOLLOW -UP EVALUATION
METABOLIC
Asymptomatic a mylase or lipase ≥ 
CTCAE grade 3Test weekly (or more frequently) until ≤ CTCAE grade 2.
A CT scan or equivalent imaging procedure to assess the pancreas, 
liver, and gallbladder is recommended within [ADDRESS_742412] 
occurrence of any ≥ CTCAE grade 3 result, to exclude disease 
progression or potential other liver or pancreatic disease.
CARDIAC
≥ CTCAE grade 3
QTcF ≥ 501 ms (CTCAE grade 3)Test weekly (or more frequently) until ≤CTCAE grade 2.
When QTcF ≥ 501 ms (CTCAE grade 3), perform the following :
Call the study’s central ECG review laboratory immediately and 
request an immediate manual read of the ECG.
Perform an analysis of serum potassium, calcium, phosphorus, and 
magnesium, and if below lower limit of normal, correct with 
supplements to within normal limits.
Review concomitant medication usage forthe potential to inhibit 
CYP3A4/5 (Table 6 -5)and/or to prolong the QT -interval (Table 6 -6).
Check compliance with correct dose and administration of INC280.
Perform a repeat ECG within one hour of the first QTcF of ≥501 ms.
If QTcF remains ≥ [ADDRESS_742413] once daily until the QTcF returns to < 501 ms.
Repeat ECGs 7 days and 14 days (and then every 21 days) after dose 
resumption for all patients who had therapy interrupted due to QTcF ≥ 
501 ms.
If QTcF of ≥ 501 ms recurs, repeat ECGs as described above.
Notes:
The i nvestigator should contact [CONTACT_565304] a patient with QTcF 
prolongation should be maintained on study.
If the central ECG report shows a QTcF ≥ 501 msec (not previously 
documented on the site machine), contact [CONTACT_565305]/her to suspend INC280 and return for a repeat ECG as soon as 
possible. The central ECG reader should be called for a manual read 
of the repeat ECG immediately, and the above guidance followed.

[COMPANY_001] Confidential Page 92
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
TOXICITY FOLLOW -UP EVALUATION
GASTROINTESTINAL
Diarrhea
Naus ea and VomitingInitiate anti -diarrhea treatment after first signs of abdominal crampi[INVESTIGATOR_007], 
loose stools or overt diarrhea.
Consider/Investigate potential concomitant medication, food or 
comorbidity driven causes of diarrhea (including infectious causes) a nd 
remedy these causes if possible (e.g. discontinuation of concomitant 
medication, dietary modification, treatment of comorbidity).
The patient should be monitored for signs of dehydration and instructed 
to take preventive measures against dehydration as soon as diarrhea 
occurs. Antidiarrheal medication must be initiated at the first sign of 
abdominal crampi[INVESTIGATOR_007], loose stools or overt diarrhea. Concomitant 
medication for the treatment of diarrhea should follow local practice and 
the investigator’s best judgm ent and may follow “the recommended 
guidelines for the treatment of cancer treatment -induced diarrhea” 
(Benson et al 2004 ). For example:
For uncomplicated diarrhea ( grade 1 or 2 without complicating sig ns 
or symptoms), loperamide given at a standard dose (e.g. initial 
administration of 4 mg, then 2 mg every 2 -4 hours, maximum of 16 
mg/day), along with oral hydration and dietetic measures should be 
considered. Note: complicating signs or symptoms include: moderate 
to severe crampi[INVESTIGATOR_007], decreased performance status, fever, 
neutropenia, frank bleeding or dehydration.
For complicated diarrhea (all grade 3 or 4, grade 1-2 with 
complicating signs or symptoms), management should involve 
intravenous (IV) fluids, and consider treatment with octreotide (at 
starting dose of 100 to 150 µg sub -cutaneous tid or 25 to 50 µg IV) 
and antibiotics (e.g. fluoroquinolone) should be given.
The investigator should consider/investigate potential concomitant 
medication, food or com orbidity driven causes of nausea and/or vomiting 
and remedy these causes if possible (e.g. discontinuation of concomitant 
medication, dietary modification, treatment of comorbidity).
Individualized supportive and anti -emetic treatment should be initiated, 
as appropriate, at the first signs and/or symptoms of these AEs. In 
patients with vomiting, the patient should be monitored for signs of 
dehydration and instructed to take preventive measures against 
dehydration.
Concomitant medication for the treatment of nausea and/or vomiting 
should follow local practice and the investigator’s best judgmen t.
SKIN TOXICITY (rash and 
photosensitivity)
CTCAE grade 1
CTCAE grade 2
≥ CTCAE grade 3Consider to initiate institute appropriate skin toxicity therapy (suc h as 
antihistamines, topi[INVESTIGATOR_63951] -dose systemic 
corticosteroids)
Initiate/intensify appropriate skin toxicity therapy (such as antihistamines, 
topi[INVESTIGATOR_63951] -dose systemic corticosteroids) .
Intensify appropriate skin t oxicity therapy and monitor weekly or more 
frequently until resolved to grade ≤ 2

[COMPANY_001] Confidential Page 93
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
TOXICITY FOLLOW -UP EVALUATION
Peripheral edema
≤ CTCAE grade 2
≥ CTCAE grade 3Consider to initiate c onservative measures such as leg elevation, 
compression stockings, and dietary salt modification as clinically 
indicated
Initiate/intensify conservative measures
RESPI[INVESTIGATOR_565260] /Pneumonitis
CTCAE Grade [ADDRESS_742414] scan (high -resolution with lung windows) recommended, with serial 
imaging to monitor for resolution or progression -re-image at least every 
[ADDRESS_742415] scan (high -resolution with lung windows)
Monitor symptom s daily, consider hospi[INVESTIGATOR_059]
Clinical evaluation and laboratory work up for infection
Consult pulmonologist
Pulmonary function tests a - if normal at baseline, repeat every 8 
weeks 
Bronchoscopy with biopsy and/or BAL recommended c
Symptomatic therapy including corticosteroids if clinically indicated 
(1 to 2 mg/kg/day prednisone or equivalent as clinically indicated) b
CT scan (high -resolution with lung windows)
Clinical evaluation and laboratory work -up for infection
Consult pulmonologist
Pulmonary f unction testsa-if < normal, repeat every 8 weeks until ≥ 
normal
Bronchoscopy with biopsy and/or BAL if possiblec
Treat with IV steroids (methylprednisolone 125 mg) as indicated. W hen 
symptoms improve to ≤ Grade 1, a high dose oral steroid (prednisone 1 
to 2 mg/kg once per day or dexamethasone 4 mg every 4 hours)b.
If IV steroids followed by [CONTACT_458532] 48 to 72 hours, consider non -corticosteroid 
immunosuppressive medication
*Note: this table refers only to the evaluation schedule to monitor selected toxicities. Refer to Table 6 -3for dose 
modifications required for applicable toxicities
**Note: except if the patient is Grade 2 at baseline in which cas e: it is ≥ CTCAE grade 3
aPFT (Pulmonary function tests) to include: diffusing capacity corrected for hemoglobin (DLCO); spi[INVESTIGATOR_038]; 
resting oxygen saturation
Guideline for significant deterioration in lung function: Decrease in spi[INVESTIGATOR_10230]/or DLCO of 30% and/or O 2
saturation ≤ 88% at rest on room air.
bDuration and dose of course of corticosteroids will vary according to circumstances but should be as limited as 
possible. Consider tapering dosage at end.
cIf bronchoscopy is performed, bronchoalveolar lavage (BAL) should be done where possible to exclude alveolar 
hemorrhage, opportunistic infections, cell count + determination lymphocyte CD4/8 count where possible.

[COMPANY_001] Confidential Page 94
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[IP_ADDRESS] Follow up on potential drug -induced liver injury cases
Patients with transaminase incre ase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically  important events. 
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value s; patients meeting any of the follow ing criteria will require further follow -up as outlined 
below:
For patients with normal AL T andAST and TBIL value at baseline: AST or AL T > 3.[ADDRESS_742416] combined with TBIL > 2.0 x UL N 
For patients with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_742417]] OR [AST or ALT > 8.[ADDRESS_742418]], whichever is lower, 
combined with [TBIL > 2 x baseline AND > 2.[ADDRESS_742419]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as: ALP elevation > 2.[ADDRESS_742420] with R value (ALT/ALP in x ULN) < 2 in patients without 
bone metastasis, or elevation of AL P liver fraction in patients with bone metastasis.
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment , and repeat LFT testing as soon as possible, 
preferably  within 48 hours from 
the awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 
Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 
A detailed history , including relevant i nformation, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history  of any  pre-existing liver 
conditions or risk factors, should be collected. 
Further testing for acute hepatitis A, B, C or E infection and live r imaging (eg, biliary  tract) 
may be warranted. 
Obtain PK sample, as close as possible to last dose of study  drug, if PK analy sis is 
performed in the stud y. 
Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist. 
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term “potential drug -induced liver injury ”. All events should be followed u p with the outcome 
clearl y documented.
6.3.5 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria as well as specific dose modification and stoppi[INVESTIGATOR_63956]. Recommended guidelines for proph ylactic or supportive treatment 
for expected toxicities, including management of study -drug 
induced adverse events, i.e., 

[COMPANY_001] Confidential Page 95
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
nausea, vomiting and diarrhea are provided in Section 6.[ADDRESS_742421] current [Investigator’s Brochure ].
6.4 Concomitant medications
Drugs in Table 6-5and Table 6-6are presented by [CONTACT_565306] . Table 6-7
presents drugs known to cause Torsades des Point es.
In general, the use of any concomitant medicat ion/therapy  deemed necessary  for the care of 
the patient (e.g. such as anti-emetics, 
anti-diarrhea) is permitted (see Section 6.4.1), except 
when specificall y prohibited (see 
Section 6.4.3).
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (excluding study  treatment and prior 
antineoplastic treatments), blood transfusions, surgeries and procedures (including physical 
therap y) administered within [ADDRESS_742422] dose of INC280 will be recorded in the Concomitant Medications or 
Surgi cal and Medical Procedures eCRF, respectively . Medications include not only physician 
prescribed medications, but also all over-the counter medications, herbal medications, food 
supplements and vitamin s.
The following restrictions apply  during the entire duration of the study :
No other investigational therapy should be given to patients
No anticancer agents other than the stud y medication (INC280) should be given to patients.
6.4.1 Permitted concomitant therapy
Patients are permitted to use the following medicati ons while taking INC280:
Oral or topi[INVESTIGATOR_8163]
Medications to prevent or treat nausea , vomiting or diarrhea
Growth factors (e.g. G -CSF, GM -CSF, ery thropoietin, platelets growth factors, etc.) are 
allowed per the investigator ’sjudgement and per local guidelines.
Treatment with bisphosphonates for pre -existing bone metastases is permitted, if clinically  
indicated, and following existing local guidelines. Treatment with bisphosphonates should 
preferabl y begin before the study treatment is initiated, but can also be initiated during 
therap y onl y if absence of radiological bone disease progression is well documented (in 
this case, the reason for its use must be clearl y documented; i.e. “pre -existing, non -
progressing, bone metastases”).
Oxygen therap y and b lood products or transfusions
Nutritional support or appetite stimulants
Pain medication
Local bone radiotherap y for analgesic purposes or for ly tic lesions at risk of fracture may  
be carried out if required. If palliative radiotherap y is initiated after s tart of study  
treatment, the reason for its use must be clearl y documented and progression as per 
RECI ST 1.[ADDRESS_742423] be interrupted on the day s of 
radiotherap y and can be resumed the day  after its completion .

[COMPANY_001] Confidential Page 96
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
6.4.2 Permitted c oncomitant therapy  requiring caution and/or action
INC280 is a moderate CYP1A2 inhibitor. Co-administration of INC280 increased 
sensitive CYP1A2 probe substrate (caffeine) AUC by 135% (see Section [IP_ADDRESS]). The 
dose of CYP1A2 substrates with narrow therapeutic index may need to be reduced when 
used concurrentl y with INC280 as INC280 may increase their exposure. Consult the 
product information of concomitant drug for dose adjustment.
Co-admin
istration of IN C280 increased Pgp substrate (digoxin) exposure (AUC and Cmax 
by 47% and 74%, respectively ) and BCRP substrate (rosuvastatin) exposure (AUC and 
Cmax by  108% and 204%, respectively ) (see Section [IP_ADDRESS] ). Monitor patients closely  for 
symptoms of increased exposure to Pgp or BCRP substrates. Consult the concomitant Pgp 
or BCRP substrate product information when considering dose adjustment.
Co-administrating INC280 with strong CYP3A4 inhibitor (itraconazole) increased 
INC280 AUC by 40%. There is no change in INC280 Cmax. Execute caution when using 
astrong CYP3A4 inhibitor concurrentl y with INC280. 
In healthy  subjects, co-administration of PPI [INVESTIGATOR_565261]280 AUC infby 25% and Cmax
by 38%. In cancer patients [CINC280A2108
], ~30% lower AUC,ss was observed in 
patients with concomitant use of PPI [INVESTIGATOR_565262]. The 
decrease in exposure imposes caution on the use of PPI  [INVESTIGATOR_565263]280 is taken.
Short acting gastric acid modulators containing aluminum hydroxide and magnesium 
hydroxide, or calcium carbonate can be taken with caution . However, it is recommended 
to take these drugs at least 1 hour before or 2 hours after administration of INC280. 
H2 receptor antagonists should be used with caution . If patients are using H2 receptor 
antagonists during the course of this study , INC280should be administered at least [ADDRESS_742424] .
INC280 is a weak to moderate inhibitor of CYP2C8, CYP2C9 and CYP2C19 in vitro . 
Substrates of CYP2C8, CYP2C9 and CYP2C19 with a narrow therapeutic index should be 
administered with caution
Refer to Table [ADDRESS_742425] of the medications that require caution when concomitan tly 
used with INC280.
Table 6-5 Drugs to be used with caution while on study
Mechanism of Interaction Drug Name
[CONTACT_15105]3A inhibitor ombitasvir/paritaprevir/dasabuvir/rito navir (Viekira Pak), indinavir/ritonavir, 
tipranavir/ritonavir, ritonavir, cobicistat, indinavir, ketoconazole, 
troleandomycin, telaprevir, danoprevir/ritonavir, elvitegravir/ritonavir, 
saquinavir/ritonavir, lopi[INVESTIGATOR_054]/ritonavir, itraconazole, voriconazole, mibefradil, , 
posaconazole, telithromycin, grapefruit juice, conivaptan, nefazodone, 
nelfinavir, idelalisib, boceprevir, atazanavir/ritonavir, darunavir/ritonavir
CYP1A2 substrate with NTI theophylline, tizanidine
CYP2C9 substrate with NTI warfarin
CYP2C19 substrate with NTI (S)-mephenytoin
P-gp substrates afatinib, alfuzosin, aliskiren, alogliptin, ambrisentan, api[INVESTIGATOR_3822], apremilast, 
aprepi[INVESTIGATOR_053], boceprevir, bosentan, carvedilol, carvedilol, caspofungin, ceritinib,  
colchicine, cyclosporine, dabigatran, digoxin, doxepin, doxorubicin, eribulin, 
everolimus, fidaxomicin, fluvastatin, fosamprenavir, idelalisib, iloperidone, 
indacaterol, irbesartan, lacosamide, lapatinib, levetiracetam, linagliptin, 

[COMPANY_001] Confidential Page 97
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Mechanism of Interaction Drug Name
[CONTACT_565331], maraviroc, mirabegron, naloxegol, nateglinide, nin tedanib, 
olodaterol, pantoprazole, paroxetine, pazopanib, posaconazole, pravastatin, 
quinine, ranolazine, riociguat, risperidone, rivaroxaban, saquinavir, silodosin, 
simeprevir, sirolimus, sitagliptin, sorafenib, telaprevir, tenofovir, ticagrelor, 
tipranav ir, tolvaptan, topotecan, umeclidinium, valsartan, vardenafil, 
vincristine, voriconazole, atorvastatin, docetaxel, fentanyl, fexofenadine, 
linezolid, loperamide, nadolol, nevirapi[INVESTIGATOR_050], paclitaxel, proguanil, ritonavir, 
simvastatin, sofosbuvir, tacrolimus
BCRP substrates Atorvastatin, daunorubicin, dolutegravir, doxorubicin, hematoporphyrin, 
imatinib, methotrexate, mitoxantrone, paritaprevir, pi[INVESTIGATOR_2830], rosuvastatin, 
irinotecan, ethinyl estradiol, simvastatin, sofosbuvir, sulfasalazine, tenofovir, 
topoteca n, venetoclax
Proton pump inhibitor Omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, 
dexlansoprazole
Short acting gastric acid 
modulator and H2 receptor 
antagonistranitidine, nizatidine, famotidine, cimetidine, aluminum hydroxide, alum inum 
carbonate, calcium hydroxide, calcium carbonate, bismuth subsalicylate
Source: The list is adapted from the [COMPANY_001] Institutes for Biomedical PK Sciences internal memorandum (Jan 
2018 ): drug-drug interactions (DDI) database, which is compi[INVESTIGATOR_565264]’s “Clinically Relevant” Table (medicine.iupui.edu/flockhart/table.htm), the University of W ashington’s Drug 
Interaction Database (druginteractioninfo.org), and the FDA’s “Guidance for Industry, Drug Intera ction Studies”
This may not be an exhaustive list, will be updated periodically.
NTI: narrow therapeutic index
6.4.3 Prohibited concomitant therapy
Co-administrating INC280 with strong CYP3A4 inducer (rifampi[INVESTIGATOR_2513]) decreased INC280 
AUC by  66% and Cmax by  56%. Concurrent use of strong CYP3A4 inducers isprohibited 
as decreased INC280 exposure may  lead to reduced efficacy .
Drugs with a known risk of Torsades des Point
es (TdP) are prohibited. For identification 
of drugs with known risk of TdP please refer to qtdrugs. org (refer to Table 6 -7). 
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies while on treatment.
The prohibited medications ar
e listed in the Table [ADDRESS_742426]. John’s wort (Hypericum perforatum )
Source: The list is adapted from th e [COMPANY_001] Institutes for Biomedical PK Sciences internal memorandum (Jan 
2018 ): drug- drug interactions (DDI) database, which is compi[INVESTIGATOR_252368]’s “Clinically Relevant” Table (medicine.iupui.edu/flockhart/t able.htm), the University of W ashington’s Drug 
Interaction Database (druginteractioninfo.org), and the FDA’s “Guidance for Industry, Drug Interaction Studies” This 
may not be an exhaustive list, will be updated periodically.
Table 6-7 Drugs with a kno wn risk of T orsades des Pointesprohibited while on 
study
Class of medication Drug Name
[CONTACT_565332], anagrelide, arsenic trioxide, astemiz ole, azithromycin , 
chloroquine, chlorpromazine, cilostazol, ciprofloxacin, cisapride, citalopram , 
clarithromycin , disopyramide, dofetilide, domperidone , donepezil, dronedarone, 

[COMPANY_001] Confidential Page 98
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Class of medication Drug Name
[CONTACT_565333], erythromycin, escitalopram, flecainide, fluconazole, gatifloxacin , 
halofantrine, haloperidol, ibutilide, levofloxacin , levomepromazine, 
levosulpi[INVESTIGATOR_14956], methadone, moxifloxacin , ondansetron, oxaliplatin, papaverine 
HCl (intra -coronary), pentamidine, pi[INVESTIGATOR_3924], procainamide, propofol, quinidine , 
roxithromycin, sevoflurane, so talol, sulpi[INVESTIGATOR_14956], sultopride, terlipressin, terodiline, 
thioridazine, vandetanib
This may not be an exhaustive list .
Check :  crediblemeds.org/healthcare -providers/drug -list for the most updated list.
6.[ADDRESS_742427] Number (Subject No.), that is assigned 
when the patient is first enrolled for pre-screening and is retained as the primary  identifier for 
the patient throughout his/her entire participation in the trial. The Subject No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the molecular pre-screening informed consent form, the patient 
is assigned to the next sequential Subject No. available to the investigator through theOracle 
Clinical RDC interface.
At the molecular pre-screening visit, the investigator or designated staff will contact [CONTACT_565307] t o register them into the I RT. 
Once assigned, the Subject No. must not be reused for any other subject and the Subject No. 
for that individual must not be changed, even if the patient is re -screened.
6.5.2 Treatment assignment
At the main screening visit, the investigator or his/her delegate will call or log on to the IRT 
and confirm that the patient fulfills the molecular pre -screening criteria. Prior to dosing he/she 
or delegate will call or log on to the IRT again (at the C1D1 visit) to confirm that the patient 
fulfills all main screening inclusion/exclusion criteria and that the patient can initiate study  
treatment. If the patient fails to start treatment for any reason, the reason will be entered into 
the Screening Disposition eCRF page.
IRT must be notified within 2 day s if the patient did not start treatment.
The assignment of a patient to a particular cohort will be coordinated by [CONTACT_565308]-screening and prior treatment status results 
either:
Cohort 1: Patients with cMET GCN ≥ 6, including:
Sub-cohort 1a: Patients with cMET GCN of ≥ 10, or
Sub-cohort 1b: Patients with cMET GCN of ≥ 6 and < 10, or
Cohort 2: P re-treated p atients with cMET GCN ≥4 and < 6, or
Cohort 3: P re-treated p atients with cM ET GCN < 4, or
Cohort 4: P re-treated p atients with cMET m utations regardless of cMET GCN , or
Cohort 5 treatment -naïve patients with cMET dysregulation, including:  

[COMPANY_001] Confidential Page 99
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Sub-cohort 5a: Patients with cMET GCN of ≥10, or
Sub-cohort 5b: Patients with cMET mutation s regardless of cMET GCN , or
Cohort 6: Pre -treated patients with either cMET GCN ≥ 10 without cMET mutations or 
cMET mutations regardless of cMET GCN , or
Cohort 7: T reatment -naïve patients with cMET mutations regardless of cMET GCN
In addition, in Cohort 2 (if not stopped for futility  at the IA), the study  enrollment target of 
~40% of patients (i.e. at least 11 patients for the IA and 28 patients for the final enrollment) 
with GCN ≥5 and < 6 at the time of both the interim and the final analy siswill be managed 
viaIRT. To achieve this target, the IRT system may close the enrollment of patients with 
GCN ≥ 4 and < 5 when the target of 60% (i.e. at least 17 patients for the IA and 41 pa tients 
for the final enrollment) of the patients with GCN ≥ 4 and < [ADDRESS_742428] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study 
must be recorded on the Dosage Admin istration Record eCRF.
Table 6-[ADDRESS_742429] their 
next scheduled study visit.Not applicable
6.6.1 Study drug packaging and labeling
The study  medicati on packaging has a 2-part label. Immediatel y before dispensing the 
package to the patient, site personnel will detach the outer part of the label from the packaging 
and affix it to the source document (Drug Label Form) 
for that patient’s unique patient 
number.
Medication labels will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions for the drug and the medication number 
but no information about the patient.
Table 6-9 Packaging and labeling
Study  treatments Packaging Labeling
INC280 Tablets in 
bottlesMedication labels comply with the legal requirements of each country and 
will be printed in the local language. They will supply no information about 

[COMPANY_001] Confidential Page 100
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Study  treatments Packaging Labeling
the patient. The storage conditions for the study drug will be described on 
the medication label.
6.6.[ADDRESS_742430] access. Upon receipt, INC280 should be stored according to 
the instructions specified on the drug labels and in the current [Investigato r’s Brochure ].
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Data for all doses of study  medication will be recorded on the Dosage Administration eCRF 
page.
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit.
[IP_ADDRESS] Study drug accountability
The investigator or designee mus t maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_5364] . Patients will be asked to return 
allunused study  treatment and packaging on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused study treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided 
in the investigator folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.6.[ADDRESS_742431] y can also be destro yed at the site if permitted by [CONTACT_565309] a prior ag reement.

[COMPANY_001] Confidential Page 101
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these asse ssments must be supported in the patient’s source 
documentation. The table indicates which assessments produce data to be entered into the 
database (D) or remain in the source documents only  (S) (“Category ” column). The eCRF will 
not be used as a source do cument.
Written informed consent must be obtained before any study  specific assessments are 
performed, including those at 
molecular screening and screening. Main screening evaluations 
and baseline radiological tumor assessments should be performed within 28 days of treatment 
start.
Each treatment cycle is 21 days(the 21 days cycle length is fixed regardless of 
whether the 
dose of INC280 is withheld).
All visits are to be scheduled according to the appropriate number of calendar days from 
Cycle [ADDRESS_742432] be made to follow the schedule 
of assessments within the windows outlined in the protocol.
After screening:
All assessments have a ±3 day window unless otherwise indicated
Radiological tumor assessments may be performed within a ±4day window, unless 
otherwise indicated
If a given visit is out of window, the next visit should be performed with reference to the 
day of first dose in order to get the patient back on schedule
If an off-schedule imaging assessment is performed, subsequent imaging assessments 
should be performed in accordance with the original imaging schedule
Laboratory  assessments and height/weight performed as part of the screening evaluations 
and within [ADDRESS_742433] dose of study  drug, will not be required to be repeated on 
Cycle 1, Day  1
All assessments on Cycle 1, Day [ADDRESS_742434] dose unless otherwise 
specified. It is recommended that the investigator checks the pre-dose laboratory  results 
prior to starting treatment
Patients who discontinue INC280 treatment must have EOT visit performed ≤ 7 day s after 
stoppi[INVESTIGATOR_565265]
Permitted cont act windows for survival follow -up: +/- 7 day s
Additional assessments may  be performed as clinically  indicated.

[COMPANY_001] Confidential Page 102
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Table 7-[ADDRESS_742435] -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
Pre-Screening
Confirmation of EGFR w ild-
type & ALK-negative
rearrangement statusD5.2 X
Obtain Molecular Pre -
Screening ICFD7.1.1 X
Newly obtained tumor biopsy 
(preferred) o r archival tumor 
sample to confirm ALK-
negative rearrangement 
status , only if ALK local testing 
not availableD7.1.1.1 X
Newly obtained tumor biopsy 
(preferred) or archival tumor 
sample to confirm cMET 
amplification and/ormutation
statusD7.1.1.1 X
Main Screening
Obtain Main ICF D7.1.2 X
IRT Registration S6.5.1 X X X X

[COMPANY_001] Confidential Page 103
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201CategoryProtocol 
Section 
referenceMolecular pre -
screening and 
Main Screening 
Phase sStudy  Treatment Phase Post -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
Patient History
Demography D7.1.2.3 X
Information on prior local 
testing for cMET amplification 
and cMET mutation including
prior c entral NGS result, if 
applicable D7.1.2.3 X
Inclusion/exclusion criteria D5.2; 5.3 X
Eligibility check S7.1.2.1 X
Relevant medical 
history/current medical 
conditions D7.1.2.3 X
Smoking His tory D7.1.2.3 X
Diagnosis and extent of 
cancer D7.1.2.3 X
Prior antineoplastic therapi[INVESTIGATOR_014] 
(meds, surgery, radiation)D7.1.2.3 X
Prior and current concomitant 
medications (including OTC 
meds); procedures and 
significant non -drug therapi[INVESTIGATOR_565266]7.1.2.3 Continuo us until ≥ [ADDRESS_742436] dose of INC280

[COMPANY_001] Confidential Page 104
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201CategoryProtocol 
Section 
referenceMolecular pre -
screening and 
Main Screening 
Phase sStudy  Treatment Phase Post -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
Physical Examination
Complete physical 
examination, including 
neurological examsS7.2.2.1 X If clinically indicated
Targeted physical examinat ion S7.2.2.1 X X X X X X
Height D7.2.2.3 X
Weight D7.2.2.3 X X X X X X
ECOG Performance status D7.2.2.4 X X X X X X
Vital signs D7.2.2.2 X X X X X X X
Laboratory  assessments
Hematology D7.2.2.5 X X X X X X X
Chemistry D X X X X X X X
Coagulation D X If clinically indicated
Urinalysis (dipstick) with 
micro -analysisDX If clinically indicated
Serum pregnancy test (if 
applicab le)DX X X X X X
Tumor assessments RECIST 1.[ADDRESS_742437], 
abdomen, pelvis (EOT scan 
not required if previous scan 
was performed within ≤28 D7.2.1 X X C5D1 
and 
every 6 
wksX X(every 
6wks)

[COMPANY_001] Confidential Page 105
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201CategoryProtocol 
Section 
referenceMolecular pre -
screening and 
Main Screening 
Phase sStudy  Treatment Phase Post -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
days)
Whole body bone scan D X Only if clinically indicated
CT scan or MRI of brain DX C3D1 and every 6 wks (if positive at baseline) or if 
clinically indicated
CT scan or MRI of other
metastatic sites (e.g., neck, 
etc)DX (if other 
metastatic 
sites)C3D1 and every 6 wks (if positive at baseline) or if 
clinically i ndicated
Localized bone CT scan, MRI
or X-ray (for any lesions 
identified on the whole body 
bone scan that are not visible 
on the chest/abdomen/pelvis 
CT scan or MRI)DX (only if 
lesions on 
whole 
body scan 
that are 
not visible 
on the 
CAP 
scans)C3D1 and every 6 wks (if positive at baseline) or if 
clinically indicated
Photography (for skin lesions) DX (only if 
skin 
lesions)C3D1 and every 6 wks (if positive at baseline) or if 
clinically indicated
Safety  assessments
Adverse events D8.1 Continuous until ≥ [ADDRESS_742438] dose of INC280

[COMPANY_001] Confidential Page 106
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201CategoryProtocol 
Section 
referenceMolecular pre -
screening and 
Main Screening 
Phase sStudy  Treatment Phase Post -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
Study  drug administration
INC280 dosing D6.1 Continuous twice daily dosing (BID)

[COMPANY_001] Confidential Page 107
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201CategoryProtocol 
Section 
referenceMolecular pre -
screening and 
Main Screening 
Phase sStudy  Treatment Phase Post -treatment Follow -
Up phase (safety follow -
up within 30d of last dose 
for all patients and
efficacy follow -up every 6 
weeks until BIRC -
confirmed disease 
progression)Survival 
Follow -up 
Phase
Cycle 1
(21 day s)Subsequent cy cles (21 
days per c ycle)End of 
study  
treatment 
(EOT)
Visit Name
[CONTACT_565334]-screenScreening 
Visit (D -
28 to D -1)C1
D1C1
D15 C2
D1C3
D1C4D1 
C5D1 
etc…EOT Visit 
(within 7d of 
last dose)Tumor 
Follow -Up 
(every 6 wks)
Study 
Evaluation 
CompletionSurvival 
Follow -Up 
(every 3 mo)
Pharmacokinetics and ECG assessments
12-Lead ECG D7.2.2.6 X X X X X
Blood for INC280 PK D7.2.3 X X X
Other
Antineoplastic therapi[INVESTIGATOR_014] 
(medications, surgeries, 
radiotherapi[INVESTIGATOR_014]) since 
discontinuation of study drugD7.1.4 X (continuous until last follow -up visit )
End of Phase Disposition D4.1 X X X
Safety Follow -Up D7.1.5.1 X
Survival
(survival information can be 
obtained via telepho ne 
contact)D4.1.5 X
Abbreviations: C, cycle; CAP, chest/abdomen/pelvis; CT, computed tomography; D, entered into database; d, day; ECG, electroca rdiogram; EOT, end of treatment; EOS, 
end o f study; FUp, follow -up; i.v., intravenous; MRI, magnetic resonance imaging; NSCLC, non -small cell lung cancer; PD, progressive disease; PK, pharmacokinetic; S, 
remains in source document only; Tx, treatment; wks, weeks;

[COMPANY_001] Confidential Page 109
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Please refer to Section 6.5 for patient numbering, IRT procedures and cohort assignment.
7.1.2 Screening
Once the cMET amplification and mutation status (and ALK rearrangement status, if 
applicable) is confirmed by [CONTACT_565310]-
screening analysis, patients may enter the screening phase. Written informed consent must be 
obtained before any study  specific procedure is performed. Screening assessments to confirm 
eligibility  into the main study  should be performed as per the schedule of assessments
between Day-[ADDRESS_742439] dose of study  treatment
. Only  laboratory  results from the [COMPANY_001] -designated central 
Laboratory  can be used to determine patient’s eligibility  for the study . The cardiac eligibility 
criteria should be assessed with the central ECG report .  
A patient who has a laboratory  test result(s) that does not satisfy the entrance criteria may 
have the test(s) repeated within the 28-day screening period. In these cases, the patient is not 
required to sign another ICF and must retain the same Subject No. In the event that the 
laboratory  test(s) cannot be performed w ithin the [ADDRESS_742440](s) do not meet the entrance criteria, or other eligibility  criteria have changed and are 
not met any more, the patient is considered a screen failure, and must be discontinued from the 
study .A new ICF will need to be signed if the investigator chooses to re-screen the patient 
after a patient has screen failed, however, the Subject No will remain the same.
Patients who fail screening due to laboratory  parameters (inclusion criterion # 7) 
or baseline 
tumor assessment (inclusion criterion # 5) may  be re -screened. Patients who met all eligibility  
criteria but fail to be started on treatment as scheduled may be also re-screened, provided the 
patient was not registered previousl y in IRT as having entered the Treatment Period. Re-
screening of a patient must be performed within the 28-day re-screening period, and is
allowed only once per patient. All required screening activities must be performed when the 
patient is re -screened for participation in th
e study .
All eligibility  criteria must be re-checked, based on the most recent data available, and met 
prior to enrollment of the patient into the study .
If any cohort /sub-cohort is closed to enrollment, then only patients with the cMET
amplification or mutation status required for the open cohort (s)/sub-cohort(s) will be eligible 
for main screening for study  enrollment. Enrollment of patients with GCN ≥ 4 and < 5 in 
Cohort 2 may be stopped when the target of 60% (i.e. at least 17 patients for the IA and 41 
patients for the final enrollment) 
with GCN ≥ 4 and < 5 is reached .
[IP_ADDRESS] Eligibility  screening
The main screening period commences as soon as the patient signs the main ICF and ends 
when the patient fails screening or starts treatment. Evaluations will be performed within 4 
weeks (i.e., within 28 calendar days) prior to the first dose of study  drug, unless otherwise 
noted. All screening assessments, including laboratory  assessments, must be performed as 
described in the protocol (Table 7-1). Any imaging assessments alread y completed as 

[COMPANY_001] Confidential Page 111
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Informed consent
Inclusion/Exclusion Criteria
Withdrawal of consent (if applicable)
Death (if applicable)
No other data will be entered into the clinical database for patients who are screen failures, 
unless the patient experienced a Serious Adverse Event during the Screening Phase (see 
Section 8 for SAE reporting details). For molecular pre-screening failures, only SAEs 
possibly  related to a study  procedure will be reported. 
If the patient fails to be enrolled, the IRT must be notified within 2 day s of the screen fail that 
the patient was not enrolled.
[IP_ADDRESS] Patient demographics and other b aseline characteristics
Data to be collected include:
EGFR m olecular status
ALK rearrangement status
Information on local testing for cMET amplification and cMET mutation prior to patient 
consideration forthis study , if available.
Demography (including: date of birth, age, patient initials, gender, childbearing potential, 
race and ethnicit y, or as allowed by [CONTACT_427])
Relevant medical history
Smoking history
Cohort /sub-cohort assignment
NSCL C diagnosis and extent of disease, including:
Date of di agnosis and stage of NSCL C
Site of active disease
Characteristics of disease
Prior antineoplastic therapi[INVESTIGATOR_014] (medications, radiation, surgeries)
Prior and current concomitant medications, surgical and medical procedures
Note: All other medications taken within [ADDRESS_742441] eCRF .

[COMPANY_001] Confidential Page 112
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
7.1.4 Discontinuation of study treatment
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discontinue from the study  treatment, the investigator should make a 
reasonable effor t (e.g. telephone, e-mail, letter) to understand the primary  reason for this 
decision and record this information in the patient’s chart and on the appropriate CRF pages. 
They  may be considered withdrawn if they state an intention to withdraw, fail to return for 
visits, or become lost to follow -up for an y other reason. 
The investigator should discontinue study  treatment for a given patient if, on balance, he/she 
believes that continuation would be detrimental to the patient’s well -being.
Study  treatment mu st be discontinued under the following circumstances: 
Emergence of specific adverse events or laboratory abnormalities under some 
circumstances as outlined in Section 6
Pregnancy (pregnancy  will be followed for outc ome)
Use of prohibited treatment s (refer to Section 6.4.3 )
Any protocol deviation that results in a significant risk to the patient’s safety
Patients who discontinue INC280 treatment should NOT be consi dered withdrawn from the 
study . They  should return for the assessments indicated in Section 7.2.1. If they fail to return 
for these assessments for unknown reasons, every effort (e.g. telephone, email, letter) should 
be made to contact [CONTACT_15026] 7.1.[ADDRESS_742442] the IRT to register the patient’s 
discontinuation from study  
treatment.
Patients who become pregnant must cease all tumor assessments regardless of whether or not 
they developed Progressive Disease according to BIRC .
Patients who discontinue INC280 should be scheduled for an EOT visit as soon as possible 
and within [ADDRESS_742443]’s last treatment and reason for 
stoppi[INVESTIGATOR_79558].

[COMPANY_001] Confidential Page 113
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
7.1.5 Follow -up-period
[IP_ADDRESS] Follow -upfor Safety  Evaluations
All patients must have s afety  evaluations for [ADDRESS_742444] dose of study  treatment.
At the end of this period, the investigator should assess and discuss with the patient any AE 
observed/concomitant medication taken since discontinuation of study  treatment. This can be
done via a phone contact. 
Data collected should be added to the Adverse Events eCRF and the Concomitant 
Medications eCRF. Antineoplastic therapi[INVESTIGATOR_565267] 'Antineoplastic therapi[INVESTIGATOR_565268]' eCRF page. 
Patients whose treatment is permanently  discontinued due to an AE (clinical or based on 
abnormal laboratory  value) must be followed until resolution or stabilization of the event, 
whichever comes first. I n case of an abnormal laboratory  value, blood tests sho uld be repeated 
until resolution or stabilization.
[IP_ADDRESS] Post -Treatment follow -up
All patients who discontinued treatment during the treatment phase for reasons other than 
death, lost to follow -up, pregnancy  or disease progression as determined by [CONTACT_565311] (Section 7.1.4) should not be considered withdrawn from the study and 
should continue with tumor  assessments every  [ADDRESS_742445] Treatment Disposition (Study  Phase 
Completion) eCRF page should be completed . Antineoplastic therapi[INVESTIGATOR_565269]. If patients refuse to return for these visits or 
are unable to do so, every  effort should be made to contact [CONTACT_18622] a knowledgeable 
informant by  [CONTACT_565312].
[IP_ADDRESS] Survival follow -up
All patients who had PD determined by [CONTACT_565313]  [ADDRESS_742446]. Antineoplastic therapi[INVESTIGATOR_565267] 
'Antineoplastic therapi[INVESTIGATOR_565270]' eCRF page following the 
last dose of the study treatment.
[IP_ADDRESS] Replacement policy
Patients lost to follow -up or withdrawing consent from the study  without observed BIRC 
confirmed PD will be censored for the primary  analy sis and will not be replaced.

[COMPANY_001] Confidential Page 114
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
7.1.[ADDRESS_742447]:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_5366] -up.
All efforts should be made to comple te the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data 
resul ting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form. 
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by [CONTACT_1289]. They  will be stored according to 
applicable legal r equirements.
7.1.[ADDRESS_742448] to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_15027], family  or family  physician as agreed in the informed consent and by [CONTACT_15028], e.g.,dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been comple ted. Patients lost to follow -up should be recorded as such on the appropriate 
Disposition eCRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Tumor response will be assessed locall y and by [CONTACT_565314] 3.1 (Appendix 1) based on RECI ST 1.1 (Eisenhauer et al 2009). Patients should have 
at least one documented measurable lesion at study  entry as per RECI ST 1.1. The imaging 

[COMPANY_001] Confidential Page 115
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
assessment collection plan is presented in Table 7-2.Details of the central review process will 
be described in the independent review charter.
Imaging data will be centrally  collected and checked for qualit y by [CONTACT_565315]. The results of the central BIRC evaluations will be used for primary 
analysis purposes .The local investigator’s assessment will be used for treatment decision 
making.
Table 7-2 Imaging collection plan
Procedure Screening/Baseline During Treatment/Follow-Up
CT or MRI (chest, abdomen, 
pelvis) with i.v. contrastMandated Mandated until PD determined by [CONTACT_565316], every [ADDRESS_742449] or MRI of other metastatic 
sites (e.g. , neck, etc.), if 
applicableOnly if other metastatic sites 
are suspectedMandated if patient has other metastatic sites 
at baseline (following the same schedule as 
CT/MRI of chest/a bdomen/pelvis) or 
otherwise, only if clinically indicated
CT or MRI of brain with i.v. 
contrastMandated Mandated if positive at baseline (following the 
same schedule as CT/MRI of 
chest/abdomen/pelvis), or otherwise, only if 
clinically indicated
Whole bo dy bone scan
[e.g.,Tc-99 bone scan, whole 
body bone MRI, 
fluorodeoxyglucose positron 
emission tomography (FDG -
PET) or sodium fluoride (NaF )-
PET]Mandated If clinically indicated
Localized bone CT, MRI or X-
rayOnly if clinically indicated (for 
any lesion s identified on the 
whole body bone scan that 
are not visible on the CT/MRI 
of chest/abdomen/pelvis )Mandated if positive at baseline (following the 
same schedule as CT/MRI of 
chest/abdomen/pelvis), or otherwise, only if 
clinically indicated
Color photogr aphs with a metric 
ruler (only if skin lesions are 
present)Only if other skin metastases 
are presentMandated if patient has skin lesions at 
baseline (following the same schedule as 
CT/MRI of chest/abdomen/pelvis) or 
otherwise, only if clinically indicate d
[IP_ADDRESS] Baseline imaging assessment
Imaging assessments will be performed at screening/baseline Day  -[ADDRESS_742450] 
dose cannot be considered baseline images.
Imaging requirements at baseline
Patients must have measurabl e disease as per RECI ST 1.1 ( Appendix 1 ). Measurable 
(“target”) lesions include ly tic or mixed (ly tic + blastic) bone lesions with an identifiable 
soft tissue component that meets the measurabilit y crit eria per RECI ST 1.1 (Appendix 1 ).
Patients with only  non- measurable lesions are not eligible.

[COMPANY_001] Confidential Page 116
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
Any potentiall y measurable lesion that has been previously treated with radiotherap y 
should be considered as a non- measurable (“non - target”) lesion. However, if a lesion 
previously  treated with radiotherap y has clearly progressed since the radiotherap y, it can 
be considered as a measurable lesion.
All measurable lesions up to a maximum of 5 nodal and/or non-nodal lesions in total (and a 
maximum of 2 lesions per organ), representative of all involved organs, should be identified 
as target 
lesions and recorded and measured at baseline.
Tumor assessment srequired at baseline
The following assessments will be performed:
Computed Tomograph y (CT) with I V contrast or Magnetic Resonance Imaging (MRI) of 
chest , abdomen and pelvis .
The preferred rad iologic technique is CT with intravenous (IV) contrast. If a patient is 
known to have a contraindication to CT contrast media or develops a contraindication 
during the trial, a non -contrast CT of the chest (MRI  is not recommended due to 
respi[INVESTIGATOR_565271]) plus a contrast -enhanced MRI (if possible) of the abdomen and 
pelvis should be performed.
A whole bod y bone scan accordi ng to institutional guidelines [ e.g. Tc -99 bone scan, whole 
body  bone MRI, Fluorodeox yglucose positron emission tomograph y (FDG -PET)or 
sodium fluoride positron emission tomograph y (NaF PET) ].
After screening, whole body  bone scans is not required , unless clinicall y indicated. If 
indicated, the same methodology  as at screening should be used.
Localized CT, MRI  or X -rays of a nyskeletal lesions identified on the screening whole 
body  bone scan, which are not visible on the chest , pelvis and abdomen CT/MRI .
If skeletal lesions are documented at baseline, scans need to be continued following 
the same schedule as CT/MRI  of chest, abdomen andpelvis. The same methodology  
as at screening should be used.
Brain CT with IV contrast or MRI  scan.
If brain lesions are documented at baseline, scans need to be continued following the 
same schedule as CT/MRI  of chest, abdomen and pelvis. The same method ology  as at 
screening should be used. Contrast enhanced brain MRI  is preferred, however, if MRI 
contrast is contraindicated, then MRI without contrast or CT with/without contrast is 
acceptable.
Color photographs , if skin lesions are present, using a digita l camera in clear focus, 
including a scale/ruler, in such a way  that the size of the lesion(s) can be determined from 
the photograph .
If skin lesions are documented at baseline, photographies need to be continued 
following the same schedule as CT/MRI  of ch est, abdomen and pelvis. 
CT or MRI of any  other site of disease not captured by  [CONTACT_487712] (e.g., 
neck).

[COMPANY_001] Confidential Page 117
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
If additional sites of disease are documented at baseline, scans need to be continued 
following the same schedule as CT/MRI  of chest, abdomen and pelvis. The same 
methodology  as at screening should be used.
Chest x -ray or ultrasound must not be used to measure tumor lesions.
[IP_ADDRESS] Subsequent imaging for response assessment
Imaging assessments as described inTable 7-2 should be performed at the timepoints 
specified using the same imaging modality  used at baseline, irrespective of study  treatment 
interruption or actual dosing (see Table 7
-1). Imaging assessments for response evaluation 
will be performed every  6 weeks starting from Day  1of cy cle 1 (+/ - 4 day s window).
Additional imaging assessments may be performed at any time during the study  at the 
investigator’s discretion to support the efficacy  evaluations for a patient, if necessary . Clinical 
suspi[INVESTIGATOR_436650] a physical examination and imaging 
assessments to be performed promptly  rather than waiting for the next scheduled imaging
assessment.
Each lesion that is measured at baseline must be measured by [CONTACT_286802] (either same 
imaging method or by [CONTACT_269304] y, including a metric ruler) and when possible, the same 
local radiologist/phy sician throughout the study  so that the comparison is consis
tent. If an off -
schedule imaging assessment is performed because progression is suspected, subsequent 
imaging assessments should be performed in accordance with the original imaging schedule.
Combined PET/CT may be used only if the CT is of similar diagnos tic quality  as a CT 
performed without PET, including the utilization of oral and IV contrast media. At the 
discretion of the Investigators, FDG -PET scans may be performed to document PD per 
RECI ST 1.1 ( Appendix 1 ).
All study  imaging (including any off-schedule imaging studies) performed to evaluate 
progression or response should be submitted to the designated imaging vendor for qualit y 
control and review b y the BIRC, promptly after acquisition. 
[IP_ADDRESS] Transmis sion of efficacy  data to BIRC
All radiological assessments will be read locally  and should be submitted promptly  after 
acquisition to the imaging vendor designated by [CONTACT_5343]. Rapid image transmission to the 
central imaging vendor will be accomplished by [CONTACT_565317] a secured website (e.g.: via the internet) . In all instances, the 
process at the imaging vendor will ensure that the central reviewers remain blinded to the 
results of the local assessment and the expedited nature of the review.
[IP_ADDRESS] Timepoints without locally  determined progression
All imaging timepoints without locally  determined progression will be read on an ongoing
non-expedited basis as detailed in the imaging manual to be provided by [CONTACT_565318]. 
However expedited review may be required 
at the time of the interim analysis. Results of these readings will not be communicated to the 
sites.

[COMPANY_001] Confidential Page 118
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[IP_ADDRESS] Timepoints at which progression is determined locally
All patients who have disease progression determined by [CONTACT_565319] r response review by [CONTACT_115365]. If PD has been determined locally  at a 
timepoint, the investigator must seek an expedited review andindicate this request to the 
imaging vendor on a designated form or by [CONTACT_565320] g 
vend or.The imaging vendor will ensure that the BIRC reviewers are blinded to BI RC reading 
requests.
Rapid image transmission to the central imaging vendor may be accomplished by [CONTACT_565321]. The imaging will undergo expedited central review (within 5 business days from the 
time of the receipt of images at the imag ing vendor ) and the results of the central review will 
be communicated to the site. While the investigator is a
waiting the results of the central 
review, it is preferable that the patient continue on study  treatment. However, during this time, 
the investig ator should do whatever is medicall y necessary  for his/her patient.
If the central review determines disease progression, then the patient may discontinue study 
treatment and subsequent follow -up tumor assessments are no longer required. Treatment with 
INC280 may be continu ed beyond RECIST 1.1-defined PDdetermined by [CONTACT_565322], if, in the judgment of the investigator, there is evidence of clinical 
benefit and the patient wishes to continue on the study  treatment. 
If the centra l review does not determine disease progression, the patient should continue 
receiving the study  treatment unless there is a medical need (i.e., rapid progression or clinical 
deterioration) for an immediate change in therapy per the investigator’s clinical judgment .
Patients will continue to have imaging performed as per protocol (Table 7-1) until the central 
review determines disease progression.
Note
:If an investigator would like to discuss the centra l review results, there will be an 
independent physician at the imaging vendor who is not part of the central review pool for this 
study . This independent physician will be able to discuss the central review findings with the 
investigator. The central revi ewer s are completel y excluded from such discussion. The contact
[CONTACT_565323] a discussion, as specified in the manual provided by 
[CONTACT_565324].
7.2.2 Safety  and tolerability assessments
Safety  will be monitored using the following clinical and laboratory  assessments: hematology , 
chemistry , coagulation parameters, urinal ysis, 12-lead ECG, pregnancy  test as well as 
collecting of the adverse events and concomitant medications at every  visit. For details on AE 
collection andreporting, refer toSection 8. Significant findings that were present prior to the 
signing of informed consent must be included in the relevant medical history /current medical 
conditions page on the pa
tient’s eCRF. Significant new findings that begin or worsen after 
informed consent must be recorded on the Adverse Event page of the patient’s eCRF.

[COMPANY_001] Confidential Page 119
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
[IP_ADDRESS] Physical examination
Acomplete physical examination must be performed at screening and later as clinically
indicated and will include the examination of general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, 
vascular, and neurological assessments. 
A targeted (short) physical exam will be performed as per schedule in Table 7-1and will 
include the examination of general appearance and vital signs (
blood pressure and pulse).
Information about the physical examination must be present in source documentation at the 
study  site. Significant findings that were present prior to the signing of informed consent must 
be included in the Medical History  page on the patient’s CRF. Significant new findings that 
begin or worsen after informed consent must be recorded on the Adverse Event page of the 
patient’s CRF.
[IP_ADDRESS] Vital signs
Vital signs include body temperature, blood pressure and pulse measurements and will be 
performed as per schedule in Table 7-1. Blood pressure (systolic and diastolic) and pulse 
should be measured after the patient has been sitting for five minutes.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured. Height will be measured at screening only 
(Refer to Table 7 -
1).
[IP_ADDRESS] Performance status
Assessment of ECOG performance status ( Table 7-3) will be performed as per the assessment 
schedule in Table 7-1, even if study  treatment is being interrupted . More frequent 
examinations may  be performed at the investigator’s discretion, if me dically
 indicated.
Table 7-3 ECOG performance status scale
Score Performance Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restr icted in phy sically  strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g. light housework, office work
2 Ambulator y and capable of all self -care but unable to carry out any work activities. Up 
and about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking 
hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
[IP_ADDRESS] Laboratory  evaluations
[COMPANY_001] -designated central laboratories will be used for the anal ysis of scheduled hematology , 
biochemistry  and other blood specimens collected as part of safet y monitoring (as detailed in
Table 7-4). The frequency  of the assessments is indicated in Table 7-1. Dipstick urinaly sis 

[COMPANY_001] Confidential Page 120
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
will be performed locall y, except in the case of any  significant findings, a urine sample will be 
sent to central laboratory for further micros copic analysis. Laboratory  values obtained prior to 
treatment from central laboratory  will be used to assess patient’s eligibility . Only laboratory 
results from the [COMPANY_001] -designated central Laboratory  can be used to determine patient’s 
eligibility  for the study . The time windows granted for laboratory  evaluations are identical to 
the corresponding visit time windows for each visit (refer to Section 7.1).
Local laboratory  assessments may only be perfor med when an immediate clinical decision 
needs to be made. In those cases locally  unscheduled testing may be performed. However 
samples should also be sent to the central lab. In such cases, local laboratories values should 
be recorded on the local laborato
ry eCRFs as unscheduled visits only if a severity  grade 
differs from a severity  grade reported by  [CONTACT_2237] .
Each time local laboratory  results are reported on the unscheduled local laboratory  eCRF page, 
the study  monitor will collect and subm it promptly  the local laboratory  normal ranges and 
local laboratory  certification.
Details on the collection, shipment of samples and reporting of results by [CONTACT_447267] -
designated central laboratory  are provided to investigators in a separate [ Laboratory Manual ].
Table 7-[ADDRESS_742451] Name
[CONTACT_157131], Hemoglobin, Platelets, W hite blood cells, Differentials (Ba sophils, 
Eosinophils, Lymph ocytes, Monocytes, Neutrophils)
Chemistry Album in, Alkaline phosphatase, ALT, A mylase, AST, Calcium, Creatinine, 
Creatinine Clearance, Total Bilirubin, Direct Bilirubin (only if total bilirubin is ≥ 
grade 2), GGT, Lipase, Magnes ium, Sodium, Potassium, Phosphate (inorganic 
phosphorus), fasting Glucose (non-fasting allowed post-baseline ), Blood Urea 
Nitrogen (BUN) or Urea
Bicarbonate, Ch loride and Uric Acid: at screening and the reafter if clinically 
indicated
Urinalysis
(at scree ning and thereafter if 
clinically indicated)Macroscopic panel (dipstick) (bilirubin, blood, glucose, WBC, pH, protein,
specific gravity)
Microscopic panel (RBC, W BC, cast s)
Coagulation
(at screening and thereafter if 
clinically indicated)International n ormalized ratio (INR) and Prothrombin time (PT), or Quick Test 
(QT)
[IP_ADDRESS].1 Hematology
Hematology  assessments of the parameters listed in Table 7-4will be tested as per the 
schedule of assessments (Table 7-1). More frequent hematology  testing may also be 
performed as medically necessary . Additional results from unscheduled hematology  lab 
evaluations should be recorded on the appropriate Unscheduled Visit eC RF.
[IP_ADDRESS].2 Clinical chemistry
Blood chemistry  assessments of the parameters listed in Table 7-4will be tested as per the 
schedule of assessments (Table 7
-1).

[COMPANY_001] Confidential Page 121
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
More frequent clinical chemistry  testing may also be performed as medically  necessary . 
Additional results from unscheduled clinical chemistry  lab evaluations should be recorded on 
the appropriate Unscheduled Visit eCRF.
Note: Creatinine clearance shoul d be calculated (e.g Cockcroft -Gault formula) at screening 
and need to be repeated on Cycle [ADDRESS_742452] dose, unless screening assessment was 
performed within 7 day sprior to the Cy cle 1 Day  1 visit.
[IP_ADDRESS].3 Urinalysis
Dipstick measurements will be perfor med as per Table 7-4and according to the schedule of 
assessments (Table 7-1). Any significant findings on dipstick will be followed up with 
microsc opic evaluation as per Table 7-4and recorded on the appropriate eCRF page. Dipstick 
urinaly sis will be performed locally . In the case of any out of range parameters are noticed on 
local urinal ysis, uri ne sample will be sent to central laboratory  for further analy sis.
[IP_ADDRESS].[ADDRESS_742453] as per the 
schedule of assessments (Table 7-1).Central laboratories will be used for the analy sis of 
serum pregnancy  tests.
Women who are determined not to be of child bearing potential before the study  will only be 
tested at screening.
For postmenopausal women to be considered “of non-childbearing potential”, patient should 
meet 
the criteria as outlined in Section 5.3.
Please refer toSection 
8.4for information on reporting any pregn ancies that occur while the 
patient is on study .
If a pregnancy  test is performed in between study  visits by [CONTACT_565325] , 
the patient must immediately  notify  the investigator.
[IP_ADDRESS].5 Coagulation
International normalized ratio (INR) and prothrombin time (PT) or Quick Test will be 
measured a ccording to the schedule of assessmen t.
[IP_ADDRESS] Cardiac assessments 
[IP_ADDRESS].1 Electrocardiogram (ECG)
Standard triplicate 12 lead ECG assessments will be performed as outlined inTable 7-5and 
Table 7
-6.
Table 7-5 ECG collection plan for approximately 30enrolled patients at selected 
sites
Cycle Day Time ECG Type Number of ECGs
Screening Anytime 12 Lead 3

[COMPANY_001] Confidential Page 122
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Cycle Day Time ECG Type Number of ECGs
[ADDRESS_742454]- dose 1 h (within 15 min prior to PK )
Post- dose 2 h (within 15 min prior to PK)
Post- dose 4 h (within 15 min prior to PK)
Post- dose 8 h (within 15 min prior to PK)[ADDRESS_742455]- dose 1 h (within 15 min prior to PK)
Post- dose 2 h (within 15 min prior to PK)
Post- dose 4 h (within 15 min prior to PK)
Post- dose 8 h (within 15 min prior to PK)12 Lead 3
3 1 Pre-dose (within 15 min prior to PK) [ADDRESS_742456]-dose 2 h (within 15 min prior to PK) 12 Lead 3
3 1 Pre-dose 12 Lead 3
EOT Anytime 12 Lead 3
Unscheduled ECG Anytime if clinically indicated 12Lead 3
Baseline is defined as the pre-dose assessment on Cycle 1 Day 1  b efore study  drug 
administration.
All ECG assessments will be performed in the supi[INVESTIGATOR_2547]. Detailed instructions regarding 
the ECG collection will be provided to the investigator s in a separate manual prior to the start 
of the study . INC280 pharmacokinetic evaluation will be conducted in parallel to cardiac 
evaluations (see Section 7.2.3). All ECGs should be performed within [ADDRESS_742457] be made by a qualified physician. Each ECG tracing should 
be labeled with the study  number, patient initials (where regulations permit)
, patient number, 
ECG nominal day and time, ECG actual date and time (using a 24-hour clock, record up to 
second), ECG replic ate number, measured variables (QT, RR, PR, QRS), derived variables 

[COMPANY_001] Confidential Page 123
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
(QTcB, QTcF, and HR), ECG lead date, and kept in the source documents at the study  site. 
Clinically  significant abnormalities present when the patient signed informed consent should 
be reported on the Medical History  eCRF page. Clinically  significant findings must be 
discussed with [COMPANY_001] prior to enrolling the patient in the study . New or worsened clinicall y 
significant findings occurring after informed consent must be recorded on the Adverse Events 
eCRF page.
7.2.[ADDRESS_742458] study  drug dose prior to the sampling, should be obtained on all sampling days and 
recorded on the PK eCRF and/or CRO requisition form(s) .
An additional unscheduled PK blood sample will be collected if a patient experiences an AE 
suspected to be related to study  treatment that results in an unscheduled visit or fits the criteria 
of an SAE (unless patient has interrupted INC280 for 7 day s ormore).
PK parameters will be estimated from each individual plasma concentration -time profile using 
appropriate methods and software , if possible . A table of PK parameter s to be evaluated (e.g., 
Cmax, Tmax , AUC) is to be included in the statistical and data analy sis Section 10.5.4 of the 
protocol .
Table 7-7 Pharmacokinetic bloo d collection log for approximately 30enrolled
patients at selected sites
Cycle Day Scheduled Time Point Dose Reference IDPK Sample 
NoSample 
Volume (mL)
1 1 Pre-dose/0h [ADDRESS_742459]-dose 0.5h (± 5min) [ADDRESS_742460]-dose 1h (± 10min) [ADDRESS_742461]-dose 2h (± 10min) [ADDRESS_742462]-dose 4h (± 20min) [ADDRESS_742463]-dose 6h (± 20min) [ADDRESS_742464]-dose 8h (± 2 0min) 1 7 3
1 15 Pre-dose/0h [ADDRESS_742465]-dose 0.5h (± 5min) [ADDRESS_742466]-dose 1h(± 10min) [ADDRESS_742467]-dose 2h(± 10min) [ADDRESS_742468]-dose 4h(± 20min) [ADDRESS_742469]-dose 6h (± 2 0min) [ADDRESS_742470]-dose 8h (± 2 0min) 2 14 3
3 1 Pre-dose/0h 3 301a15 3

[COMPANY_001] Confidential Page 125
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201

[COMPANY_001] Confidential Page 126
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201

[COMPANY_001] Confidential Page 127
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201

[COMPANY_001] Confidential Page 128
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsenin g of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.
For patients who sign the molecular pre-screening ICF, AEs which occur after signature [CONTACT_565335] 8.2.2 and are reported to be causall y related with study  procedures (e.g. an invasive 
procedure such as biopsy ). Once the main study ICF is signed, all AEs per the descriptions 
below will be captured in the Adverse Event eCRF.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms  are considered clinically  significant, 

[COMPANY_001] Confidential Page 129
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be re corded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least [ADDRESS_742471] dose of study  treatment. Adverse events 
(including lab abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible, rather than individual underly ing signs and symptoms. When a clear 
diagnosis cannot be identified, each sign or symptom should be reported as a separate 
Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life-threatening, corresponding tograde s 1 - 4, will be used. CTCAE grade 5 (death) will 
not be used in this study; but is collected as a seriousness criteria; rather, information about 
deaths will be collected though a Death form .
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunte ered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be 
evaluated to determine:
The severit y grade (CTCAE grade 1-4)
Itsduration (Start and end dates)
Its relationship to the study  treatment (Reasonable possibili ty that AE is related: No, Yes)
Action taken with respect to study  (none, dose adjusted, temporaril y interrupted, 
permanentl y discontinued, unknown, not app licable)
Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.[ADDRESS_742472] been met
If the event worsened, the event should be reported a second time in the CRF noting the start 
date when the even worsens in toxicity . For Grade 3 and 4 adverse events only, if 
improvement to a lower grade is determined a new entry  for this event should be reported in 
the CRF noting the start date when the event improved from having been Grade 3 or Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 

[COMPANY_001] Confidential Page 130
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_15039] (RECI ST criteria for solid tumors) , should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_742473] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events eCRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided 
(e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meet s the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be an 
adverse event and must be reported as such.
8.1.[ADDRESS_742474] (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by [CONTACT_64104]. Such events may require further investigation in order to characterize and 
understand them.
Adverse events of special interest are defined on the basis of an ongoing review of the safet y 
data. AESIs are discussed in detail in the I nvestigator Brochure .
[IP_ADDRESS] Definitions and reporting
A
dverse events of special interest to be monitored for capmatinib (INC280) include : 
Hepatotoxicity  
Renal dy sfunction 
ILD/P neumonitis

[COMPANY_001] Confidential Page 131
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Central nervous s ystem toxicity  
Phototoxicity  
Teratogenicity
Pancreatitis
Drug -drug interactions with strong CYP3A4 inhibitors
QTc interval prolongation
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_1081], 
Note that hospi[INVESTIGATOR_14944]:
Routine treatment or moni toring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_5317] y of the definitions o f a SAE given above 
is not a serious adverse event .
8.2.2 Reporting
For patients who sign the molecular pre -screening ICF, SAE collection will start upon signing 
the molecular pre-screening ICF. SAEs will only be reported if the event is suspected to be 
causall yrelated to a study  procedure as assessed by [CONTACT_093] (e.g. an invasive 
procedure such as biopsy ). SAEs will be followed until resolution or until clinically  relevant 
improvement or stabilization. If the main ICF is not signed (molecular screen failure), SAE 
collection ends [ADDRESS_742475] 30 days after the patient has 

[COMPANY_001] Confidential Page 132
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
stopped study  treatment must be reported to [COMPANY_001] within [ADDRESS_742476] be reported as follow -up to the original epi[INVESTIGATOR_5319] 24 
hours of the investigator receiving the follow -up information. An SAE o ccurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
Any SAE experienced after this 30 day safety evaluation follow -up period should only be 
reported t o [COMPANY_001] if the investigator suspects a causal relationship to the study  treatment.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide aclinically 
thorough report. Instructions regarding the SAE submission process and requirements for 
signatures are to be found in the investigator folder provided to each site. The investigator 
must assess and record the relationship of each SAE to each specific study  treatment (if there 
is more than one study  treatment), complete the SAE Report Form in English, and submit the 
completed form within [ADDRESS_742477] as the original SAE Report .Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the [Investigator’s Brochure ]or Package Insert 
(new occurrence) and is thought to be related to the Novart is study  treatment, an oncology 
[COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) department associate may urgently  require 
further information from the investigator for Health Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 
ethics committees in accor dance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.[ADDRESS_742478] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.

[COMPANY_001] Confidential Page 133
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_18540] (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes
should be obtained from the mother.
Women of childbearing potential should be advised to use highly  effective contraception 
methods while they  are receiving study  treatment and up to [ADDRESS_742479] 3 months.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure ]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data Monitoring Committee
Not applicable .
8.7 Steering Committee
A Steering Committee (SC) will be formed prior to initiation of the trial and will be appointed 
by [CONTACT_5343]. Itwill consist of investigators participating in the trial and [COMPANY_001] 
representatives from the Clinical Trial Team. The SC will ensure transparent management of 
the study  according to the protocol through recommending and approving modifications as 
circumstances require. The SC will review protocol amendments as appropriate. Together 
with the clinical trial team, the SC will also develop recommendations for publications of 
study  results including authorship rules. The details of the role of the Steering Committee will 
be defined in a Steeri ng Committee charter.
[ADDRESS_742480] of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information

[COMPANY_001] Confidential Page 134
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The rights of a research subject to revoke their a uthorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced an y new or worsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individu ally assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), thesystem will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements 
and to enable appropriate age-
related normal ranges to be used in assessing laboratory  test 
results.
9.2 Site monitoring
Before study  initiation , at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifica tions. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria 
and documentation of SAEs. Additional checks of the consistency  of the source data with the 
eCRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
The designated investigator staff will enter the data required by [CONTACT_230787] (eCRF). The eCRFs have been built using fully validated 
ents, Investigator site 

[COMPANY_001] Confidential Page 137
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) includes all patients who receive at least one dose of 
INC280.Unless otherwise specified the FAS will be the default analy sis set used for all 
analyses, including the primary anal ysis.
10.1.[ADDRESS_742481] one dose of INC280. All safety  data 
will be anal yzed using the Safet y Set.
The FAS and Safet y Set in this study  are identical .
10.1.3 Per-Protocol Set
The Per-Protocol Set (PPS) consists of a subset of patients in the FAS who have no major 
protocol deviations, who have an adequate tumor assessment at baseline and have a follow -up 
tumor assessment > 5 weeks after starting treatment (unless PD is observed before that time).
All major protocol deviations leading to exclusion from the PPS will be detailed in the 
Reporting and Anal ysis Plan (RAP).
10.1.4 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) consists of all patients who received at least one dose 
of INC280 and had at least one evaluable po st-baseline IN C280 concentration measurement.
APK sample is considered as non-evaluable if it is collected after a patient has vomited 
within [ADDRESS_742482] -dose.
The definition of an evaluable PK concentration profile will be further specified in the RAP.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be summarized 
descriptivel y by [CONTACT_9084] /sub-cohort
based on the FAS. Categorical data will be presented as 
frequencies and percenta ges. For continuous data, mean, standard deviation, median, 
minimum, and maximum will be presented.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], compliance)
The safet y set will be used for the analyses below.
The actual dose and duration in days of INC280 as well as the dose intensity  (computed as the 
ratio of total dose received and actual duration) and the relative dose intensity  (computed as 
the ratio of dose intensity  and planned dose received/planned duration), will be listed and 
summarized by [CONTACT_9084] /sub-cohort . Dose reductions and dose interruptions (including the 
reasons for these) will be listed and summarized by [CONTACT_9084] /sub-cohort .
Concomitant medications and significant non-drug therapi[INVESTIGATOR_565272] /sub-cohort .

[COMPANY_001] Confidential Page 138
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
10.4 Primary  objective
The primary  objective is to demonstrate the antitumor activity  of INC280, as measured by 
[CONTACT_34426] (ORR) to INC280 by [CONTACT_565281] (BIRC) 
assessment , by [CONTACT_9084] /sub-cohort .
10.4.1 Variable
The primary  variable used to evaluate the anti -tumor activity  of INC280 is the overall 
response rate (ORR), defined as the proportion of patients with a best overall confirmed 
complete response (CR) or partial response (PR), as assessed p er RECI ST 1.[ADDRESS_742483] 95% confidence interval (CI) (Clopper and Pearson 1934) provided 
by [CONTACT_9084] /sub-cohort . 
In Cohorts 1-4, t reatment with INC280 would be considered to have clinically  relevant 
efficacy  in a cohort /sub-cohort if an ORR of ~
35% is observed in that cohort for the 
corre sponding primary  analy sis.
In addition, 5hypotheses will be tested as following for the cohorts/sub
-cohorts respectivel y 
(Hi0and H i1correspond to cohort /sub-cohort i where i=1a, 1b, 2, 3 or 4)
Hi0: ORR ≤ 25%
In favor of the alternative
Hi1: ORR > 2
5%
For Sub-cohorts 5a, 5band Cohort 7,treatment with INC280 would be considered to have 
clinically  relevant efficacy  if an ORR of ~55% is observed in that cohort for the 
corresponding primary  analysis. In addition, 3hypotheses will be tested as following forthe 
cohorts/sub- cohorts (H i0and H i1correspond to Sub-c ohort i where i=5a , 5bor 7):
Hi0: ORR ≤ 35%
In favor of the alternative
Hi1: ORR > 35%
The tests will be performed based on the exact CI for ORR in each cohort /sub-cohort using a 
one-sided α= 0.025 level. Based on historical data, as referred in Section 1.1.1 , a 25% ORR is 
a reasonable threshold to be considered as clinically  relevant in this specific setting of second 
and third line advanced NSCL C patients ( de Marinis 2008, Weiss 2013, NCCN Guidelines 
2014 )in Cohorts/Sub -cohorts 1a, 1b, 2, 3 and 4.Similarly , a 35% ORR is a reasonable 
threshold to be considered as clinically  relevant in the treatment -naïve setting for advanced 
NSCL C patients (Zhou 2015, Scagliotti 2008) in S
ub-cohorts 5a , 5band Cohort 7 .Since a one 
sided α =0.025 is used for a particular hypothesis testing, the testing will be conducted based 
on two- sided 95% exact confidence interval. The null hypothesis will be rejected if the lower 
bound of the two-sided 95% exact CI is >25%in Cohorts/Sub -cohorts 1a, 1b, 2, 3 and 4. And 

[COMPANY_001] Confidential Page 139
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
the null hypothesis will be rejected in Sub- cohorts 5a and 5b if the lower bound of the two-
sided 95% exact CI  is >35%
.
No hypothesis testing is planned for Cohort 6. 
10.4.3 Handling of missing values/censoring/discontinuations
Confirmed PR or CR reported prior to any additional anticancer therap y will be considered as 
responses in the calculation of the ORR irrespective of the number of missed assessments 
before response.
Patients with a best overall response (BOR) of ‘Unknown’ per RECI ST 1. [ADDRESS_742484] disease progression and continue to receive study  drug after progression 
will qualify  for PD at the time of progression and will be counted as PD in the derivation of 
efficacy  endpoints.
10.4.4 Supportive analy ses
The primary  anal ysis on FAS will also be repeated on the PPS.
For Sub-cohorts 1a and 1b, and Cohort s 2 and 3, sensitivity  analysis on the primary  endpoint 
may be performed excluding patients with cMET mutations.
Data from Cohor t 6 will help further characterize the safet y and efficacy of INC280 in the 
pre-treated Sub-cohort 1a andCohort 4. Efficacy and safet y data will be presented for Cohort 
6 alone and may alsobeanalyzedfor pre - treated patients with cMET GCN ≥ [ADDRESS_742485] 6 cycles of 
treatment (18 weeks) or discontinued treatment earlier .  
10.5 Secondary  objectives
All secondary  anal yses will be perfor med on the FAS, unless otherwise specified.
10.5.1 Key secondary  objective(s)
The key secondary  objective is to evaluate duration of response (DOR) as assessed by [CONTACT_14988], 
by [CONTACT_9084] /sub-cohort .
Among patients with a confirmed response (PR or CR) per RECI ST 1.1, DOR is defined as 
the time from first documented response (PR or CR) to the date of first documented disease 
progression or death due to any cause. If a patient has not had an event, DOR is censored at 
the date of last adequate tumor assessment. DOR will be described in tabular and graphical 

[COMPANY_001] Confidential Page 140
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
format, by [CONTACT_9084], using Kaplan -Meier methods. The Kaplan -Meier estimate of the 
distribution function will be constructed. The number of patients at risk at certain time points 
will be shown on the plot. The estimated media n (in months) along with 95% CIs, as well as 
25thand 75thpercentiles will be reported.
10.5.2 Other secondary  efficacy  objectives
ORR by [CONTACT_3138] , by [CONTACT_9084] /sub-cohort :The evaluation of ORR will be 
also conducted based on investigator assessment . ORR will be estimated and the exact 
binomial 95% CI  will be provided by  [CONTACT_9084] /sub-cohort .
DOR by [CONTACT_3138] , by [CONTACT_9084] /sub-cohort :The evaluation of DOR will be 
conducted based on investigator assessment. DOR will be analy zed as described a bove for the 
analyses based on BI RC assessment.
Overall survival (OS) , by [CONTACT_9084] /sub-cohort :OS is defined as the time from the date of first 
dose of INC280 to the date of death due to any cause. If the patient is alive at the date of the 
analysis cut-off or lost to follow -up, then OS will be censored at the last contact [CONTACT_565326]-offdate. OS will be described in tabular and graphical format, by [CONTACT_9084] /sub-cohort , 
using Kaplan -Meier methods, including estimated median (in months) with 95% CI, 25th and 
75th percentiles and Kaplan -Meier estimated probabilities with corresponding 95% CIs at 
several time points. Censoring reasons will also be summarized.
The following secondary efficacy  objectives will be assessed separatel y based on investigator 
assessment and BIRC assessment per RECI ST 1.1:
Time to response (TTR) , by [CONTACT_9084] /sub-cohort : Time to overall response of CR or PR 
(TTR) is defined as the time from start of study  drug to first documented response (CR or PR, 
which must be confirmed subsequen tly) for patients with a confirmed CR or PR. 
TTR will be summarized in 6 -week intervals, by  [CONTACT_9084]/sub -cohort , using descriptive statistics. 
Disease control rate (DCR) , by [CONTACT_9084] /sub-cohort : DCR is defined as the proportion of 
patients with best overall response of CR, PR, or SD per RECI ST 1.1. DCR will be estimated 
and the binomial exact 95% CI  will be provided by  [CONTACT_9084]/sub -cohort . 
Progression -free survival (PFS) , by [CONTACT_9084] /sub-cohort : PFS is defined as the time from the 
date of first dose of INC280 to the date of first radiologicall y documented disease progression 
per RECI ST 1.1 or death due to any cause. PFS events documented after the initiation of new 
anti-neoplastic therapy  (i.e. RECI ST 1.1 documented disease progression or death) will be 
considere d for the primary  analy sis provided tumor assessments continue after initiation of the 
new cancer therapy . Clinical deterioration will not be considered as a qualify ing event for 
progression. PFS will be censored at the last adequate tumor assessment if one of the 
following occurs: absence of event; the event occurred after two or more missing tumor 
assessments. PFS will be described in tabular and graphical format, by [CONTACT_9084] /sub-cohort , 
using Kaplan -Meier methods, including estimated median (in months) with 95% CI, 25th and 
75th percentiles and Kaplan -Meier estimated probabilities with corresponding 95% CIs at 
several time points. Censoring r easons will also be summarized.
Additional analy sis of all secondary  efficacy  objectives in pre-
treated patients with a cMET 
GCN of ≥ 10 may be carried out combining the patients with a cMET GCN of ≥ 10 from Sub -

[COMPANY_001] Confidential Page 141
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
cohort 1a and Cohort 6 to further evaluate the precision of the efficacy estimates. Similar 
analysis will be carried out for pre-treated patients with cMET mutat ions regardless of cMET 
GCN combining the patients from Cohort 4 and Cohort 6.Cohort 7 may also be combined 
with Sub -cohort 5b.
10.5.3 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_9084] /sub-cohort for all patients.
The overall observation period will be divided into three mutually  exclusive segments:
Pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
On-treatment period: from day  of first dose of study  medication to [ADDRESS_742486] dose 
of study  medication
Post-treatment period: starting at day  [ADDRESS_742487]-
treatment period flagged.
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs observed during the on-
treatment 
period. However, all safet y data (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and after the on-treatment 
period will be flagged.
The incidence of treatment -
emergent AEs (new or worsening from baseline) will be 
summarized by  [CONTACT_5379]/ or preferred term, severit y (based on CTCAE grade s), 
type of AE, and relation to study  treatment by [CONTACT_9084] /sub-cohort . Deaths reportable as SAEs 
and non-fatal SAEs will be list ed by [CONTACT_565327] /sub-
cohort .
Specific safety  event categories (SEC) may be considered. Such categories consist of one or 
more well-defined safet y events which are similar in nature and for which there is a specific 
clinical interest in connection with the study  treatment.
For each specified category , number and percentage of patients with at least one event per 
category  will be summarized by  [CONTACT_9084] /sub-cohort .
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  tests covered by [CONTACT_113945] 4.03, the study’s biostatistical and 
reporting team will grade laboratory  data accordingl y. For laboratory  tests covered by 
[CONTACT_3989], a grade 0 will be assigned for all non-missing values not grade d as 1 or higher. 
Further details will be specifi ed in the reporting analy sis plan (RAP). Grade 5 will not be used.

[COMPANY_001] Confidential Page 142
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
For laboratory  tests where grade s are not defined by [CONTACT_3989], results will be grade d by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges.
The following summaries will be generated separatel y for hematology, biochemistry  and 
urinary laboratory  tests by  [CONTACT_9084]/sub -cohort :
shift tables using CTCAE grade s to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grade s are not defined, shift tables using the 
low/normal/high/(low and high)
Listing of all laboratory  data with values flagged to show the corresponding CTCAE grade s 
and the classifications relative to the laboratory  normal ranges will be generated.
A separate listing will display  notable laboratory  abnormalities (i.e., newly  occurring CTCAE 
grade 3 or 4 laboratory  toxicities).
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the RAP.
[IP_ADDRESS] Other safety  data
Data from other tests (including ECGs and vital signs) will be summarized and listed by 
[CONTACT_9084] /sub-cohort . Notable values will be flagged, and any  other information collected will be 
listed as appropriate. Definitions of notably abnormal results will be provided in the RAP.
[IP_ADDRESS] Tolerability
Tolerability  will be summarized in terms of dose reductions or drug interruption due to an AE 
by [CONTACT_9084] /sub-cohort .
10.5.[ADDRESS_742488] one evaluable PK sample . Summar y 
statistics include n, arithmetic mean, median, SD, geometric mean, coefficient of variation 
(CV) (%) and geometric CV (%), minimum and maximum. PK parameters as listed in Table 
10-1 will be derived using non-compartm ental analysis with the aid of WinNonlin Pro 
(Version 5.0 or higher) andreported, if feasible. Graphical presentation will be provided on 
mean concentration at each scheduled time point for PK sub-population where the full PK 
profile is available. In addi tion, summary  statistics on PK parameters will be reported for PAS.
Concentration values below the lower limit of quantitation (LLOQ) will be display ed in 
listings as zero with a flag and handled as zero in any calculations of summary  statistics, but 
handl ed as missing for the calculation of the geometric means and their CV. Any missing PK 
parameter data will not to be imputed.
Table 10-1 Noncompartmental pharmacokinetic param eters
AUCinf The AUC from time zero to infinity (mass x time x volume -1)
AUC0 -t The AUC from time zero to defined time t (mass x time x volume -1)

[COMPANY_001] Confidential Page 143
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
AUCtau The AUC within the dosing int erval (τ ) (mass x time x volume -1)
Cmax The maximum (peak) observed pla sma, blood, serum, or other body fluid drug concentration 
after single dose administration (mass x volume -1)
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration after single dose administration (time)
T1/2 The elimination half -life associated with the terminal slope ( z) of a semi logarithmic 
concentration -time curve (time). Use qualifier for other half-lives
CL/F The apparent total body clearance of drug from the plasma (volume x time -1)
Vz/F The apparent volume of distribution during terminal phase (associated with z) (volume)
Racc Accumulation ratio

[COMPANY_001] Confidential Page 144
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201

[COMPANY_001] Confidential Page 146
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
study  if the study  continued beyond interim, (i.e., till the final analy sis), given the interim 
observed data (x) and success among n patients. Thus,
POS = Prob[ Final observed ORR ≥ 35% |  x,n]
Minimally  informative Beta distribution prior (Neuenschwander et al 2008) with prior mean 
equal to 25% will be used, i.e., the prior distribution will be Beta (0.3333, 1) for the POS 
calcul ations at the interim analy sis.
The respective cohort will be stopped for futility  at the interim analysis if the respective POS 
< 10%. The interim analy sis will be performed by  [CONTACT_565328]. In 
addition, for Sub-cohort 1a and 1b, Cohorts 2 and 3, sensitivity  analysis on the primary 
endpoint may  be performed at interim anal ysis excluding patients with cMET mutations.
All evaluable patients at the time of the data cut-off 
for the interim analy sis will be used to 
obtain the futili ty boundary  using the POS criteria. The futility  boundary will be calculated 
according to the actual number of evaluable patients in the interim analy sis.
Sub-cohort 1a, Sub -cohort 1b , Cohort 2 and Cohort 4 
With 28 evaluable patients for interim analy sis in each of the Sub-cohorts 1a and 1b, Cohort
s
2and 4, if ≤ 7 responses (POS =0.0543) are observed then the respective cohort /sub-cohort
will be stopped for futility . Further details of POS are provided in With 28 evaluable patients 
for interim analysis in each of the Sub-cohorts 1a and 1b, Cohorts 2 and 4, if ≤ 7 responses 
(POS =0.0543) are observed then the respective cohort/sub
-cohort will be stopped for futility . 
Further details of POS are provided in Table 10-2. For each of the Sub-cohorts 1a and 1b, 
C
ohorts [ADDRESS_742489] not yet been observed, accrual in the cohort/sub- cohort may be temporarily  suspended 
until either the minimum number of 8 responders are observed or results of the interim 
analysis allow that cohort/sub -cohort to continue. 
Table 10-2 Probability  of Success at the Final A nalysis Based on Various Number 
of Responders Observed at IA  for Sub- cohort 1a ,Sub
-cohort 1b, 
Cohort 2and Cohort 4
Responder at IA out of 28 evaluable patients at IA Probability  of Success
≤ 5 <0.01
6 0.0164
7 0.0543
8 0.1398
9 0.2863
10 0.4794
11 0.6766
≥12 >0.83
Table 10-3 Number of Responders for Various Number of Evaluable Patients at 
Interim A nalyses by  [CONTACT_565329] -cohort 
1a,Sub- cohort 1b, Cohort 2 and Cohort 4 
Number of Evaluable patients at IA Responders at IA Probability  of Success
26 6 0.0368
26 7 0.1050

[COMPANY_001] Confidential Page 147
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Number of Evaluable patients at IA Responders at IA Probability  of Success
27 7 0.0765
27 8 0.1829
28 7 0.0543
28 8 0.1398
29 7 0.0377
29 8 0.1044
30 8 0.0760
30 9 0.1792
31 8 0.0540
31 9 0.1369
32 8 0.0373
32 9 0.1020
33 9 0.0740
33 10 0.1739
34 9 0.0523
34 10 0.1323
35 10 0.0980
35 11 0.2152
Cohort 3
With 20 evaluable patients for interim analy sis in Cohort 3 if ≤ 5 responses (POS=0.0999) are 
observed then the cohort will be stopped for futility . All evaluable patients at the time of the 
data cut-off for the interim analy sis will be used to obtain the futility  boundary  using the POS 
criteria. Further details of POS are provided in Table [ADDRESS_742490] not yet been observed, accrual in the cohort may be 
temporaril y suspended until either the minimum number of 6 responders are observed or 
results of the interim analysis allow the 
cohort to continue .
Table 10-4 Probability  of Success at the Final A nalysis Based on Various Number 
of Responders Observed at IA for Cohort 3 
Responder at IA out of 20 evaluable patients at IA Probability  of Succe ss
1 0.0001
2 0.0009
3 0.0066
4 0.0309
5 0.0999
6 0.2379
7 0.4382
8 0.6533
10.8 Sample size calculation
Approximately 456patients (69 patients per Sub-cohort in Cohort 1 and 69 patients per cohort 
in Cohorts 2-4, 27 patients per each S ub-cohort in C ohort 5,approximately 30 patients in 
Cohort 6and approximately  27in Cohort 7) will be enrolled in the study  if none of the four 
cohort s (Cohort 1-4)is stopped for futility  at the time of the interim analysis. The exact 95%
CIs for various sample sizes and observed ORRs in each cohort /sub-cohort are shown in 

[COMPANY_001] Confidential Page 148
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Table 10-[ADDRESS_742491] Binomial 95 percent Confidence Intervals for Various Sample 
Sizes and Observed ORRs in each Cohort /Sub -cohort 1a, 1b, 2, 3 and 
4
Sample s ize (N) Number of 
respondersObserved ORR (%) 95% exact CI (% )
[ADDRESS_742492] Binomial 95 percent Confidence Intervals for Various Sample 
Sizes and Observed ORRs in each Sub- cohort 5a , 5band Cohort 7
Sample size (N) Number of responders Observed ORR (%)95% exact CI (% )
25 14 56.0 34.9 75.6
26 15 57.7 36.9 76.6
27 15 55.6 35.3 74.5
28 16 57.1 37.2 75.5
29 16 55.2 35.7 73.6
The operating characteristics (with 69 subjects per cohort /Sub-cohort 1a, 1b, 2, 3 and 4) are 
shown inTable 10-7 and Table 10-8.Thetable sshow probability  of stoppi[INVESTIGATOR_270409], 
probability  for positive conclusion (i.e., not stoppedat IAfor futility  and success criter ia met 
at final analysis) and negative conclusion (i.e., not stopped at IA for futility  but success 
criteria not met at final analysis) under different underl ying true ORR. The operating 
characteristics (with 27 subjects per S
ub-cohort in 5a , 5b and Cohort 7 ) are shown in Table 
10-9. The table shows the probability  of meeting the success criteria under different 
underly ing true ORR .
Sub-cohort 1a
,Sub-cohort 1b ,Cohort [ADDRESS_742493] > 50% probability  of stoppi[INVESTIGATOR_565273] < 25%. Also, when the true ORR is 35% then the probabilit y 
of positive conclusion at the final analy sis with 69 patients is ≥ 44%. If the true ORR is 45% 
or higher, the probability of positive conclusion at the final anal ysis with 69 patients is > 90%.
Table 10-7 Operating Characteristics for Sub- cohort 1a ,Sub-cohort 1b ,Cohort 2 
and Cohort 4
True ORR 
(%)Probability  of a 
cohort to stop at 
IA* (%)Probability  for positive 
conclusion in final 
analy sis for a cohort (% )Probability  for negative conclusion in
final analy sis for a cohort 
(i.e. not stop at IA* and success criterion 
not met at final analy sis) (% )
10 99.50 0.00 0.50

[COMPANY_001] Confidential Page 149
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
True ORR 
(%)Probability  of a 
cohort to stop at 
IA* (%)Probability  for positive 
conclusion in final 
analy sis for a cohort (% )Probability  for negative conclusion in
final analy sis for a cohort 
(i.e. not stop at IA* and success criterion 
not met at final analy sis) (% )
20 81.82 0.12 18.06
25 59.97 2.34 37.68
30 36.48 15.01 48.51
35 18.21 44.00 37.79
40 7.40 75.38 17.22
45 2.42 93.11 4.47
50 0.63 98.73 0.64
*Assuming interim analysis at [ADDRESS_742494] > 60% probability  of stoppi[INVESTIGATOR_565273] < 25%. With 69 patients and 20 evaluable patient s for 
interim analysis, when the true ORR is 10% then the probability  of stoppi[INVESTIGATOR_565274] > 90%. If the true ORR is 20%, the probability  of stoppi[INVESTIGATOR_565275] > 80% and the probability  of positi ve conclusion at the final analy sis is 
< 1%.
Table 10
-8 Operating Characteristics for Cohort 3
True ORR (%)Probability  of a 
cohort to stop at 
IA* (%)Probability  of positive
conclusion in final 
analy sis for a cohort (% )Probability  of negative conclusion 
in final analy sis for a cohort (i.e., 
not stop at IA* and success criterion 
not met at final analy sis) (% ) 
10 98.87 0 1.13
20 80.42 0.11 19.47
25 61.72 2.17 36.12
30 41.64 13.98 44.39
35 24.54 41.41 34.05
40 12.56 71.99 15.45
45 5.53 90.46 4.01
50 2.07 97.36 0.57
*Assuming interim analysis at [ADDRESS_742495] < 36% prob ability  of the trial 
meeting the success criteria when the true ORR is ≤50%. If the true ORR is ≥60%, the 
probability  of the trial meeting the success criteria is ≥ 75%.
Table 10-9 Operating Characteristics for Sub -cohort 5a , 5band Cohort 7
Sample size (N) True ORR (%)Probability  (%) that ORR>=55%  with 
lower 95%  CI>35%
27 40 7.4
27 45 18.1
27 50 35.1

[COMPANY_001] Confidential Page 150
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Sample size (N) True ORR (%)Probability  (%) that ORR>=55%  with 
lower 95%  CI>35%
27 55 55.6
27 60 75.0
27 65 88.9
Cohort 6 
In expansion Cohort 6, patients with either cMET GCN ≥ 10 without cMET mutations or 
cMET mutations regardless of cMET GCN will be enrolled. Based on the rarit yof this patient 
population and considering recruitment within areasonable timeframe ,approximately  30 
patients are expected to be enro lled in Cohort 6.
Data from Cohort 6 will help further characterize the safet y and efficacy of INC280 in the 
pre-treated population (from S ub-cohort 1a and Cohort 4). 
10.9 Power for analy sis of key
 secondary  variables
Not applicable .
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent 
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documente d in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their CRFs.

[COMPANY_001] Confidential Page 152
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsored Research, 
please refer to www.novartis.com .
11.[ADDRESS_742496] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examin e (and when required by [CONTACT_1289], to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memo
randa, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supe rvision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the study . The investigator should ensure the accuracy , completeness, legibility, 
and timeliness of the data reported in the CRFs andall other required reports. Data reported 
on the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must beexplained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary ) and should not obscure the original 
entry . For electronic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator 
should retain reco rds of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the comple tion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.

[COMPANY_001] Confidential Page 153
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
11.[ADDRESS_742497] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_742498] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.[ADDRESS_742499] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwiths tanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such case s, [COMPANY_001] should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.

[COMPANY_001] Confidential Page 158
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Scagliotti G, Parikh P, von Pawel J et al (2008). Phase III study  comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherap y-naïve patients with advanced-
stage non –small - cell lung cancer. J Clin Oncol. 2008;26:3543 –3551.
Sca
gliotti G, von Pawel J, Novello S et al (2015). Phase III multinational, randomized, 
double -blind, placebo -controlled study  of tivantinib (ARQ 197) plus erlotinib versus erlotinib 
alone in previousl y treated patients with locally  advanced or metastatic non squamous non–
small -cell lung cancer. J Clin Oncol;33:2667
-74. 
Schildhaus HU, Schultheis AM, Ruschoff J, et al (2014) . MET amplification status in 
therap y
-naïve adeno -and squam ous cell carcinomas of the lung. Clin Cancer Res; Dec 9 
(Epub). 
Schuler MH, B erardi R, Lim W T, Van Geel R (2016). Phase I Study  of the Safet y and 
Efficacy  of the cMET Inhibitor Capmatinib (I NC280) in Patients With Advanced cMET+ 
Non-small Cell L ung Cancer. J Clin Oncol; (34) (suppl; abstr 9067)
Sequist L , Yang J, Yamamoto N et al ( 2013). Phase III Study  of Afatinib or Cisplatin Plus 
Pemetrexed in Patients With Metastatic L ung Adenocarcinoma With EGFR Mutations. J Clin 
Oncol ;31(27):3327-34.
Shaw AT, Engelman JA (2013a) . ALK in lung cancer: past, present, and future. J Clin Oncol; 
31:1105 - 11.
Shaw AT, Kim D, Nakagawa K et al (2013 b). Crizotinib versus Chemotherapy  in Advanced 
ALK -Positive L ung Cancer. N Engl J Med; 368:[ADDRESS_742500] FA, Rodrigues Pereira J, Ciuleanu T et al. (2005) Erlotinib in previously  treated 
non-small -cell lu ng cancer. N Engl J Med; 353: 123–132.
Solomon B, Mok T, Kim D et al (2014). First-Line Crizotinib versus Chemotherap y in ALK-
Positive Lung Cancer. N Engl J Med; 371:2167-2177.
Siegel R, Ma J, Zou Z et al (2014). Cancer statistics, 2014. CA Cancer J Clin; 64(1):9-29. 
Spi[INVESTIGATOR_15174] D, Edelman M, O’By[CONTACT_7943] K et al (2014) .Onartuzumab plus erlotinib versus erlotinib in 
previously  treated stage IIIb or IV NSCL C: Results from the pi[INVESTIGATOR_565276], 
multicenter, placebo -controlled METL ung (OAM4971g) global tri al. J Clin Oncol; (suppl; 
abstr 8000): 32:5s.
TCGA web portal (201 5). <//tcga -data.nci.nih.gov/tcga/>
Tong JH, Yeung SF, Chan AW et al (2016). MET amplification and exon 14 splice site 
mutation define unique molecular subgroups of Non- small Cell L ung Carcinoma with poor 
prognosis. Clin Cancer Res; 22(12):3048 -56.
Waqar SN, Morgensztern D, Sehn J (2015) MET Mutation Associated with Responsiveness to 
Crizotinib. J Thorac Oncol. May ;10(5):e29-31.
Weiss JM, Stinchcombe TE (2013). Second -Line Therapy  for Advanced NSCL C. The 
Oncologist ;18(8):947-53.
Wolf J, Seto T , Han JY et al (2018). LBA52 Results of the GEOMETRY mono- 1 phase II 
study  for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with 
METΔex14 mutated advanced non -small cell lung cance r (NSCLC) . Annals of Oncology , 
Volume 29, I ssue suppl_8

[COMPANY_001] Confidential Page 161
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

[COMPANY_001] Confidential Page 162
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.[ADDRESS_742501] criteria for tumor responses (Therasse et al 2000) and the 
revised RECI
ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.1.[ADDRESS_742502] response. Section 14.1.18 is summarizing the “time to 
event” variables and rules which are mainly  derived from internal discussions and regulatory 
consultations, as the RECI ST criteria do not define these variables in detail. Section 14.1.28
of this guideline describes data handling and programming rules. This section is to be referred 
to in the RAP (Reporting 
and Analy sis Plan) to provi de further details needed for 
programming.
14.1.[ADDRESS_742503] criteria ( Therasse et 
al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-[ADDRESS_742504] guidelines (version 1.1) (Eisenhauer et al 2009) 
European Journal of Cancer; 45:228 -
247.
14.1.3 Definitions
14.1.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in 
order to classify  lesions appropriatel y at baseline. In defining measurability , a distinction also 
needs to be made between nodal lesions (pathological ly mph node s) and non -nodal lesions.
Measurable disease - the presence of at least one measurable nodal or non-nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients wi thout measurable disease see Section 14.1.26.
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baselin e should be no less than double the slice thickness or 10mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at baseline, 
regardless of the slice thickness, are normal and not co nsidered indicative of disease.

[COMPANY_001] Confidential Page 163
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be considered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
[CONTACT_108], simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions -all other lesions are considered non-measurable, including small 
lesions (e.g. longest diameter <[ADDRESS_742505]/MRI  or pathological ly mph nodes with  10 to 
< 15 mm short axis), as well as truly non-measurable lesions e.g., blastic bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast disease, 
lymphangitis cutis/pulmonis, abdominal 
masses/abdominal organomegaly  identified by 
[CONTACT_522214] b y reproducible imaging techniques.
14.1.5 Eligibility  based on measurable disease
If no measurable lesions are identified at basel ine, the patient may be allowed to enter the 
study  in some situations (e.g. in Phase III studies where PFS is the primary  endpoint). 
However, it is recommended that patients be excluded from trials where the main focus is on 
the Overall Response Rate (ORR) . Guidance on how patients with just non-measurable 
disease at baseline will be evaluated for response and also handled in the statistical anal yses is 
given in Section 14.1.26.
14.1.6 Methods of tumor measurem ent 
-general guidelines
In this document, the term “contrast” refers to intravenous (i.v) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evaluations should be performed as closel y as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the treatment.
Imaging- based evaluation is preferred to evaluation by  [CONTACT_12148] w hen both 
methods have been used to assess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a [ADDRESS_742506]/MRI  scan 
slice thickness should not exceed [ADDRESS_742507] or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respi[INVESTIGATOR_14943]) plus contrast- enhanced MRI of abdomen and pelvis.

[COMPANY_001] Confidential Page 164
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
A change in methodology  can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_14967], like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a change in technique (e.g. from CT to 
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology  
will r esult by [CONTACT_15074] a UNK overall lesion response assessment. Ho wever, another 
response assessment than the [COMPANY_001] calculated UNK response may  be accepted from the 
investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.
FDG -PET : can comple ment CT scans in assessing progression (particularly  possible for 
‘new’ disease). New lesions on the basis of FDG- PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a si gn of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by  
[CONTACT_4654], this is PD.
If the positive FDG -PET at follow -up is not confirmed as a n ew site of disease on CT, 
additional follow -up CT are needed to determine if there is trul y progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).
If the positive FDG -PET at follow -up corresponds to a p re-existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by [CONTACT_6776]. However, C T is preferable.
Ultrasound : When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible 
alternative to clinical measurements of superficial palpable l ymph nodes, subcutaneous 
lesions and thy roid nodules. US might also be useful to confirm the complete 
disappearance of superficial lesions usually  assessed by  [CONTACT_198278].
Endoscopy and laparoscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha -FP, LDH and Beta- hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be considered in complete clinical response when all 
lesions have disappeared.
Cytology and histolog y: Cy tology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 

[COMPANY_001] Confidential Page 165
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation o f neoplastic nature of an y effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable wh en they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  [CONTACT_6775] , including a ruler to estimate the size of the lesion, is 
recommended.
14.1.7 Baseline documentation of target and non -target l esions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non -target lesions:
Target lesions
: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) a nd 
their suitability  for accurate repeated measurements (either by  [CONTACT_15078] ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  [CONTACT_15079] (e.g. clinical examination, photograph y) should be at least [ADDRESS_742508] diameter. See Secti on 14.1.4.
Nodal target : See Section 14.1.4.
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by [CONTACT_14218]. 
Each target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
Non-target lesions : All other lesions are considered non
-target lesions, i.e. lesions not 
fulfilling the criteria for target lesions at baseline. Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions 
are not required. Multiple non -target lesions involved i n the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
14.1.8 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 

[COMPANY_001] Confidential Page 166
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
for the target (Table 14-1) and non-target lesions (Table 14 -2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target 
and n on-target lesions together ( Table 14 - 3) as well as the presence or absence of new lesions.
14.1.[ADDRESS_742509] to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance 
of the cut from the longest diameter; such les ions may  appear to have responded or progressed 
on subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as [ADDRESS_742510] slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than [ADDRESS_742511] diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably  measured for reasons ot her than its size (e.g., 
borders of the lesion are confounded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated.
14.1.11 Nodal lesions
A nodal lesion less than 10 mm in size by [CONTACT_565330] l. Lymph nodes are 
not expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become [ADDRESS_742512] slice thickness 
(but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.

[COMPANY_001] Confidential Page 167
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.12 Determination of target lesion response
Table 14-1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph nodes 
assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the 
baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of di ameter of all measured target lesions, taking as 
reference the smallest sum of diameter of all target lesions recorded at or after baseline. In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which 
would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not been 
assessed or have been assessed using a different method than baseline.3
1. SOD for CR may not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non- nodal target lesions are still not present and all nodal lesions are 
<10 m m in size. In this case, the target lesion response is CR
3. Methodology change See Section 14.1.6 .
Notes on target lesion response
Reappearance of lesions : If the lesion appears at the same anatomical location where a target 
lesion had previously  disappeared, it is advised that the time point of lesion disappearance 
(i.e., the “0 mm” recording) be re-evaluated to make sure that the lesion was not actuall y 
present and/or not visualized for technical reasons in this previous assessment. If it is not 
possible to change the 0 value, then the investigator/radiologist has to decide between the 
following three possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be conside red 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented i n Table 14- 1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at or 
after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, please refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for [ADDRESS_742513] -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 

[COMPANY_001] Confidential Page 168
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal lesion decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal 
in order not to overstate progres sion should it be based on increase in the size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non- nodal lesion, short axis - nodal lesions) of 
the two split lesions should be added together and the sum recorded in the diameter field on 
the case report form under the original lesion number. This value will be included in the 
sum of diameters when deriving target lesion response. The individual split lesions will not 
be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible that two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coal esced such that they  
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the case report form, the diam eter of the “merged lesion” 
should be recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.
The measurements for nodal lesions , even if less than [ADDRESS_742514]  with slight modifications.
Since lesions less than [ADDRESS_742515] disappeared.
Once a CR target lesion response has been assigned a CR will continue to be 
appropriate (in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non- nodal target lesion “reappears” or if any  single nodal lesion is at least [ADDRESS_742516] 20% increase in sum of the diameters of all nodal target 
lesions relative to nadir with at leas t 5 mm increase in the absolute sum of the 
diameters.

[COMPANY_001] Confidential Page 169
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.13 Determination of non -target lesion response
Table 14-2 Response criteria for non -target lesions
Response Criteria Evalua tion of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non-target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have 
not been assessed or have been assessed using a different method than baseline.
1. Although a cl ear progression of non -target lesions only is exceptional, in such circumstances, the opi[INVESTIGATOR_140943] (or 
study chair).
Notes on non -target lesion r esponse
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions returned 
to normal size (i.e. < 10 mm). I f any  of the non -target lesions ar e still present, or there are 
any abnormal nodal lesions (i.e.  10 mm) the response can onl y be ‘ Non-CR/Non -PD’ 
unless any  of the lesions was not assessed (in which case response is UNK) or there is 
unequivocal progression of the non -target lesions (in which case response is PD).
Unequivocal progression: To achieve “unequivocal progression” on the basis of non -target 
disease there must be an overall level of substantial worsening in non -target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has 
increased sufficientl y to merit discontinuation of therap y. A modest “increase” in the size 
of one or more non
-target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of o verall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the di sease must be substantial even in cases where there is no measurable disease 
at baseline. If there is unequivocal progression of non- target lesion(s), then at least one of 
the non- target lesions must be assigned a status of “Worsened”. Where possible, similar 
rules to those described in Section 14.1.[ADDRESS_742517] s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scan ned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 

[COMPANY_001] Confidential Page 170
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should b e UNK, as for an y of this patient's assessment 
(see Section 14.1.15).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size t
o [ADDRESS_742518] time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See 
Section 14.1.6 .
14.1.15 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target 
lesion response, non-target lesion response and presence of new lesions as shown below in
Table 14
-3.
Table 14-3 Overall lesion response at each assessment
Target lesions Non-target lesions New Lesions Overall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 14.1.8 .
If there are no baseline scans available at all, then the overall lesion response at each 
assessment should be consid ered Unknown (UNK).
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to confirm the CR.
14.1.[ADDRESS_742519] y the same concepts.

[COMPANY_001] Confidential Page 171
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.[ADDRESS_742520] response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements 
recorded since the treatment started). In general, the patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while ontreatment. However, if any assessments occur after treatment withdrawal the 
protocol should specifically  describe if these will be included in the determination of best 
overall response and/or whether these additional assessments will be required for sensitivity  
or supportive analyses. As a default, any assessments taken more than [ADDRESS_742521] overall response determination. If response assessments 
taken after withdrawal from study  treatment and/or alternative therapy  are to be included in 
the main endpoint determination, then this shoul d be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by  [CONTACT_15085] [ADDRESS_742522] be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials intended to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at l east two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart befo re progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required
SD = at least one SD assessment (or better) > 6 weeks after randomization/start of 
treatment (and not q ualify ing for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than [ADDRESS_742523] 12 weeks)
Overall lesion responses of CR must stay the same until progression sets in, with the 
exception of a UNK status. A patient who had a CR cannot subsequentl y have a lower status 

[COMPANY_001] Confidential Page 172
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
other than a PD, e.g. PR or SD, as this would imply a progression based on one or more 
lesions reappearing, in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improv e over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective 
status at that assessment should be SD. Once a confirmed PR was seen, the overall lesion 
response should be considered PR (or UNK) until progression is documented or the lesions 
totally  disappear in which case a CR assignment is applicable. In studies where confirmation 
of response is not required after a single PR the overall lesion response should still be 
considered PR (or UNK) until progression is documented or the lesion totally  disappears in 
which case a CR assignment is applicable.
Example: In a
 case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the 
subsequent visits. Assuming that non-target lesions did not progress, the overall lesion 
response would be PR 
-SD - PR -PR -PR. The second assessment with 140 mm confirms the 
PR for this patient. All subsequent assessments are considered PR even if tumor 
measurements decrease only by 20% compared to baseline (200 mm to 160 mm) at the 
following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall r esponse.
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:
Investigator overall lesion response
Central Blinded Review overall lesion response
[COMPANY_001] calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or pu blications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR 
or PR or SD.

[COMPANY_001] Confidential Page 173
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is use d:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs of Dent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be 
at 8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with 
an unknown (UNK) assessment at that time point and no PD before, will not be counted as 
early progressors in the analysis but may be included in the denominator of the EPR rate, 
depending on the analysis population used. Similarly when examining overall response and 
disease control, patients with a best overall response assessment of unknown (UNK) will not 
be regarded as “responders” but may be included in the denominator for ORR and DCR 
calculation depending on the ana lysis population (e.g. populations based on an ITT approach).
14.1.18 Time to event variables
The protocol should state which of the following variables is used in that study.
14.1.19 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression- free survival is censored at the date of last adequate 
tumor assessment.
14.1.[ADDRESS_742524] seen alive / last known date patient alive, the date of death and the reason 
of death (“Study  indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomizatio n/start of treatment to 
date of death due to any cause. If a patient is not known to have died, survival will be 
censored at the date of last known date patient alive.
14.1.21 Time to progression
Some studies might consider only death related to underl ying cancer as an event which 
indicates progression. In this case the variable “Time to progression” might be used. TTP is 
defined as PFS except for death unrelated to underly ing cancer.

[COMPANY_001] Confidential Page 174
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Time to progression (TTP) is the time from date of randomization/start of treatme nt to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate 
tumor assessment.
14.1.[ADDRESS_742525] of 
discontinuation reasons to be considered or not as treatment failure may be adapted according 
to the specificities of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation 
due to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to 
treatment failure for patients who did not experience treatment failure will be censored at last 
adequate tumor assessment.
14.1.[ADDRESS_742526] been 
reports where a treatm ent with a significantl y higher response rate had a significantl y shorter 
duration of response but where this probably  primarily  reflected selection bias which is 
explained as follows: It is postulated that there are two groups of patients: a good risk group 
and a poor risk group. Good risk patients tend to get into response readily  (and relativel y 
quickly ) and tend to remain in response after they have a response. Poor risk patients tend to 
be difficult to achieve a response, may have a longer time to respond, and tend to relapse 
quickly  when they do respond. Potent agents induce a response in both good risk and poor 
risk patients. Less potent agents induce a response mainly  in good risk patients only. This is 
described in more detail by  [CONTACT_15088] (1988) .
It is recommended that an analysis of all patients (both 
responders and non-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then 
interpreted with caution by  [CONTACT_15089]. 
If an inferential comparison between treatments is required this should only be performed on 
all patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such 
as the techniques described in Ellis et al (2008) . It should also be stated in the protocol if 
duration of response is to be calculated in addition for unconfirmed response.
For summary  statistics on “responders” only the following definitions are appropriate. 
(Specific definitions for an all -patient analysis of these endpoints are not appropriate since the
status of patients throughout the study  is usually  taken into account in the analy sis).
Duration of overall response (CR or PR): For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end 
date and censoring is defined the same as that for time to progression.

[COMPANY_001] Confidential Page 175
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The following two durations might be calculated in addition for a large Phase III study  in 
which a reasonable number of responders is seen.
Duration of overall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to 
be confirmed) or SD the start and end date as well as censoring is defined the same as that for 
time to progression.
14.1.24 Time to response
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may need to be 
confirmed depending on the type of study  and its importance. Where the response needs to be 
confirmed then time to response is the time to the first CR or PR observed.
Althou gh an analysis on the full population is preferred a descriptive analy sis may be 
performed on the “responders” subset only, in which case the results should be interpreted 
with caution and in the context of the overall response rates, since the same kind of selection 
bias may be introduced as described for duration of response in Section 14.1.23. It is 
recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a “responders only” descriptive analysis 
is presented. Where an 
inferential statistical comparison is required, then all patients should definitely be included in 
the analy sis to ensure the statistical test is valid. For analysis including all patie nts, patients 
who did not achieve a response (which may  have to be a confirmed response) will be censored 
using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis) for patients who had a 
PFS event (i.e. progressed o r died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date otherwise. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endp oint described for the time to overall response endpoint.
14.1.25 Definition of start and end dates for time to event variables
Assessment date
For each 
assessment (i.e. evaluation number), the assessment date is calculated as the latest 
of all measurement dates (e.g. X-ray, CT-scan) if the overall lesion response at that 
assessment is CR/PR/SD/UNK. Otherwise - if overall lesion response is progression -the 

[COMPANY_001] Confidential Page 176
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
assessment date is calculated as the earliest date of all measurement dates at that evaluation 
number.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documen ted response is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates which are us ed to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made befo re an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time wi ndow for the next 
tumor assessment as per protocol (see Section 14.1.26).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact [CONTACT_15090]. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow -up page is 
used. If no survival follow
-up is available, the date of discontinuation is used as la st 
contact [CONTACT_568].
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
14.1.26 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non-measurable disease present at baseline are entered 
into the study , either because of a protocol violation or by [CONTACT_8345] (e.g. in Phase III studies 

[COMPANY_001] Confidential Page 177
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
with PFS as the primary endpoint). In such cases the handling of the response data requires 
special consider ation with respect to inclusion in any analysis of endpoints based on the 
overall response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoint s.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response forpatients with measurable 
disease is derived slightly differentl y according to Table 14 -
4.
Table 14-4 Overall lesion response at each assessment: patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.1.8 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particul ar by 
[CONTACT_141041]- CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.
For ORR it is recommended that the main (ITT) analysis includes data from patients with 
only non-measurable disease at baseline, handling patients with a best response of CR as 
“responders” with respect to OR R and all other patients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non-measurable disease at baseline, with possible sensitivity  analyses 
which exclude these particula r patients. Endpoints such as PFS which are reliant on the 
determination and/or timing of progression can incorporate data from patients with only non-
measurable disease.
14.1.27 Sensitivity analy ses
This section outlines the possible event and censoring dates forprogression, as well as 
addresses the issues of missing tumor assessments during the study . For instance, if one or 
more assessment visits are missed prior to the 
progression event, to what date should the 
progression event be assigned? And should progres sion event be ignored if it occurred after a 
long period of a patient being lost to follow -up? It is important that the protocol and RAP 
specify  the primary  analysis in detail with respect to the definition of event and censorin g 
dates and also include a description of one or more sensitivity  anal yses to be performed.

[COMPANY_001] Confidential Page 178
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
Based on definitions outlined in Section 14.1.25, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 
2005) as a reference, the following analy ses can be considered:
Table 14
-5 Option s for event dates used in PFS, TTP, duration of response
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAPOutcome
A No baseline assessment (1) Date of randomization/start of treat ment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) D ate of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)
1.=Definitions can be found in Section 14 .1.25
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 14.1.25.
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case of only  one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without 
documented progression :By [CONTACT_15094], option (1) is used for situation E as patients without 

[COMPANY_001] Confidential Page 179
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
documented PD should be followed for progression after discontinuation of treatment. 
However, option (2) may be used as sensitivity  analysis. If progression is claimed based on 
clinical deterioration instead of tumor assessment by e.g. CT -scan, option (2) may  be used for 
indications with high early  progression rate or difficulties to assess the tumor due to clinical 
deterioration.
Situation F: New cancer therapy given : the handli ng of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensit ivity analyses may include analy ses to check for 
potential bias in follow -up schedules for tumor assessments, e.g. by [CONTACT_111914]. The latter could be handled by  [CONTACT_111915] 14-5 the “Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled 
assessment (from baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tu
mor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investigators’ assessme nts of response rather 
than the calculated response. The need for these types of sensitivity  analyses will depend on 
the individual requirements for the specific study and disease area and have to be specified in 
the protocol or RAP documentation.
14.1.28 Data han dling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
14.1.29 Study/project specific decisions
For each study  (or project) vari ous issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.1.[ADDRESS_742527] to follow -
up, the investigator or designee should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, 
etc.

[COMPANY_001] Confidential Page 180
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
The end of treatment visit and its associated assessments should occur within [ADDRESS_742528] study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressive disease
Study  terminated by  [CONTACT_456]
Non-compliant with study  treatment
No longer requires treatment
Treatment duration compl eted as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
14.1.[ADDRESS_742529] -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study 
treatment and post -treatme nt evaluations but prior to collecting survival follow -up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
New therap y for stud y indication
Progressive disease
Study  terminated by  [CONTACT_456]
14.1.[ADDRESS_742530] regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) 
and not available evaluations (i.e. if any target or non-target lesion was not evaluated the 
whole overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 

[COMPANY_001] Confidential Page 181
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
assessments may be re-evaluated by [CONTACT_111916]. In addition, 
data review reports will be available to identify  assessments for which the investigators’ or 
central reader’s opi[INVESTIGATOR_565277]. This may be queried for clarification. However, the investigator or central 
reader’s response assessment will never be overruled.
If [COMPANY_001] elect to invalidate an overall lesion response as evaluated by [CONTACT_15099], the calculated overall lesion 
response at that specific assessment is to be kept in a dataset. This must be clearl y 
documented in the RAP documentation and agreed before databa se lock. This dataset should 
be created and stored as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
[CONTACT_15100] y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
14.1.33 Programming rules
The following should be used for programming of efficacy  results:
14.1.34 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
14.1.35 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.1.25). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.1.[ADDRESS_742531].

[COMPANY_001] Confidential Page 182
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.37 Non- target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non
-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.1.38 Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
14.1.39 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the following censoring reasons are possible:
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the follow ing censoring reasons are 
possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -5)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section 14.1.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off 
(or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason 
should also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study  evaluation completion page), when patients are not 
followed for progre ssion after treatment completion or when onl y UNK assessments are 
available just prior to data cut -off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to fol low-up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.

[COMPANY_001] Confidential Page 183
Amended Protocol Version 06 ( Clean ) Protocol No. CINC280A2201
14.1.40 References (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stoppi[INVESTIGATOR_14974] y progression, J Clin Oncol; 19: 785
-791
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005
FDA Guideline s: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guide lines to Evaluate the Response to 
Treatment in Solid Tumor
